

MFT TRUST FORMULARY**Manchester University**
NHS Foundation Trust

	BNF Chapter
Section 1:	Gastro-Intestinal System
Section 2:	Cardiovascular System
Section 3:	Respiratory System
Section 4:	Central Nervous System
Section 5:	Infections
Section 6:	Endocrine System
Section 7:	Obstetrics, gynaecology & urinary tract disorders
Section 8:	Malignant disease & immunosuppression
Section 9:	Nutrition & blood
Section 10:	Musculoskeletal & Joint Diseases
Section 11:	Eye
Section 12:	Ear, nose & oropharynx
Section 13:	Skin
Section 14:	Immunological products & vaccines
Section 15:	Anaesthesia
Section 16:	Miscellaneous

Version 8.10 (November 2023)

Prescribers must always bear in mind when prescribing medicines recommended as "treatment options" by NICE, that this is an opportunity for the clinician and the patient to consider and discuss its use alongside other potential treatment options available.

Formulary status definitions

Formulary (OK to be prescribed - but after any 1st or 2nd line options)

1st line formulary (when there are few formulary options, this is the 1st choice)

2nd line formulary (when there are few formulary options, this is the 2nd choice)

Where there is no preferred 1st line agent provided, the drug choice appears in alphabetical order.

1st line medicines for certain therapeutic groups and any restrictions placed upon prescribing are indicated in the box after the medicine name. Where modified release preparations of a formulary drug are available a comment will clarify its status. Newly licensed modified release preparations of existing formulary drugs will remain non-formulary until a review is carried out and recommendations are published. Where published guidance from NICE, MTRAC or the CSM is available, a reference to this is made either in the box after the medicine name or under the section title. Prescribing guidance issued by the Area Prescribing Committee is also included where it is available.



PCT Red/Amber/Green classifications



Adult RAG, DNP & Grey list Paediatric RAG, DNP & Grey list

Red

Drugs considered to be specialist medicines and prescribing responsibility for these medicines should normally remain with the consultant or specialist clinician. These drugs should not be initiated or prescribed in primary care. It is recommended that the supply of these specialist medicines should be organised via the hospital pharmacy or specialist service. This may include arranging for supply via a home care company.

Amber

Drugs suitable for shared care arrangements under a shared care protocol.

Prescribing and monitoring responsibilities may be transferred from specialist teams to primary care prescribers in line with a shared care protocol. Shared care arrangements will usually be supported by a GMMMG shared care protocol (SCP). [See here for a list of GMMMG approved SCPs.](#)

Green

Drugs that are suitable for initiation and ongoing prescribing within primary care.

Green

specialist initiation

Drugs that are suitable for ongoing prescribing within primary care following initiation by a specialist service. Little or no monitoring is required.

Green

following specialist recommendation

Drugs that are suitable for initiation by primary care following written or verbal advice from a specialist service. Little or no monitoring is required.

Do Not Prescribe: DNP

Products which are not recommended for prescribing in any setting. "Do Not Prescribe" status may relate to a specific medicine, or to prescribing for a particular indication. This is in addition to all medicines with a "not NHS" or "Drugs of Low Clinical Value" classification in the BNF, and those medicines with a NICE "Do not do" recommendation.

Grey: Grey

Products which are not suitable for routine prescribing but suitable for exceptional use in a defined patient population. Prescribers should ensure that more suitable alternatives have been considered and ruled out as not being appropriate before recommending or prescribing a medicine with a GREY list status. In these cases a RAG of RED, AMBER or GREEN will also be assigned to clarify in which care setting prescribing responsibility lies.

Unlicensed: U

Unlicensed indications are automatically classified as red unless designated otherwise on the list below. If a medicine is unlicensed this should be highlighted in the template as follows: drug name^U

MMC Medicines Management Committee decision tables

Summary of Product Characteristics

Blueteq Enabled Forms

British National Formulary (BNF)

Controlled Drug

British National Formulary for Children (BNFC)

High Cost Medicine

NICE guidance

Payment by Results high cost excluded drug

NOT STOCKED Not routinely stocked, can be ordered if existing patient supply is exhausted

PCT Guidelines

Greater Manchester Medicines Management Group FORMULARY



GMMMG Adult **Red/Amber/Green**; DNP and Grey Drug List

GMMMG Paediatric **Red/Amber/Green**; DNP and Grey Drug List

GMMMG Approved Shared Care Protocols

Useful Links

All Wales Medicines Strategy Group

British HIV Association (BHIVA)

British National Formulary (**No password required**)

British National Formulary for Children (**No password required**)

Commission on Human Medicines (CHM)

electronic Medicines Compendium (eMC)

General Pharmaceutical Council (GPhC)

Greater Manchester Medicines Management Group (GMMMG)

Medicines and Healthcare products Regulatory Agency (MHRA)

Midlands Therapeutics Review and Advisory Committee (MTRAC)

National Institute for Health and Clinical Excellence (NICE)

Scottish Medicines Consortium (SMC)

Specialist Pharmacist Service (SPS)

Section 1: Gastro-Intestinal System

Supported by the
formulary ([click here](#))



1.1 Dyspepsia & gastro-oesophageal reflux disease

- 1.1.1 Antacids & Simeticone
- 1.1.2 Compound Alginates & Proprietary Indigestion Preparations

1.2 Anti-spasmodics & other drugs altering gut motility

- Antimuscarinics
- Other Antispasmodics
- Motility Stimulants

1.3 Antisecretory drugs & mucosal protectants

- 1.3.1 H₂-Receptor Antagonists
- 1.3.3 Chelates & Complexes
- 1.3.5 Proton Pump Inhibitors

1.4 Acute diarrhoea

- 1.4.2 Antimotility Drugs

1.5 Chronic bowel disorders

- 1.5.1 Aminosalicylates
- 1.5.2 Corticosteroids & Enemas
- 1.5.3 Drugs Affecting the Immune Response
 - Cytokine Modulators

1.6 Laxatives

- 1.6.1 Bulk-forming Laxatives
- 1.6.2 Stimulant Laxatives
- 1.6.3 Faecal Softeners
- 1.6.4 Osmotic Laxatives
- 1.6.5 Bowel Cleansing Preparation
- 1.6.6 Peripheral opioid-receptor antagonists
- 1.6.7 Other drugs used in constipation

1.7 Local preparations for anal & rectal disorders

- 1.7.2 Compound Haemorrhoidal Preparations with Corticosteroids
- 1.7.4 Management of anal fissures

1.9 Drugs affecting intestinal secretions

- 1.9.1 Drugs affecting biliary composition & flow
- 1.9.2 Bile acid sequestrants
- 1.9.4 Pancreatin

1.10 Miscellaneous preparations

Trust Guidelines

Adult medicines and prescribing guidelines
 Paediatric medicines and prescribing guidelines
 Neonatal guidelines (link to Staffnet site)
[Non-formulary Conversion Table](#)

NICE Guidance

Biosimilar Medicines (KTT15)
 Faecal Incontinence (CG49)
 Irritable Bowel Syndrome (CG61)
 Diarrhoea and vomiting in children under 5 (CG84)
 Constipation in children and young people (CG99)
 Acute upper GI bleeding (CG141)
 Dyspepsia and gastro-oesophageal reflux disease (CG184)
 Coeliac disease: recognition, assessment and management (NG20)
 Crohn's disease: management (NG129)
 Ulcerative colitis: management (NG130)
 Ulcerative colitis (acute exacerbations) - infliximab (TA163)
 Crohn's disease - infliximab & adalimumab (TA187)
 Constipation (women) - prucalopride (TA211)
 Infliximab, adalimumab & golimumab for treating moderately to severely active ulcerative colitis (TA329)
 Vedolizumab for treating moderately to severely active ulcerative colitis (TA342)
 Naloxegol for treating opioid induced constipation (TA345)
 Vedolizumab for treating moderately to severely active Crohn's disease after prior therapy (TA352)
 Obeticholic acid for treating primary biliary cholangitis (TA443)
 Ustekinumab for moderately to severely active Crohn's disease after previous treatment (TA456)
 Tofacitinib for moderately to severely active ulcerative colitis (TA547)
 Darvadstrocel for treating complex perianal fistulas in Crohn's disease (TA556)
 Ustekinumab for treating moderately to severely active ulcerative colitis (TA633)
 Naldemedine for treating opioid-induced constipation (TA651)
 Budesonide orodispersible tablet for inducing remission of eosinophilic oesophagitis (TA708)
 Filgotinib for treating moderately to severely active ulcerative colitis (TA792)
 Teduglutide for treating short bowel syndrome (TA804)
 Ozanimod for treating moderately to severely active ulcerative colitis (TA828)
 Upadacitinib for treating moderately to severely active ulcerative colitis (TA856)
 Risankizumab for previously treated moderately to severely active Crohn's disease (TA888)
 Upadacitinib for previously treated moderately to severely active Crohn's disease (TA905)

GMMM Formulary

Formulary Homepage
 Chapter 1: Gastro-Intestinal system (Complete)
 GMMM Adult [Red](#)/[Amber](#)/[Green](#); DNP and Grey Drug List
 GMMM Paediatric [Red](#)/[Amber](#)/[Green](#) Drug List

1.1 Dyspepsia & gastro-oesophageal reflux disease		GMMMG
1.1.1 Antacids & Simeticone		
Aluminium & Magnesium Containing Antacids		
Co-magaldrox	 195/220 suspension ^{SF}	1st line use
Magnesium Trisilicate	 suspension	
Simeticone alone (activated dimeticone)		
Simeticone	 Infacol® 40mg/mL liquid	RESTRICTED Paediatric use only
1.1.2 Compound Alginates & Proprietary Indigestion Preparations		
Alginate raft-forming oral suspensions^{SF}	 suspension	

1.2 Anti-spasmodics & other drugs altering gut motility



Antimuscarinics

Hyoscine Butylbromide

tablets; injection



MHRA Drug Safety Update (Feb-17): Hyoscine butylbromide (Buscopan) injection: risk of serious adverse effects in patients with underlying cardiac disease

Glycopyrronium Bromide (Glycopyrrolate)

Green

(Robinul®, Sialanar®) tablets; injection; oral solution; cream



Other Antispasmodics

Mebeverine Hydrochloride

135mg tablets

1st line use

Peppermint oil

capsules



Motility Stimulants

Metoclopramide

10mg tablets (see also section 4.6)

1st line use

MHRA (Aug-13): Metoclopramide: risk of neurological adverse effects

Domperidone

Green

10mg tablets (see also section 4.6)

Use where 1st line unsuitable

MHRA Drug Safety Update (Dec19): Domperidone for nausea and vomiting: lack of efficacy in children; reminder of contraindications in adults and adolescents

MHRA Drug Safety Update (Apr-16): Apomorphine with domperidone: minimising risk of cardiac side effects

MHRA Drug Safety Update (May-14): Domperidone: risks of cardiac side effects

1.3 Antisecretory drugs & mucosal protectants



1.3.1 H₂-receptor antagonists

Famotidine

Green

20mg; 40mg tablets

MMC BNF emc

Ranitidine

150mg; 300mg tablets



1.3.3 Chelates & Complexes

Sucralfate

Green

1g tablets; oral suspension (restricted Wythenshawe)

Bismuth Subsalicylate (*Pepto-Bismol*®)

262.5mg chewable tablets

RESTRICTED
Adults, H. Pylori eradication regime

1.3.5 Proton Pump Inhibitors

Omeprazole

10mg; 20mg; 40mg capsules; 40mg infusion

Lansoprazole

15mg & 30mg capsules; 15mg & 30mg orodispersible tablets

RESTRICTED
tablets - enteral feeding tubes /
dysphagia

Esomeprazole

40mg infusion

RESTRICTED
PPI indicated / enteral route not
available/appropriate

MHRA (Apr-10): Clopidogrel and proton pump inhibitors: interaction—updated advice

MHRA Drug Safety Update (Sep-15): Proton pump inhibitors: very low risk of subacute cutaneous lupus erythematosus

Other PPIs are not available at this Trust

1.4 Acute diarrhoea		
1.4.2 Antimotility Drugs		
Loperamide hydrochloride 2mg capsules; 1mg/5mL syrup ^{SF}	  	1st line use
Codeine Phosphate 15mg; 30mg & 60mg tablets	 	RESTRICTED Adults - high output stomas
Teduglutide   Revestive® injection	     	RESTRICTED Gastro. Consultants only in line with NICE TA804

1.5 Chronic bowel disorders		GMMMG
1.5.1 Aminosalicylates		
Mesalazine Green tablets; M/R tablets; M/R granules; enema; foam enema; suppositories	 	PRESCRIBE BY BRAND NAME
Balsalazide Sodium 750mg capsules	  	
1.5.2 Corticosteroids & Enemas		
Prednisolone 5mg tablets	 	1st line use
Budesonide (Budenofalk®) 3mg capsules; rectal foam	  	RESTRICTED Adults - eosinophilic esophagitis
Budesonide (Jorveza®) Green 1mg orodispersible tablets	   	
Budesonide Green 3mg CR capsules	  	RESTRICTED Adults - Gastro. Consultants only
Hydrocortisone foam enema	 	RESTRICTED Adults - Gastro. Consultants only
Short chain fatty acid enema  Nutricol® enema	  	
1.5.3 Drugs Affecting the Immune Response		
Azathioprine Amber tablets; oral solution (see also sections 8.2.1; 10.1.3 & 13.5.3)	 	1st line use
Ciclosporin (oral and I.V. preparations) Amber capsules; infusion; oral solution (see also section 8.2.2)	  	
Mercaptopurine Amber tablets; oral suspension (see also section 8.1.3)	 	
Methotrexate (s/c and oral preparations) Amber tablets; injection; oral solution (see also section 10.1.3)	  	
MHRA Drug Safety Update (Aug-23): Methotrexate: advise patients to take precautions in the sun to avoid photosensitivity reactions MHRA Drug Safety Update (Sep-20): Methotrexate once-weekly: new measures to reduce risk of fatal overdose due to inadvertent daily instead of weekly dosing		
Ozanimod Red  Zeposia® capsules	     	RESTRICTED Gastro. Consultants in line with NICE TA828
Vedolizumab Red  infusion	     	RESTRICTED Gastro. Consultants in line with NICE TA342 & TA352

Cytokine Modulators		
Adalimumab  		RESTRICTED Gastro. Consultants for Crohn's Disease & Ulcerative colitis as per NICE
injection (see also sections 10.1.3, 11.4.2 & 13.5.3)      		
MHRA Drug Safety Update (Apr-14): TNF alpha inhibitors: risk of TB — screen all patients before starting treatment and monitor them closely		
Infliximab  		RESTRICTED Gastro. Consultants for Crohn's Disease & Ulcerative colitis as per NICE
infusion (see also sections 10.1.3 & 13.5.3)      		
MHRA Drug Safety Update (Apr-14): TNF alpha inhibitors: risk of TB — screen all patients before starting treatment and monitor them closely		
Filgotinib  		RESTRICTED Gastro. Consultants for Ulcerative colitis as per NICE
100mg; 200mg tablets (see also section 10.1.3)      		
MHRA Drug Safety Update (Apr-23): JAK inhibitors: new measures to reduce risks of major CV events, malignancy, VTE, serious infections & increased mortality		
Golimumab  		RESTRICTED Gastro. Consultants for Crohn's Disease & Ulcerative colitis as per NICE
injection (see also section 10.1.3)      		
MHRA Drug Safety Update (Apr-14): TNF alpha inhibitors: risk of TB — screen all patients before starting treatment and monitor them closely		
Risankizumab  		RESTRICTED Specialist use only in line with NICE TA888
75mg; 150mg injection      		
Tofacitinib  		RESTRICTED Consultants only in line with NICE
tablets (see also section 10.1.3)      		
MHRA Drug Safety Update (Apr-23): JAK inhibitors: new measures to reduce risks of major CV events, malignancy, VTE, serious infections & increased mortality		
MHRA Drug Safety Update (Oct-21): Tofacitinib (Xeljanz▼): new measures to minimise risk of major adverse cardiovascular events and malignancies		
MHRA Drug Safety Update (Mar-20): Tofacitinib (Xeljanz▼): new measures to minimise risk of VTE and of serious and fatal infections		
MHRA Drug Safety Update (May-19): Tofacitinib (Xeljanz▼): restriction of 10 mg twice-daily dose in patients at high risk of PE while safety review is ongoing		
Upadacitinib  		RESTRICTED Consultants only in line with NICE TA856 / TA905
MR tablet (see also section 10.1.3)      		
MHRA Drug Safety Update (Apr-23): JAK inhibitors: new measures to reduce risks of major CV events, malignancy, VTE, serious infections & increased mortality		
Ustekinumab  		RESTRICTED Gastro. Consultants as per NICE
injection (see also sections 10.1.3)      		
ICAM-1 Inhibitor		
Alicaforsen 		RESTRICTED Gastro. Consultants only - pouchitis
enema   		

1.6 Laxatives		GMMMG
1.6.1 Bulk-forming Laxatives		
Ispaghula husk		1st line use
3.5g sachets	 	
1.6.2 Stimulant Laxatives		
Docusate Sodium		1st line use
capsules; oral solution	 	
Senna		1st line use
tablets; oral solution	 	
MHRA Drug Safety Update (Aug-20): Stimulant laxatives (bisacodyl, senna and sennosides, sodium picosulfate) available OTC: new measures to support safe use		
Bisacodyl		
tablets; suppositories	 	
MHRA Drug Safety Update (Aug-20): Stimulant laxatives (bisacodyl, senna and sennosides, sodium picosulfate) available OTC: new measures to support safe use		
Glycerol		
suppositories	 	
Sodium Picosulfate		
oral solution	 	
MHRA Drug Safety Update (Aug-20): Stimulant laxatives (bisacodyl, senna and sennosides, sodium picosulfate) available OTC: new measures to support safe use		
Co-Danthramer		RESTRICTED Adults, Palliative Care only
oral suspension	 	
Co-Danthrusate		RESTRICTED Adults, Palliative Care only
oral suspension	 	
1.6.3 Faecal Softeners		
Arachis oil		
enema	 	
1.6.4 Osmotic Laxatives		
Lactulose		1st line use
oral solution	 	
Macrogols (Polyethylene glycols)		2nd / 3rd line use Rehab patients / paediatrics
sachets	  	
Phosphates (Rectal)		
128mL enema	 	
Sodium Citrate (Rectal)		
450mg micro-enema	 	
1.6.5 Bowel Cleansing Preparations		
NPSA RRR (Feb-09): Reducing risk of harm from oral bowel cleansing solutions		
Sodium Picosulfate with Magnesium Citrate		1st line use
Picolax® oral powder	 	
Macrogols (Klean-Prep® & Moviprep®) oral powder		
oral powder	 	
1.6.6 Peripheral opioid-receptor antagonists		
Methylnaltrexone Bromide		RESTRICTED Adults, Palliative Care only
injection	 	
Naldemedine		RESTRICTED Adults only in line with TA651
 200 microgram tablets	   	
Naloxegol		RESTRICTED Adults only in line with TA345
 12.5mg; 25mg tablets	   	

1.6.7 Other drugs used in constipation**Prucalopride**

Green

1mg; 2mg tablets

NICE MMC BNF emc

**RESTRICTED - Adult women, Gastro.
Consultants only****Linaclootide**

Green

290 micrograms capsules

MMC BNF emc

**RESTRICTED - 3rd line use Adults
Gastro. Consultants only**

1.7 Local preparations for anal & rectal disorders		GMMMG
1.7.2 Compound Haemorrhoidal Preparations with Corticosteroids		
Anusol®		
ointment	 	
Proctosedyl®		
ointment	 	
Scheriproct®		
ointment; suppositories	 	
1.7.4 Management of anal fissures		
Glyceryl Trinitrate		1st line for anal fissure
<i>Rectogesic</i> ® 0.4% ointment	  	
Diltiazem Hydrochloride		
 2% cream; ointment	 	

1.9 Drugs affecting intestinal secretions		GMMMG
1.9.1 Drugs affecting biliary composition & flow		
Ursodeoxycholic acid 150mg tablets 	  	1st line use
Obeticholic acid  Ocaliva® 5mg; 10mg tablets	     	RESTRICTED Hepatology Consultants only 2 nd line per TA443
1.9.2 Bile acid sequestrants		
Colestyramine 	 	1st line use
Colesevelam Hydrochloride  625mg tablets (see also section 2.12)	  	RESTRICTED adults. Gastro & Lipid Clinic Consultants only
1.9.4 Pancreatin		
Pancreatin 	 	NOT STOCKED

1.10 Miscellaneous preparations



Glucarpidase



Voraxaze® 1,000 unit injection ([see also sections 8.4, 10.4 & 13.14](#))



MMC



RESTRICTED
2nd line rescue therapy

Section 2: Cardiovascular System

Supported by the
formulary (click here)



2.1 Positive inotropic drugs

- 2.1.1 Cardiac Glycosides
- 2.1.2 Phosphodiesterase Inhibitors

2.2 Diuretics

- 2.2.1 Thiazides & Related Diuretics
- 2.2.2 Loop Diuretics
- 2.2.3 Potassium-sparing Diuretics & Aldosterone Antagonists
- 2.2.4 Potassium-sparing Diuretics with other Diuretics
- 2.2.5 Osmotic Diuretics

2.3 Anti-arrhythmic drugs

- 2.3.2 Drugs for Arrhythmias

2.4 Beta-adrenoceptor blocking drugs

2.5 Hypertension & heart failure

- 2.5.1 Vasodilator Antihypertensive Drugs
- 2.5.2 Centrally Acting Antihypertensive Drugs
- 2.5.4 Alpha-Adrenoceptor Blocking Drugs
- 2.5.5 Drugs Affecting the Renin-Angiotensin System
 - 2.5.5.1 Angiotensin-Converting Enzyme (ACE) Inhibitors
 - 2.5.5.2 Angiotensin-II Receptor Antagonists
 - 2.5.5.3 Renin Inhibitors
 - 2.5.5.4 Heart Failure

2.6 Nitrates, calcium-channel blockers & other antianginals

- 2.6.1 Nitrates
- 2.6.2 Calcium-channel Blockers
- 2.6.3 Other Antianginal Drugs
- 2.6.4 Peripheral Vasodilators & Related Drugs

2.7 Sympathomimetics

- 2.7.1 Inotropic Sympathomimetics
- 2.7.2 Vasoconstrictor Sympathomimetics
- 2.7.3 Cardiopulmonary Resuscitation

2.8 Anticoagulants & protamine

- 2.8.1 Parenteral Anticoagulants
- 2.8.2 Oral Anticoagulants
- 2.8.3 Protamine Sulfate

2.9 Antiplatelet drugs

2.10 Stable angina, acute coronary syndromes & fibrinolysis

- 2.10.2 Fibrinolytic Drugs

2.11 Antifibrinolytic drugs & haemostatics

2.12 Lipid-regulating drugs

2.13 Local sclerosants

2.14 Miscellaneous preparations

Trust Guidelines

Adult medicines and prescribing guidelines
 Paediatric medicines and prescribing guidelines
 Neonatal guidelines (link to Staffnet site)
[Non-formulary Conversion Table](#)

NICE Guidance

Prophylaxis against infective endocarditis (CG64)
 Familial hypercholesterolaemia (CG71)
 Chest pain of recent onset (CG95)
 Stable angina (CG126)
 Lipid modification: CV risk assessment and the modification of blood lipids for the 1ry & 2ry prevention of CVD (CG181)
 Venous thromboembolism in over 16s: reducing the risk of hospital-acquired deep vein thrombosis or pulmonary embolism (NG89)
 Chronic heart failure in adults: diagnosis and management (NG106)
 Hypertension in pregnancy: diagnosis and management (NG133)
 Hypertension in adults: diagnosis and management (NG136)
 Stroke and transient ischaemic attack in over 16s: diagnosis and initial management (NG128)
 Acute coronary syndromes (NG185)
 Atrial fibrillation: diagnosis and management (NG196)
 Volanesorsen for treating familial chylomicronaemia syndrome (HST13)
 Acute coronary syndromes - glycoprotein IIb/IIIa inhibitors (review) (TA47)
 Myocardial infarction - thrombolysis (TA52)
 Guidance on the use of coronary artery stents (TA71) (partially updated by TA152)
 Myocardial perfusion scintigraphy for the diagnosis and management of angina & MI (TA73) (partially updated by TA95 & TA126)
 Hypercholesterolaemia - Ezetimibe (TA132)
 Coronary artery disease - drug eluting stents (TA152)
 Venous thromboembolism - dabigatran (TA157)
 Rivaroxaban for the prevention of VTE (TA170)
 Atrial Fibrillation - dronedarone (TA197)
 Vascular disease - clopidogrel and dipyridamole (TA210)
 Peripheral arterial disease - cilostazol, naftidrofuryl oxalate, pentoxifylline & inositol nicotinate (TA223)
 Acute coronary syndromes - ticagrelor (TA236)
 Venous thromboembolism - apixaban (hip and knee surgery) (TA245)
 Atrial fibrillation - dabigatran etexilate (TA249)
 Atrial fibrillation (stroke prevention) - rivaroxaban (TA256)
 Venous thromboembolism (treatment & long term 2ry prevention) - rivaroxaban (TA261)
 Stroke (acute, ischaemic) - alteplase (TA264)
 Chronic heart failure - ivabradine (TA267)
 Stroke & systemic embolism (prevention, non-valvular atrial fibrillation) - apixaban (TA275)
 Pulmonary embolism and recurrent venous thromboembolism - rivaroxaban (TA287)
 Prasugrel with PCI for treating ACS (review of TA182) (TA317)
 Dabigatran etexilate for the treatment and 2ry prevention of DVT and/or PE (TA327)
 Rivaroxaban for preventing adverse outcomes after acute management of acute coronary syndrome (TA335)
 Apixaban for the treatment and 2ry prevention of DVT and/or PE (TA341)
 Edoxaban for treating and for preventing deep vein thrombosis and pulmonary embolism (TA354)
 Edoxaban for preventing stroke and systemic embolism in people with non valvular atrial fibrillation (TA355)
 Ezetimibe for treating primary heterozygous-familial and non-familial hypercholesterolaemia (TA385)
 Sacubitril valsartan for treating symptomatic chronic heart failure with reduced ejection fraction (TA388)
 Alirocumab for treating primary hypercholesterolaemia and mixed dyslipidaemia (TA393)
 Evolocumab for treating primary hypercholesterolaemia and mixed dyslipidaemia (TA394)
 Ticagrelor for preventing atherothrombotic events after myocardial infarction (TA420)
 Rivaroxaban for preventing atherothrombotic events in people with coronary or peripheral artery disease (TA607)
 Dapagliflozin for treating chronic heart failure with reduced ejection fraction (TA679)
 Bempedoic acid with ezetimibe for treating primary hypercholesterolaemia or mixed dyslipidaemia (TA694)
 Andexanet alfa for reversing anticoagulation from apixaban or rivaroxaban (TA697)
 Inclisiran for treating primary hypercholesterolaemia or mixed dyslipidaemia (TA733)
 Mexiletine for treating the symptoms of myotonia in non-dystrophic myotonic disorders (TA748)
 Empagliflozin for treating chronic heart failure with reduced ejection fraction (TA773)
 Icosapent ethyl with statin therapy for reducing the risk of cardiovascular events in people with raised triglycerides (TA805)
 Finerenone for treating chronic kidney disease in type 2 diabetes (TA877)
 Dapagliflozin for treating chronic heart failure with preserved or mildly reduced ejection fraction (TA902)

GMMM Formulary

Formulary Homepage
 Chapter 2: Cardiovascular system (Complete)
 GMMM Adult [Red](#)/[Amber](#)/[Green](#); DNP and [Grey](#) Drug List
 GMMM Paediatric [Red](#)/[Amber](#)/[Green](#) Drug List

2.1 Positive inotropic drugs		GMMMG
2.1.1 Cardiac Glycosides		
Digoxin		1st line use
tablets; elixir; injection	 	
Digoxin-specific antibody		
 	 	
infusion		
2.1.2 Phosphodiesterase Inhibitors		
Enoximone		
<i>Perfan</i> ® 5mg/1mL injection	 	
Milrinone		1st line use Paediatrics
<i>Primacor</i> ® 10mg/10mL injection	  	
Levosimendan		RESTRICTED adults. Cardiology ITU Consultant only
<i>Simdax</i> ® 12.5mg/5mL Injection	  	

2.2 Diuretics		GMMMG
2.2.1 Thiazides & Related Diuretics		
Bendroflumethiazide		1st line use
tablets	 	
Chlortalidone		
tablets	 	
Metolazone		2nd line use with loop diuretic
 tablets	  	
MHRA Drug Safety Update (Jan-23): Xaquia (metolazone) 5mg tablets: exercise caution when switching patients between metolazone preparations		
2.2.2 Loop Diuretics		
Furosemide		1st line use
tablets; liquid; injection	 	
Bumetanide		2nd line use
tablets; oral solution	 	
2.2.3 Potassium-sparing Diuretics & Aldosterone Antagonists		
Amiloride hydrochloride		1st line use
tablets; oral solution	 	
Spirolactone		1st line use
tablets	 	
MHRA Drug Safety Update (Feb-16): Spirolactone and renin-angiotensin system drugs in heart failure: risk of potentially fatal hyperkalaemia		
Eplerenone		RESTRICTED adults. Cardiology Consultant only
 tablets	  	
Finerenone		RESTRICTED adults. Diabetes / Renal Consultant only
 <i>Kerendia</i> ® tablets	   	
2.2.4 Potassium-sparing Diuretics with other Diuretics		
Co-amilofruse		1st line use
tablets	 	
2.2.5 Osmotic Diuretics		
Mannitol		
infusion	 	

2.3 Anti-arrhythmic drugs		GMMMG
2.3.2 Drugs for Arrhythmias		
Adenosine		
injection	 	
Amiodarone Hydrochloride		
Amber Red		
tablets; injection	 	
MHRA Drug Safety Update (Mar-22): Amiodarone (Cordarone X): reminder of risks of treatment and need for patient monitoring and supervision		
Disopyramide		
capsules; tablets	 	
Flecainide Acetate		
Red Paeds - until stabilised then Green		
tablets; injection	 	
Lidocaine (Lignocaine) Hydrochloride		
injection	 	
Mexiletine		
Red		RESTRICTED Neurology only
<i>NaMuscla</i> ® 167mg capsules	   	
Mexiletine Hydrochloride		
U		RESTRICTED Cardiology / Neurology only
<i>Mexitil</i> ® 50mg; 100mg; 200mg capsules	  	
Propafenone Hydrochloride		
tablets	 	
Dronedarone		
Green		RESTRICTED adults. Cardiology Consultant only, in line with TA197
tablets	   	
MHRA Drug Safety Update (Oct-11): Dronedarone (Multaq ▼): cardiovascular, hepatic and pulmonary adverse events – new restrictions and monitoring requirements		

2.4 Beta-adrenoceptor blocking drugs		GMMMG
		NICE NG106
		NICE NG136
		NICE NG196
2.4 Beta-Adrenoceptor Blocking Drugs		
Atenolol	 tablets; liquid; injection	
Bisoprolol Fumarate	  tablets	RESTRICTED adults. Cardiology Consultant only
Carvedilol	  tablets	RESTRICTED adults. Cardiology Consultant only ALSO 2ND LINE FOR VARICEAL BLEED
Esmolol Hydrochloride	 injection	RESTRICTED .I.V. only
Etilefrine Hydrochloride	  tablets	RESTRICTED Haematology Consultants - SCD
Labetalol Hydrochloride	 tablets; injection	RESTRICTED oral preps in pregnancy
Metoprolol Tartrate	 tablets; injection	
Nadolol	  tablets	RESTRICTED paed. ventricular arrhythmias in long QT syndrome
Nebivolol	 tablets	
Propranolol Hydrochloride	 tablets; capsules; oral solution; injection	RESTRICTED not in Cardiology
Sotalol Hydrochloride	 tablets	

2.5 Hypertension & heart failure		GMMMG
		NICE NG106
		NICE NG136
		NICE NG196
2.5.1 Vasodilator Antihypertensive Drugs		NHSE PAH
Hydralazine Hydrochloride		1st line use
tablets; injection	 	
Minoxidil		
tablets	 	
Ambrisentan		RESTRICTED PAH in line with NHSE
 	   	
tablets		
Bosentan		RESTRICTED PAH in line with NHSE
 	   	
tablets		
Sildenafil		RESTRICTED PAH in line with NHSE
 	  	
Revatio® tablets; injection (see also section 7.4.5)		
MHRA Drug Safety Update (Nov-18): Sildenafil (Revatio and Viagra): reports of PPHN following in-utero exposure in a clinical trial on intrauterine growth restriction		
Macitentan		RESTRICTED PAH in line with NHSE
 	   	
Opsumit® tablets		
Tadalafil		RESTRICTED PAH in line with NHSE
 	   	
Adcirca® tablets (see also section 7.4.5)		
2.5.2 Centrally Acting Antihypertensive Drugs		
Clonidine Hydrochloride		
tablets; oral solution; injection; patches	 	
Methyldopa		
tablets	 	
Moxonidine		RESTRICTED 3rd line use after other treatments fail
	  	
tablets		
2.5.4 Alpha-Adrenoceptor Blocking Drugs		
Doxazosin		1st line use
	 	
1mg; 2mg & 4mg tablets		
Phenoxybenzamine Hydrochloride		RESTRICTED adults. Specialist initiation only
10mg capsules	 	
Phentolamine Mesilate		RESTRICTED adults. Specialist use, theatres only
injection	 	
2.5.5 Drugs Affecting the Renin-Angiotensin System		
2.5.5.1 Angiotensin-Converting Enzyme (ACE) Inhibitors		
MHRA Drug Safety Update (Feb-16): Spironolactone and renin-angiotensin system drugs in heart failure: risk of potentially fatal hyperkalaemia		
Ramipril		
1.25mg; 2.5mg; 5mg & 10mg capsules	 	
Captopril		RESTRICTED Paediatrics only
12.5mg; 25mg & 50mg tablets	 	
Lisinopril		1st line use
2.5mg; 5mg; 10mg & 20mg tablets	  	GMMMG
Perindopril		
	 	
2mg; 4mg & 8mg tablets		

2.5.5.2 Angiotensin-II Receptor Antagonists		
MHRA Drug Safety Update (Feb-16): Spironolactone and renin-angiotensin system drugs in heart failure: risk of potentially fatal hyperkalaemia		
Candesartan Cilexetil Green 2mg; 4mg; 8mg; 16mg & 32mg tablets   	1st line use hypertension 	
Losartan Potassium 12.5mg; 25mg; 50mg & 100mg tablets   	2nd line use hypertension	
Irbesartan 75mg; 150mg & 300mg tablets   	2nd line use hypertension	
Valsartan 40mg; 80mg & 160mg capsules   	2nd line use hypertension	
Sacubitril / Valsartan Green 24mg / 26mg; 49mg / 51mg & 97mg / 103mg tablets    	RESTRICTED use in line with NICE TA388	
2.5.5.3 Renin inhibitors		
Aliskiren DNP 150mg; 300mg tablets   	RESTRICTED adults. Specialist initiation only	
MHRA Drug Safety Update (Mar-12): Aliskiren (Rasilez ▼): risk of cardiovascular and renal adverse reactions		
2.5.5.4 Heart Failure		
Dapagliflozin Green Forxiga ® tablets    	RESTRICTED adults. Specialist initiation in line with TA679	
Empagliflozin Green Jardiance ® tablets    	RESTRICTED adults. Specialist initiation in line with TA773	

2.6 Nitrates, calcium-channel blockers & other antianginals		GMMMG
2.6.1 Nitrates		
Glyceryl Trinitrate		
S/L tablets; S/L spray; patches; Injection; ointment	 	
Isosorbide Mononitrate		
tablets; capsules	 	
2.6.2 Calcium-channel Blockers		
Amlodipine		1st choice dihydropyridine
tablets; oral solution	 	GMMMG
Diltiazem		1st choice non-dihydropyridine
tablets; capsules; ointment	 	PRESCRIBE BY BRAND NAME
Nifedipine		2nd choice dihydropyridine
tablets; capsules; oral drops	 	PRESCRIBE BY BRAND NAME
Verapamil Hydrochloride		2nd choice non-dihydropyridine
tablets; injection; oral solution	 	
Nimodipine		RESTRICTED subarachnoid haemorrhage / I.V. then oral
tablets; infusion	 	
2.6.3 Other Antianginal Drugs		
Nicorandil		1st line use
tablets	 	
MHRA Drug Safety Update (Jan-16): Nicorandil (Ikorel): now 2nd-line treatment for angina - risk of ulcer complications		
Ivabradine		RESTRICTED adults 2nd line. Cardiology Consultant only
Green tablets	   	
MHRA Drug Safety Update (Dec-14): Ivabradine (Procoralan) in the symptomatic treatment of angina: risk of cardiac side effects		
Ranolazine		RESTRICTED adults 3rd line angina patients not suitable for surgery
Green M/R tablets	  	
2.6.4 Peripheral Vasodilators & Related Drugs		
Naftidrofuryl Oxalate		
capsules	  	
Defibrotide		RESTRICTED Specialist use only in line with NHSE
Red  infusion	    	

2.7 Sympathomimetics		GMMMG
2.7.1 Inotropic Sympathomimetics		
Dobutamine		RESTRICTED / V. Specialist use only
infusion	 	
Dopamine Hydrochloride		RESTRICTED / V. Specialist use only
infusion	 	
Dopexamine		RESTRICTED / V. Specialist use only
infusion	 	
Isoprenaline		RESTRICTED / V. Specialist use only
injection	 	
2.7.2 Vasoconstrictor Sympathomimetics		
Ephedrine Hydrochloride		RESTRICTED / V. Specialist use only
injection	 	
Metaraminol		
 injection	 	
Midodrine		Specialist use Cardiology / Healthcare of the elderly
 tablets	  	
Noradrenaline acid tartrate		RESTRICTED / V. Specialist use only
infusion	 	
Phenylephrine Hydrochloride		RESTRICTED / V. Specialist use only
injection	 	
2.7.3 Cardiopulmonary Resuscitation		
Adrenaline / Epinephrine		
injection	 	

2.8 Anticoagulants & protamine		GMMMG
2.8.1 Parenteral Anticoagulants		NICE NG89
ACD-A Anticoagulant Citrate Dextrose		RESTRICTED Specialist use only CRRT
solution	MMC BNF emc	
Dalteparin Sodium		1 st line LMWH
injection	MMC BNF emc	
Epoprostenol		RESTRICTED / I.V. Specialist use only
infusion	PbR X BNF emc	
MHRA Drug Safety Update (Dec-14): Veletri (epoprostenol) powder for solution for infusion: incompatibilities with some models of administration devices		
Heparin		
injection; infusion	BNF emc	
Bivalirudin		RESTRICTED adults. Cardiac Catheter Lab only.
infusion	NICE MMC BNF emc	
Fondaparinux Sodium		RESTRICTED adults. Haematology Consultants only.
injection	MMC BNF emc	
Tinzaparin Sodium		RESTRICTED Obs & Gynae; ACS & VTE in Renal impairment only. Paeds: haemodialysis
injection	MMC BNF emc	
Enoxaparin Sodium		RESTRICTED ACS & VTE in Renal impairment only.
injection	MMC BNF emc	
Argatroban monohydrate		RESTRICTED adults. Treatment of HIT
infusion	MMC BNF emc	

2.8.2 Oral Anticoagulants		
Acenocoumarol		RESTRICTED warfarin intolerant patients only.
tablets	 	
Phenindione		
tablets	 	
Warfarin Sodium		
tablets	 	
<p>MHRA Drug Safety Update (Oct-20): Warfarin and other anticoagulants: monitoring of patients during the COVID-19 pandemic MHRA Drug Safety Update (Jan-17): Direct-acting antivirals to treat chronic hepatitis C: risk of interaction with vitamin K antagonists and changes in INR MHRA Drug Safety Update (Jul-16): Warfarin: reports of calciphylaxis</p>		
Apixaban		RESTRICTED in line with NICE
		
tablets	    	
<p>MHRA Drug Safety Update (May-23): Direct-acting oral anticoagulants (DOACs): paediatric formulations; reminder of dose adjustments in patients with renal impairment</p>		
Dabigatran Etxilate		RESTRICTED in line with NICE
		
capsules	    	
<p>MHRA Drug Safety Update (May-23): Direct-acting oral anticoagulants (DOACs): paediatric formulations; reminder of dose adjustments in patients with renal impairment MHRA Drug Safety Update (Jul-12): Dabigatran (Pradaxa ▼): risk of serious haemorrhage</p>		
Edoxaban		RESTRICTED in line with NICE
		
tablets	    	
<p>MHRA Drug Safety Update (May-23): Direct-acting oral anticoagulants (DOACs): paediatric formulations; reminder of dose adjustments in patients with renal impairment</p>		
Rivaroxaban		RESTRICTED in line with NICE
		
tablets	    	
<p>MHRA Drug Safety Update (May-23): Direct-acting oral anticoagulants (DOACs): paediatric formulations; reminder of dose adjustments in patients with renal impairment MHRA Drug Safety Update (Jul-19): Rivaroxaban (Xarelto ▼): reminder that 15 mg and 20 mg tablets should be taken with food MHRA Drug Safety Update (Oct-18): Rivaroxaban (Xarelto ▼) after TAVR: increase in all-cause mortality, thromboembolic and bleeding events in a clinical trial</p>		
Antidotes		
Andexanet Alfa		RESTRICTED in line with NICE
 		
Ondexxya® infusion	   	
Idarucizumab		RESTRICTED reversal of dabigatran in emergency surgery
 		
Praxbind® infusion	  	
2.8.3 Protamine Sulfate		
Protamine Sulfate		
injection	 	

2.9 Antiplatelet drugs		GMMMG
		NICE NG185
<p>Aspirin</p> <p>tablets (dispersible & E/C); suppositories</p>	 	
<p>Clopidogrel</p> <p>tablets</p> <p>MHRA Drug Safety Update (Dec-13): Clopidogrel: risk of acquired haemophilia MHRA Drug Safety Update (Apr-10): Clopidogrel and proton pump inhibitors: interaction—updated advice</p>	    	<p>For ACS patients; stroke patients intolerant of aspirin; high-risk patients who've stroked on aspirin</p>
<p>Ticagrelor</p> <p>Green</p> <p>tablets; orodispersible tablets</p>	   	<p>In combination with aspirin for primary PCI in ACS patients & in line with NICE TA420</p>
<p>Prasugrel</p> <p>Green</p> <p>tablets</p> <p>MHRA Drug Safety Update (Jan-14): Prasugrel (Efient): increased risk of bleeding MHRA Drug Safety Update (May-11): Prasugrel (Efient ▼): rare but serious hypersensitivity reactions</p>	    	<p>RESTRICTED adults. Cardiac Catheter Lab as per NICE</p>
<p>Dipyridamole</p> <p>M/R capsules; oral suspension; tablets; injection</p>	   	<p>2^{RY} prevention of stroke in patients already on aspirin</p>
<p>Tirofiban</p> <p>infusion</p>	   	<p>RESTRICTED adults. Cardiac Catheter Lab only (1st line)</p>
<p>Eptifibatide</p> <p>injection; infusion</p>	   	<p>RESTRICTED adult patients admitted on this or tirofiban</p>

2.10 Stable angina, ACS & fibrinolysis		GMMMG
<ul style="list-style-type: none"> Stable angina (BNF treatment summary) Acute coronary syndromes (BNF treatment summary) Fibrinolytic Drugs (BNF treatment summary) 		
2.10.2 Fibrinolytic Drugs		NICE CG126 NICE NG128
Tenecteplase Red injection	   	
Streptokinase Red infusion	  	
Urokinase Red injection	 	
Alteplase Red injection; infusion	   	RESTRICTED

2.11 Antifibrinolytic drugs & haemostatics		GMMMG
2.11 Antifibrinolytic Drugs & Haemostatics		
Etamsylate		
tablets	 	
Tranexamic acid		
injection; tablets	 	
Aprotinin		RESTRICTED
infusion	 	
Aminocaproic acid		RESTRICTED
sachets	  	
Emicizumab		RESTRICTED
 Hemlibra® injection	   	Haematology as per NHSE
Vonicog alfa		RESTRICTED
Veyvondi® injection	  	Haematology as per NHSE

2.12 Lipid-regulating drugs		GMMMG
Statins		
Simvastatin		
tablets	PbR X NICE BNF emc	
MHRA Drug Safety Update (Sep-23): Statins: very infrequent reports of myasthenia gravis		
Atorvastatin		1 st line use
DNP		
tablets	PbR X NICE BNF emc	
MHRA Drug Safety Update (Sep-23): Statins: very infrequent reports of myasthenia gravis		
Rosuvastatin		RESTRICTED Not stocked
tablets	PbR X NICE MMC BNF emc	
MHRA Drug Safety Update (Sep-23): Statins: very infrequent reports of myasthenia gravis		
Pravastatin Sodium		RESTRICTED MCSH for cases with potential drug interactions
tablets	PbR X NICE BNF emc	
MHRA Drug Safety Update (Sep-23): Statins: very infrequent reports of myasthenia gravis		
Bile Acid Sequestrants		
Colestyramine		
Green		
sachets (see also section 1.9.2)	BNF emc	
Colesevelam Hydrochloride		RESTRICTED adults. Gastro & Lipid Clinic Consultants only
DNP		
tablets (see also section 1.9.2)	MMC BNF emc	
Fibrates		
Bezafibrate		
M/R tablets; tablets	BNF emc	1 st line use
Fenofibrate		
67mg / 200mg / 267mg capsules; 160mg tablets	MMC BNF emc	2 nd line use
Omega-3 fatty acid compounds		
Omega-3-acid ethyl esters		
Green		2 ^{RY} prevention post MI / Prevention of preterm birth
capsules	MMC BNF emc	
Ezetimibe		
Ezetimibe		
10mg tablets	NICE MMC BNF emc	RESTRICTED adults. Lipid Clinic Consultants only
Lipid-regulating drugs		
Alirocumab		
Red		RESTRICTED adults. Lipid Clinic Consultants in line with TA393
Praluent® injection	PbR X NICE MMC BNF emc	
Bempedoic acid (see also Nustendi®)		
Green		RESTRICTED adults. Consultants in line with TA694
Nilemdo® tablets	PbR X NICE MMC BNF emc	
Bempedoic acid (see also Nilemdo®)		
Green		RESTRICTED adults. Consultants in line with TA694
Nustendi® tablets	PbR X NICE MMC BNF emc	
Evolocumab		
Red		RESTRICTED. Lipid Clinic Consultants for HoFH / & NICE TA394
Repatha® injection	PbR X NICE MMC BNF emc blueiq	
Icosapent Ethyl		
Green		RESTRICTED adults in line with NICE TA805
Vazkepa® capsules	PbR X NICE MMC BNF emc	
Inclisiran		
Green		RESTRICTED adults. Lipid Clinic Consultants in line with TA733 for Primary Care Referral
Leqvio® injection	PbR X MMC BNF emc	
Lomitapide		
Red	££	RESTRICTED adults. Lipid Clinic Consultants in line with NHSE 170059P
Lojuxta® capsules	PbR X MMC BNF emc blueiq	
Volanesorsen		
Red	££	RESTRICTED adults. Lipid Clinic Consultants in line with HST13
Waylivra® injection	PbR X NICE MMC BNF emc blueiq	

2.13 Local sclerosants		GMMMG
Local Sclerosants		
Ethanolamine Oleate		
injection	  	
Sodium Tetradecyl Sulfate		
injection	  	

2.14 Miscellaneous preparations		GMMMG
<p>Ajmaline</p> <p> U</p> <p><i>Gilurytma</i>® 50mg/10mL injection</p> <p style="text-align: right;"> </p>	<p>RESTRICTED adults. Cardiology Consultant only</p>	
<p>Dapagliflozin</p> <p> Green</p> <p>tablets</p> <p style="text-align: right;">    </p> <p style="background-color: #ffffcc; padding: 2px;">MHRA Drug Safety Update (Dec-21): Dapagliflozin (Forxiga): no longer authorised for treatment of type 1 diabetes mellitus</p>	<p>RESTRICTED in line with NICE</p>	
<p>Regadenoson</p> <p> U</p> <p><i>Rapiscan</i>® 400micrograms/5mL injection</p> <p style="text-align: right;">  </p>	<p>RESTRICTED adults. Myocardial perfusion scans</p>	

Section 3: Respiratory System

Supported by the
formulary (click here)



3.1 Bronchodilators

- 3.1.1 Adrenoceptor Agonists
- 3.1.2 Antimuscarinic Bronchodilators
- 3.1.3 Theophylline
- 3.1.4 Compound Bronchodilator Preparations
- 3.1.5 Peak Flow Meters, Inhaler Devices & Nebulisers
 - Inhaler Devices
 - Nebuliser Diluent

3.2 Corticosteroids

- Compound preparations

3.3 Cromoglicate & related therapy & leukotriene receptor antagonists

- 3.3.1 Cromoglicate & Related Therapy
- 3.3.2 Leukotriene Receptor Antagonists
- 3.3.3 Phosphodiesterase type-4 inhibitors

3.4 Antihistamines, hyposensitisation & allergic emergencies

- 3.4.1 Antihistamines
- 3.4.2 Allergen Immunotherapy
- 3.4.3 Allergic Emergencies

3.5 Respiratory stimulants & pulmonary surfactants

- 3.5.1 Respiratory Stimulants
- 3.5.2 Pulmonary Surfactants

3.6 Oxygen (refer to oxygen guidelines)

3.7 Mucolytics

3.8 Aromatic inhalations

3.9 Cough preparations

- 3.9.1 Cough Suppressants
 - Cough Suppressants (Palliative Care ONLY)
- 3.9.2 Demulcent & expectorant cough preparations

3.10 Systemic Nasal Decongestants

3.11 Antifibrotics

Trust Guidelines

Adult medicines and prescribing guidelines
Paediatric medicines and prescribing guidelines
Neonatal guidelines (link to Staffnet site)
[Non-formulary Conversion Table](#)

NICE Guidance

Idiopathic pulmonary fibrosis (CG163)
Chronic obstructive pulmonary disease in over 16s: diagnosis and management (NG115)
Inhaler devices for children under 5 (TA10)
Asthma (older children) - inhaler devices (TA38)
Asthma (in children) - corticosteroids (TA131)
Asthma (in adults) - corticosteroids (TA138)
Venom anaphylaxis - immunotherapy pharmlagen (TA246)
Mannitol dry powder for inhalation for treating cystic fibrosis (TA266)
Asthma (severe, persistent, patients aged 6+, adults) - omalizumab (review of TA133, TA201) (TA278)
Omalizumab for previously treated chronic spontaneous urticaria (TA339)
Roflumilast for treating chronic obstructive pulmonary disease (replaces TA244) (TA461)
Reslizumab for treating severe eosinophilic asthma (TA479)
Pirfenidone for treating idiopathic pulmonary fibrosis (replaces TA282) (TA504)
Benralizumab for treating severe eosinophilic asthma (TA565)
Lanadelumab for preventing recurrent attacks of hereditary angioedema (TA606)
Mepolizumab for treating severe eosinophilic asthma (replacing TA431) (TA671)
Berotralstat for preventing recurrent attacks of hereditary angioedema (TA738)
Dupilumab for treating severe asthma with type 2 inflammation (TA751)
Palforzia for treating peanut allergy in children and young people (TA769)
Tezepelumab for treating severe asthma (TA880)

GMMMG Formulary

Formulary Homepage
Chapter 3: Respiratory system (Complete)
GMMMG Adult [Red/Amber/Green](#); DNP and Grey Drug List
GMMMG Paediatric [Red/Amber/Green](#) Drug List

3.1 Bronchodilators		GMMMG
Asthma		
Methacholine Chloride  Provocholine® nebuliser solution	MMC emc	RESTRICTED detection test for bronchial airway hyperreactivity
3.1.1 Adrenoceptor agonists		GMMMG GMMMG GMMMG
3.1.1.1 Selective beta₂ agonists		
Salbutamol  injection	MMC  emc	
Terbutaline Sulfate  injection	 emc	
Salmeterol	 emc	
Formoterol Fumarate	MMC  emc	Asthma BTS step 3 add-on therapy
3.1.1.2 Other Adrenoceptor Agonists		
Ephedrine Hydrochloride	 emc	
3.1.2 Antimuscarinic Bronchodilators		GMMMG GMMMG GMMMG
Ipratropium Bromide	 emc	1st line use
Tiotropium	MMC  emc	2nd line use COPD maintenance
MHRA Drug Safety Update (Feb-15): Tiotropium delivered via Respimat compared with Handihaler: no significant difference in mortality in TIOSPIR trial		
Aclidinium Bromide Eklira Genuair®	MMC  emc	2nd line use COPD maintenance
Glycopyrronium Bromide Seebri Breezhaler®	MMC  emc	2nd line use COPD maintenance
Umeclidinium Bromide Incruse Ellipta®	MMC  emc	2nd line use COPD maintenance
Compound Preparations		
Aclidinium Bromide / Formoterol Fumarate Dihydrate Duaklir Genuair®	MMC  emc	3rd line use COPD maintenance
3.1.3 Theophylline		
Theophylline M/R tablets; M/R capsules	 emc	1st line use PRESCRIBE BY BRAND NAME
Aminophylline  injection M/R tablets; injection	 emc	PRESCRIBE BY BRAND NAME

3.1.4 Compound Bronchodilator Preparations		GMMMG
Ipratropium Bromide / Salbutamol		
<i>Combivent®</i>	 	
Glycopyrronium Bromide / Formoterol Fumarate		
<i>Bevespi Aerosphere®</i>	MMC  	3rd line use COPD maintenance
Glycopyrronium Bromide / Indacaterol Maleate		
<i>Ultibro®</i>	MMC  	3rd line use COPD maintenance
Tiotropium Bromide Monohydrate / Olodaterol Hydrochloride		
<i>Spolto Respimat®</i>	MMC  	3rd line use COPD maintenance
Umeclidinium Bromide / Vilanterol Trifenatate		
<i>Anoro Ellipta®</i>	MMC  	3rd line use COPD maintenance
3.1.5 Peak Flow Meters, Inhaler Devices & Nebulisers		GMMMG GMMMG GMMMG
Inhaler Devices		
Volumatic® (spacer inhaler)		
	 	
Aerochamber® Plus (spacer device)		
	 	
Able Spacer® (spacer device)		
	 MMC 	
Nebuliser Diluent		
Sodium Chloride		
0.9% nebuliser diluent	 	

3.2 Corticosteroids		GMMMG
Corticosteroids		GMMMG GMMMG GMMMG
MHRA Drug Safety Update (Jul-18): Pressurised metered dose inhalers (pMDI): risk of airway obstruction from aspiration of loose objects		
MHRA Drug Safety Update (Aug-17): Corticosteroids: rare risk of central serous chorioretinopathy with local as well as systemic administration		
Beclometasone Dipropionate		
MDI (Clenil Modulite® 50, 100, 200, 250)	NICE MMC BNF emc	
Beclometasone Dipropionate CFC-free		
MDI (Qvar Easi-Breathe® or Qvar Autohaler® 50, 100)	NICE MMC BNF emc	PRESCRIBE BY BRAND NAME
Budesonide		
DPI (Easyhaler®; Pulmicort® Turbohaler® 100, 200, 400) 500micrograms/2mL & 1mg/2mL nebuliser liquid	NICE MMC BNF emc	
Fluticasone Propionate		
MDI (FlixotideEvohaler®) 50, 125, 250; DPI (FlixotideAccuhaler® 50,100, 250, 500)	BNF emc	
Compound preparations		
Budesonide / Formoterol fumarate		
DPI (Fobumix Easyhaler® 80/4.5, 160/4.5, 320/9); DPI (Symbicort Turbohaler® 100/6, 200/6, 400/12); DPI (Duoresp Spiromax® 160/4.5, 320/9)	NICE MMC BNF emc	Asthma BTS step 3 management GMMMG GMMMG
Beclometasone Dipropionate / Formoterol fumarate		
MDI (Fostair®100/6, 200/6); DPI (Fostair NEXThaler® 100/6, 200/6)	MMC BNF emc	Asthma BTS step 3 management
Fluticasone Furoate / Vilanterol Trifenatate		
DPI (Relvar Ellipta® 92/22 asthma or COPD; 184/22 asthma)	MMC BNF emc	Asthma BTS step 3 management
Fluticasone Propionate / Salmeterol		
MDI (Sirdupla® 125, 250)	MMC BNF emc	Asthma BTS step 3 management
Fluticasone Propionate / Salmeterol		
MDI (SeretideEvohaler® 50, 125, 250)	NICE MMC BNF emc	Asthma BTS step 3 management
Fluticasone Propionate / Formoterol Fumarate		
MDI (Flutiform® 50/5, 125/5, 250/10)	MMC BNF emc	Asthma BTS step 3 management
Beclometasone dipropionate / Formoterol fumarate / Glycopyrronium bromide		
MDI (Trimbow 87/5/9® & 172/5/9®) DPI (Trimbow NEXThaler 88/5/9®)	MMC BNF emc	RESTRICTED - COPD patients who require triple therapy GMMMG COPD GMMMG Asthma
Fluticasone Furoate / Vilanterol Trifenatate / Umeclidinium Bromide		
DPI (Trelegy Ellipta® 92/55/22 micrograms)	MMC BNF emc	RESTRICTED - COPD patients who require triple therapy
Formoterol fumarate / Glycopyrronium Bromide / Budesonide		
DPI (Trixeo Aerosphere® 5/7.2/160 micrograms)	MMC BNF emc	RESTRICTED - COPD patients who require triple therapy
Indacaterol / Mometasone Furoate		
DPI (Ateectura® Breezhaler®)	MMC BNF emc	GMMMG Asthma Guideline 2022
Mometasone Furoate / Glycopyrronium Bromide / Indacaterol		
DPI (Enerzair® Breezhaler®)	MMC BNF emc	GMMMG Asthma Guideline 2022
MHRA Drug Safety Update (Jul-18): Pressurised metered dose inhalers (pMDI): risk of airway obstruction from aspiration of loose objects		
MHRA Drug Safety Update (Aug-17): Corticosteroids: rare risk of central serous chorioretinopathy with local as well as systemic administration		

<h3>3.3 Cromoglicate & related therapy & leukotriene receptor antagonists</h3>		
<h4>3.3.1 Cromoglicate & Related Therapy</h4>		
<p>Sodium Cromoglicate</p>		
	 	
<h4>3.3.2 Leukotriene Receptor Antagonists</h4>		
<p>Montelukast</p>		<p>BTS step 2 or 3 in paediatrics</p>
<p>tablets; chewable tablets; sachets</p>	  	
<p>MHRA Drug Safety Update (Sep-19): Montelukast (Singulair): reminder of the risk of neuropsychiatric reactions</p>		
<h4>3.3.3 Phosphodiesterase type-4 inhibitors</h4>		
<p>Roflumilast</p>		<p>RESTRICTED as per NICE TA461</p>
<p>Green</p>	   	
<p>tablets</p>		

3.4 Antihistamines, hyposensitisation & allergic emergencies		GMMMG
3.4.1 Antihistamines		
Non-sedating antihistamines		
Cetirizine Hydrochloride		
tablets; oral solution	 	
Loratadine		
tablets; oral solution	 	
Desloratadine		RESTRICTED children 1-2 years old
tablets; oral solution	  	
Fexofenadine Hydrochloride		
tablets	  	
Sedating antihistamines		
Chlorphenamine Maleate		
tablets; oral solution; injection	  	
Hydroxyzine Hydrochloride		
tablets; oral solution	 	
MHRA Drug Safety Update (Apr-15): Hydroxyzine (Atarax, Ucerax): risk of QT interval prolongation and Torsade de Pointes		
Promethazine Hydrochloride		
tablets; oral solution	  	
Alimemazine Tartrate		
DNP tablets; oral solution	 	
3.4.2 Allergen Immunotherapy		
Allergoid immunotherapy tablets		RESTRICTED Immunology Consultants only
 Lofarma Lais®	  	
Bee venom extract		RESTRICTED Immunology Consultants only
Red injection	  	
Wasp venom extract		RESTRICTED Immunology Consultants only
Red injection	   	
Grass & Rye or tree pollen extract		RESTRICTED Immunology Consultants only
Red Pollinex®	  	
Grass Pollen extract		RESTRICTED Immunology Consultants only
DNP Grazax® oral lyophilisates	   	
House Dust Mite extract		RESTRICTED Immunology Consultants only
Red Acarizax 12-SQ HDM oral lyophilisates®	   	
Peanut Protein powder		RESTRICTED Immunology Consultants only
Red  Palforzia® oral powder in capsules; sachet	   	
Wasp venom extract		RESTRICTED Immunology Consultants only
Red injection	   	
White birch (<i>Betula verrucosa</i>) Pollen extract		RESTRICTED Immunology Consultants only
Red Itulazax 12-SQ Bet oral lyophilisates®	 	
Omalizumab		
Omalizumab		RESTRICTED as per NICE
Red DNP  injection	     	

Anti-interleukin-5 (IL-5) antibody		
Benralizumab   <i>Fasenra</i> ® injection      		RESTRICTED as per NICE TA565
Dupilumab    <i>Dupixent</i> ® injection (see also section 13.5.3)      		RESTRICTED as per NICE TA751
MHRA Drug Safety Update (Nov-22): Dupilumab (Dupixent ▼): risk of ocular adverse reactions and need for prompt management		
Mepolizumab   <i>Nucala</i> ® injection      		RESTRICTED as per NICE
Reslizumab   <i>Cinqaero</i> ® infusion      		RESTRICTED as per NICE TA479 NOT STOCKED
Tezepelumab   <i>Tezspire</i> ® injection      		RESTRICTED as per NICE TA880
3.4.3 Allergic Emergencies		
Adrenaline / Epinephrine		PRESCRIBE BY BRAND NAME
injection  		
MHRA Drug Safety Update (Jun-23): Adrenaline auto-injectors (AAIs): new guidance and resources for safe use MHRA Drug Safety Update (Nov-21): Adrenaline auto-injectors: reminder for prescribers to support safe and effective use MHRA Drug Safety Update (Aug-17): Adrenaline auto-injectors: updated advice after European review		
Berotrastat   <i>Orladeyo</i> ® capsules     		RESTRICTED specialist use only as per NICE TA738
C1 esterase inhibitor   <i>Beriner</i> ®; <i>Cinryze</i> ® injection       		RESTRICTED acute attacks of HAE
Conestat Alfa   <i>Ruconest</i> ® injection     		RESTRICTED adults acute attacks of HAE
Icatibant   <i>Firazyr</i> ® injection      		RESTRICTED adults acute attacks of HAE
Lanadelumab   <i>Takhzyro</i> ® injection      		RESTRICTED in line with NICE TA606
Oxandrolone  tablets   		RESTRICTED adults acute attacks of HAE

3.5 Respiratory stimulants & pulmonary surfactants		GMMMG
3.5.1 Respiratory Stimulants		
Doxapram Hydrochloride		
injection	 	
Caffeine Citrate		
injection	MMC  	RESTRICTED apnoea in premature babies
3.5.2 Pulmonary Surfactants		
Poractant Alfa		
 Curosurf® liquid	  	

3.6 Oxygen (refer to oxygen guidelines)



3.7 Mucolytics		GMMMG
Mucolytics		
Sodium Chloride (hypertonic)		
<i>Nebusal</i> ® 7% nebulules	 	
Mannitol inhalation powder 		RESTRICTED Respiratory only in line with NICE
<i>Bronchitol</i> ® capsules	    	
Mannitol diagnostic kit 		RESTRICTED Respiratory only
<i>Osmohale</i> ® capsules	   	
Carbocisteine		RESTRICTED COPD Consultant / referral only
capsules; oral solution; sachets	  	
Dornase Alfa  		RESTRICTED Respiratory only
<i>Pulmozyme</i> ® nebulules	   	
Elexacaftor with Tezacaftor and Ivacaftor  		RESTRICTED Specialist use only
<i>Kaftrio</i> ® tablets	   	
MHRA Drug Safety Update (Feb-22): Ivacaftor, tezacaftor, elexacaftor (Kaftrio▼) in combination with ivacaftor (Kalydeco): risk of serious liver injury; updated advice on LFT		
Ivacaftor  		RESTRICTED Paediatric Consultants only
<i>Kalydeco</i> ® tablets; granules	   	
MHRA Drug Safety Update (Feb-22): Ivacaftor, tezacaftor, elexacaftor (Kaftrio▼) in combination with ivacaftor (Kalydeco): risk of serious liver injury; updated advice on LFT		
Lumacaftor with Ivacaftor  		RESTRICTED Specialist use only
<i>Orkambi</i> ® tablets; granules	   	
MHRA Drug Safety Update (Feb-22): Ivacaftor, tezacaftor, elexacaftor (Kaftrio▼) in combination with ivacaftor (Kalydeco): risk of serious liver injury; updated advice on LFT		
Tezacaftor with Ivacaftor  		RESTRICTED Specialist use only
<i>Symkevi</i> ® tablets	   	
MHRA Drug Safety Update (Feb-22): Ivacaftor, tezacaftor, elexacaftor (Kaftrio▼) in combination with ivacaftor (Kalydeco): risk of serious liver injury; updated advice on LFT		

3.8 Aromatic inhalations



Aromatic Inhalations

Benzoin Tincture, Compound, BP

Friars' Balsam liquid

Menthol and Eucalyptus Inhalation, BP 1980

inhalation vapour



3.9 Cough preparations		GMMMG
3.9.1 Cough Suppressants		
Codeine Phosphate	 	
oral solution		
MHRA Drug Safety Update (Jul-23): Codeine linctus: public consultation on the proposal to reclassify to a prescription-only medicine		
Pholcodine	 	Withdrawn from UK market as per MHRA alert March 2023
oral solution		
MHRA Drug Safety Update (Mar-23): Pholcodine-containing cough and cold medicines: withdrawal from UK market as a precautionary measure		
Dextromethorphan hydrobromide	  MMC	RESTRICTED non-ketotic hyperglycaemia
oral solution		
Cough Suppressants (Palliative Care ONLY)		
Methadone Hydrochloride	 	
liquid		
Morphine Hydrochloride	 	
oral solution		
3.9.2 Demulcent & expectorant cough preparations		
Simple Linctus	 	
liquid		

3.10 Systemic nasal decongestants



Systemic Nasal Decongestants

NO DRUGS ARE RECOMMENDED FROM THIS GROUP



NHSE: OTC prescribing reduction

3.11 Antifibrotics



Antifibrotics

Pirfenidone



capsules; tablets



RESTRICTED
Respiratory Consultants only
NOT STOCKED

MHRA Drug Safety Update (Nov-20): Pirfenidone (Esbriet): risk of serious liver injury; updated advice on liver function testing

Chapter 4: Central Nervous System

Supported by the
formulary ([click here](#))



4.1 Hypnotics & anxiolytics

- 4.1.1 Hypnotics
- 4.1.2 Anxiolytics
- 4.1.3 Barbiturates

4.2 Drugs used in psychoses & related disorders

- 4.2.1 Antipsychotic Drugs
- 4.2.2 Antipsychotic Depot Injections
- 4.2.3 Drugs used for mania and hypomania

4.3 Antidepressant drugs

- 4.3.1 Tricyclic & Related Antidepressant Drugs
- 4.3.2 Monoamine-Oxidase Inhibitors (MAOIs)
- 4.3.3 Selective Serotonin Re-uptake Inhibitors (SSRIs)
- 4.3.4 Other Antidepressant Drugs

4.4 CNS stimulants & drugs used for ADHD

4.5 Drugs used in the treatment of obesity

4.6 Drugs used in nausea & vertigo

4.7 Analgesics

- 4.7.1 Non-Opioid Analgesics
- 4.7.2 Opioid Analgesics
- 4.7.3 Neuropathic Pain
- 4.7.4 Antimigraine Drugs

4.8 Antiepileptic drugs

- 4.8.1 Control of the Epilepsies
- 4.8.2 Drugs Used in Status Epilepticus

4.9 Drugs used in Parkinsonism & related disorders

- 4.9.1 Dopaminergic Drugs Used in Parkinsonism
- 4.9.2 Antimuscarinic Drugs Used in Parkinsonism
- 4.9.3 Drugs Used in Essential Tremor, Chorea, Tics & Related Disorders

4.10 Drugs used in substance dependence

4.11 Drugs for dementia

Trust Guidelines

Adult medicines and prescribing guidelines
 Paediatric medicines and prescribing guidelines
 Neonatal guidelines (link to Staffnet site)
[Non-formulary Conversion Table](#)

NICE Guidance

Obsessive compulsive disorder (OCD) & body dysmorphic disorder (BDD) (CG31)
 Management of Obesity (CG43) (replaces TA22, TA31 & TA46)
 Drug misuse: opioid detoxification (CG52)
 Depression with a chronic physical health problem (CG91)
 Sedation in under 19s: using sedation for diagnostic and therapeutic procedures (CG112)
 Anxiety (CG113) (replaces CG22)
 Neuropathic pain - pharmacological management (CG173)
 Psychosis and schizophrenia in adults (CG178)
 Bipolar disorder: the assessment and management in adults, children & young people in 1ry & 2ry care (CG185)
 Eating Disorders: recognition and treatment (NG69)
 Parkinson's disease in adults (NG71)
 Attention deficit hyperactivity disorder: diagnosis and management (NG87)
 Stop smoking interventions and services (NG92)
 Dementia: supporting people with dementia and their carers in health and social care (NG97)
 Post-traumatic stress disorder (NG116)
 Depression in children and young people: identification and management (NG134)
 Epilepsies in children, young people and adults (NG217)
 Depression in adults: treatment and management (NG222)
 Motor Neurone Disease: Riluzole (TA20)
 Guidance on the use of zaleplon, zolpidem & zopiclone for short-term management of insomnia (TA77)
 Drug Misuse: Methadone & Buprenorphine (TA114)
 Drug Misuse: Naltrexone (TA115)
 Smoking Cessation: Varenicline (TA123)
 Schizophrenia - aripiprazole (TA213)
 Alzheimer's disease - donepezil, galantamine, rivastigmine & memantine (TA217) (replaces TA111)
 Botulinum toxin type A for the prevention of headaches in adults with chronic migraine (TA260)
 Bipolar disorder (children) - aripiprazole (TA292)
 Nalmefene for reducing alcohol consumption in people with alcohol dependence (TA325)
 Vortioxetine for treating major depressive episodes (TA367)
 Xeomin (botulinum neurotoxin type A) for treating chronic sialorrhoea (TA605)
 Cannabidiol with clobazam for treating seizures associated with Dravet syndrome (TA614)
 Cannabidiol with clobazam for treating seizures associated with Lennox-Gastaut syndrome (TA615)
 Galcanezumab for preventing migraine (TA659)
 Cenobamate for treating focal onset seizures in epilepsy (TA753)
 Solriamfetol for treating excessive daytime sleepiness caused by narcolepsy (TA758)
 Fremanezumab for preventing migraine (replacing TA631) (TA764)
 Fenfluramine for treating seizures associated with Dravet syndrome (TA808)
 Eptinezumab for preventing migraine (TA871)
 Difelikefalin for treating pruritus in people having haemodialysis (TA890)
 Rimegepant for preventing migraine (TA906)

GMMM Formulary

Formulary Homepage
 Chapter 4: Central Nervous system (Complete)
 GMMM Adult [Red/Amber/Green](#); DNP and Grey Drug List
 GMMM Paediatric [Red/Amber/Green](#) Drug List

4.1 Hypnotics & anxiolytics		GMMMG
4.1.1 Hypnotics		NICE CG112
Benzodiazepines		
Temazepam		
 tablets; oral solution	 	
Nitrazepam		
tablets; oral suspension	 	
Zaleplon, Zolpidem & Zopiclone		
Zopiclone		
tablets	  	
Chloral & Derivatives		
Chloral Hydrate		
oral solution; suppositories	 	
MHRA Drug Safety Update (Oct-21): Chloral hydrate, cloral betaine (Wellform): restriction of paediatric indication		
Clomethiazole		
192mg capsules	 	
Sodium Oxybate		
Sodium Oxybate		
   oral solution	    	RESTRICTED 2 nd line narcolepsy with cataplexy
Melatonin		
Melatonin		
capsules; tablets; oral solution	  	RESTRICTED GMMMG
Melatonin (licensed product 1 st line) - Paediatric patients, e.g. sleep disorders, ADHD		Amber
Melatonin (licensed product only) - Adult patients over 55yrs of age		Green
Melatonin - management of jet lag		DNP
4.1.2 Anxiolytics		NICE CG113
Benzodiazepines		
MHRA Drug Safety Update (Mar-20): Benzodiazepines and opioids: reminder of risk of potentially fatal respiratory depression		
Chlordiazepoxide hydrochloride		Symptomatic relief of acute alcohol withdrawal
 capsules	 	
Diazepam		
tablets; liquid; injection; rectal tube	 	
Lorazepam		
tablets; injection	 	
Oxazepam		
tablets	 	
Busiprone		
Busiprone Hydrochloride		
tablets	 	
Others		
Pregabalin		
  capsules; oral solution	  	RESTRICTED generalised anxiety disorder after standard treatment following NICE has failed.
4.1.3 Barbiturates		
NO DRUGS ARE RECOMMENDED FROM THIS GROUP		

4.2 Drugs used in psychoses & related disorders		GMMMG
4.2.1 Antipsychotic Drugs		NICE CG178
MHRA Drug Safety Update (May-12): Antipsychotics: initiative to reduce prescribing to older people with dementia		
Chlorpromazine Hydrochloride Green tablets; oral solution; injection	  MMC BNF emc	
Haloperidol Green tablets; capsules; oral solution	  BNF emc	
MHRA Drug Safety Update (Dec-21): Haloperidol (Haldol): reminder of risks when used in elderly patients for the acute treatment of delirium		
Levomepromazine Green tablets	  BNF emc	
Promazine Hydrochloride tablets; oral solution	  BNF emc	
Sulpiride tablets; oral solution	  BNF emc	
Trifluoperazine tablets; oral solution	  BNF emc	
Zuclophenthixol tablets	  BNF emc	
Atypical Antipsychotic Drugs		
Amisulpride Amber Red tablets; oral solution	  MMC BNF emc	RESTRICTED adults. Consultant Psychiatrist only
Aripiprazole Amber Red tablets; oral solution	  NICE MMC BNF emc	RESTRICTED paediatrics. Consultant Psychiatrist only
Clozapine Red tablets	  BNF emc	
MHRA Drug Safety Update (Aug-20): Clozapine and other antipsychotics: monitoring blood concentrations for toxicity		
MHRA Drug Safety Update (Oct-17): Clozapine: reminder of potentially fatal risk of intestinal obstruction, faecal impaction, and paralytic ileus		
Olanzapine Amber Red tablets; orodispersible tablets; oral solution	  BNF emc	
Quetiapine Amber Red tablets; M/R tablets	  MMC BNF emc	RESTRICTED - Consultant initiation - schizophrenia patients
Risperidone Amber Red tablets; orodispersible tablets; oral solution	  BNF emc	
4.2.2 Antipsychotic Depot Injections		
Flupentixol Decanoate Amber injection	  BNF emc	RESTRICTED Consultant Psychiatrist only
Fluphenazine Decanoate Amber injection	  BNF emc	RESTRICTED Consultant Psychiatrist only
Haloperidol Decanoate Amber injection	  BNF emc	RESTRICTED Consultant Psychiatrist only
MHRA Drug Safety Update (Dec-21): Haloperidol (Haldol): reminder of risks when used in elderly patients for the acute treatment of delirium		
Risperidone Amber injection	  BNF emc	RESTRICTED Consultant Psychiatrist only
Zuclophenthixol Decanoate Amber injection	  BNF emc	RESTRICTED Consultant Psychiatrist only

4.2.3 Drugs used for mania and hypomania**Lithium Carbonate**

Amber

tablets; M/R tablets

**PRESCRIBE BY BRAND NAME****Lithium Citrate**

Amber

oral solution

**PRESCRIBE BY BRAND NAME****Valproic Acid**

Green

Gastro-resistant tablets



MHRA Drug Safety Update (Apr-19): Valproate medicines and serious harms in pregnancy: new Annual Risk Acknowledgement Form and clinical guidance

MHRA Drug Safety Update (May-10): Carbapenems: concomitant use with valproic acid not recommended

4.3 Antidepressant drugs		GMMMG
		NICE CG31
		NICE CG91
4.3.1 Tricyclic & Related Antidepressant Drugs		NICE NG134
Tricyclic antidepressants		NICE NG222
Amitriptyline Hydrochloride (standard release preparations only)		
tablets; oral solution	 	
Clomipramine Hydrochloride (standard release preparations only)		
capsules	 	
Doxepin Hydrochloride		
capsules	 	
Imipramine Hydrochloride		
tablets	 	
Lofepramine		1 st line use
tablets; oral suspension	 	
Nortriptyline		
tablets	 	
Trimipramine		
DNP tablets; capsules	 	
Tricyclic-related antidepressants		
Mianserin Hydrochloride		RESTRICTED initiation by Psychiatrist
tablets	 	
Trazodone Hydrochloride		RESTRICTED initiation by Psychiatrist
capsules; tablets; oral solution	 	
4.3.2 Monoamine-Oxidase Inhibitors (MAOIs)		
Isocarboxazid		RESTRICTED initiation by Psychiatrist
Red tablets	 	
Phenelzine		RESTRICTED initiation by Psychiatrist
Red 15mg tablets	 	
Tranlycypromine		RESTRICTED initiation by Psychiatrist
Red 10mg tablets	 	
Reversible Monoamine-Oxidase Inhibitors (MAOIs)		
Moclobemide		RESTRICTED 2 nd line initiation by Psychiatrist
Green 150mg; 300mg tablets	 	
4.3.3 Selective Serotonin Re-uptake Inhibitors (SSRIs)		
MHRA Drug Safety Update (Jan-21): SSRI/SNRI antidepressant medicines: small increased risk of postpartum haemorrhage when used in the month before delivery		
Fluoxetine		
capsules; tablets; dispersible tablets; oral solution	 	
Citalopram		
tablets; oral drops	 	
MHRA Drug Safety Update (Jul-16): Citalopram: suspected drug interaction with cocaine; prescribers should consider enquiring about illicit drug use MHRA Drug Safety Update (Dec-11): Citalopram and escitalopram: QT interval prolongation		
Sertraline		
tablets; oral suspension	 	
Fluvoxamine maleate		
tablets	 	
Paroxetine		
tablets; oral suspension	 	

Escitalopram tablets	 	RESTRICTED Mental Health Trust initiation only
MHRA Drug Safety Update (Dec-11): Citalopram and escitalopram: QT interval prolongation		
4.3.4 Other Antidepressant Drugs		
Venlafaxine  M/R capsules; tablets; M/R tablets	 	RESTRICTED initiation by Psychiatrist
Mirtazapine tablets; orodispersible tablets; oral solution	  	RESTRICTED initiation by Psychiatrist
Duloxetine  gastro-resistant tablets	 	RESTRICTED initiation by Psychiatrist
Flupentixol tablets	 	RESTRICTED initiation by Psychiatrist
Reboxetine tablets	  	RESTRICTED initiation by Psychiatrist
Tryptophan capsules	 	RESTRICTED initiation by Psychiatrist
Vortioxetine  tablets	   	RESTRICTED initiation by Psychiatrist

4.4 CNS stimulants & drugs used for ADHD		GMMMG
4.4 CNS stimulants & drugs used for ADHD GMMMG		NICE NG87
Atomoxetine Amber capsules NICE MMC BNF emc		RESTRICTED on Paediatric / Psychiatric advice
MHRA Drug Safety Update (Jan-12): Atomoxetine (Strattera ▼): increases in blood pressure and heart rate MHRA Drug Safety Update (Mar-09): Atomoxetine: risk of psychotic or manic symptoms in children and adolescents		
Dexamfetamine Amber Red tablets NICE BNF emc		RESTRICTED on Paediatric / Psychiatric advice
Guanfacine Amber Prolonged release tablets NICE MMC BNF emc		RESTRICTED 2 nd line use for ADHD
Lisdexamfetamine Amber CT capsules NICE MMC BNF emc GMMMG		RESTRICTED 2 nd line use for ADHD
Methylphenidate Amber CT tablets; M/R tablets; capsules; M/R capsules NICE MMC BNF emc		RESTRICTED on Paediatric / Psychiatric advice PRESCRIBE BY BRAND NAME
MHRA Drug Safety Update (Sep-22): Methylphenidate long-acting (MR) preparations: caution if switching between products due to differences in formulations MHRA Drug Safety Update (Mar-09): Methylphenidate: safe and effective use to treat ADHD		
Modafinil Green DNP Red tablets BNF emc		RESTRICTED on Paediatric / Psychiatric advice
MHRA Drug Safety Update (Nov-20): Modafinil (Provigil): increased risk of congenital malformations if used during pregnancy MHRA Drug Safety Update (Mar-11): Modafinil (Provigil): now restricted to narcolepsy		
Solriamfetol hydrochloride Red ££ Sunosi® tablets NICE MMC BNF emc		RESTRICTED Sleep Centre only in line with NICE

<h2>4.5 Drugs used in the treatment of obesity</h2>	
<h3>4.5.1 Anti-Obesity Drugs Acting on the Gastro-Intestinal Tract</h3>	<p>NICE CG43</p>
<p>Orlistat</p> <p>capsules</p> <div style="text-align: right;">     </div>	<p>RESTRICTED</p> <p>Consultant initiation - Paeds. only</p>
<p>MHRA Drug Safety Update (Mar-14): Orlistat: theoretical interaction with antiretroviral HIV medicines</p>	

4.6 Drugs used in nausea & vertigo		GMMMG
Antihistamines		
Cyclizine		1st line use
tablets; injection	 	
Promethazine Hydrochloride		
tablets; oral solution (see also section 3.4.1)	 	
Promethazine Teoclate		
tablets	 	
Phenothiazines & Related Drugs		
Prochlorperazine		
tablets; buccal tablet; injection	 	
Droperidol		RESTRICTED Consultant initiation only for PONV
injection	  	
Domperidone & Metoclopramide		
Domperidone		
tablets; oral suspension (see also section 1.2)	 	
MHRA Drug Safety Update (Dec-19): Domperidone for nausea and vomiting: lack of efficacy in children; reminder of contraindications in adults and adolescents		
MHRA Drug Safety Update (Apr-16): Apomorphine with domperidone: minimising risk of cardiac side effects		
MHRA Drug Safety Update (May-14): Domperidone: risks of cardiac side effects		
Metoclopramide Hydrochloride		
tablets; oral suspension; injection (see also section 1.2)	 	
MHRA Drug Safety Update (Aug-13): Metoclopramide: risk of neurological adverse effects		
5HT₃-receptor antagonists		
Ondansetron		RESTRICTED - Chemotherapy induced & post-op vomiting
 	 	
tablets; orodispersible tablets; injection; oral solution; orodispersible film		
MHRA Drug Safety Update (Jul-13): Ondansetron for intravenous use: dose-dependent QT interval prolongation		
MHRA Drug Safety Update (Aug-12): Ondansetron (Zofran): important new intravenous dose restriction		
Neurokinin 1-receptor antagonist		
Aprepitant		RESTRICTED highly / moderately emetogenic CINV
80mg; 125mg capsules; 25mg/mL oral suspension	  	
Cannabinoids		
Nabilone		RESTRICTED highly emetogenic CINV
	  	
0.25mg; 1mg capsules		
Hyoscine		
Hyoscine Hydrobromide		
patches; tablets (for Hyoscine Butylbromide see section 1.2)	  	
MHRA Drug Safety Update (Jul-23): Hyoscine hydrobromide patches: risk of anticholinergic side effects, including hyperthermia		
Other Drugs for Ménière's Disease		
Betahistine Dihydrochloride		
tablets	 	

4.7 Analgesics		GMMMG
4.7.1 Non-Opioid Analgesics		(see also Chapter 10 for NSAIDs)
Paracetamol		1st line use
tablets; soluble tablets; infusion; injection; oral suspension; suppositories	MMC BNF emc	
Sucrose 24% solution		RESTRICTED Pain relief in neonates
Sweet-Ease® oral solution	MMC BNF emc	
Compound Analgesic Preparations		
Paracetamol and codeine (Co-codamol®)		
tablets; effervescent tablets	BNF emc	
Paracetamol and dihydrocodeine (Co-dydramol®)		
tablets	BNF emc	
4.7.2 Opioid Analgesics		
MHRA Drug Safety Update (Sep-20): Opioids: risk of dependence and addiction		
Buprenorphine		RESTRICTED
 NOT patch	NICE BNF emc	
Codeine Phosphate		
tablets; syrup; injection	BNF emc	
MHRA Drug Safety Update (Jul-13): Codeine for analgesia: restricted use in children because of reports of morphine toxicity		
MHRA Drug Safety Update (Jun-13): Codeine: restricted use as analgesic in children and adolescents after European safety review		
Diamorphine Hydrochloride		
 injection	BNF emc	
Difelikefalin		RESTRICTED Renal Consultants in line with NICE
 <i>Kapivia</i> ® injection	PBR X NICE MMC BNF bluefeq emc	
Dihydrocodeine Tartrate standard release preparations only		
tablets	BNF emc	
Fentanyl		Spray RESTRICTED palliative care & haematology initiation (Wd44)
  NOT lozenge	MMC BNF emc	
MHRA Drug Safety Update (Oct-18): Transdermal fentanyl patches: life-threatening and fatal opioid toxicity from accidental exposure, particularly in children		
MHRA Drug Safety Update (Sep-08): Serious and fatal overdose of fentanyl patches		
Methadone Hydrochloride		RESTRICTED palliative care & substance misuse
 oral solution	NICE BNF emc	
Morphine Sulphate		
 tablets; M/R tablets; capsules; M/R capsules; oral solution; injection	BNF emc	
Morphine Sulphate		RESTRICTED palliative care / GMMMG
  <i>Actimorph</i> ® orodispersible tablets	MMC BNF emc	
Oxycodone Hydrochloride		RESTRICTED 2 nd line for morphine intolerance
 capsules; liquid; tablets; M/R tablets; injection	MMC BNF emc	
Pethidine Hydrochloride		
 injection; tablets	BNF emc	
Tapentadol Hydrochloride MR		RESTRICTED 3 rd line - Pain Team Consultants only
 tablets	MMC BNF emc	
MHRA Drug Safety Update (Jan-19): Tapentadol (Palexia): risk of seizures and reports of serotonin syndrome when co-administered with other medicines		
Tramadol Hydrochloride		
 capsules; M/R capsules; tablets; M/R tablets; soluble tablets; injection	BNF emc	

4.7.3 Neuropathic Pain		
Amitriptyline		
tablets; oral solution	 	
Carbamazepine		
Green 	 	
tablets; M/R tablets; oral solution; suppositories		
MHRA Drug Safety Update (Dec-12): Carbamazepine, oxcarbazepine and eslicarbazepine: potential risk of serious skin reactions		
Gabapentin		
Green  	 	
capsules; oral suspension		
MHRA Drug Safety Update (Apr-19): Pregabalin (Lyrica), gabapentin (Neurontin) and risk of abuse and dependence: new scheduling requirements from 1 April		
MHRA Drug Safety Update (Oct-17): Gabapentin (Neurontin): risk of severe respiratory depression		
Public Health England briefing (Dec-14): risk of misuse of gabapentin and pregabalin		
Pregabalin		3rd / 4th line use if gabapentin contraindicated or not tolerated
Green  	  	
capsules; oral solution		
MHRA Drug Safety Update (Feb-21): Pregabalin (Lyrica): reports of severe respiratory depression		
MHRA Drug Safety Update (Apr-19): Pregabalin (Lyrica), gabapentin (Neurontin) and risk of abuse and dependence: new scheduling requirements from 1 April		
Public Health England briefing (Dec-14): risk of misuse of gabapentin and pregabalin		
4.7.4 Antimigraine Drugs		
4.7.4.1 Treatment Of Acute Migraine		
Analgesics		
Aspirin		
tablets; dispersible tablets; E/C tablets; suppositories	 	
Paracetamol		
tablets; soluble tablets; oral suspension; infusion; suppositories	 	
Ibuprofen		
tablets; M/R tablets; oral suspension; sachets	 	
5HT₁ receptor agonists		
Sumatriptan		
tablets; nasal spray; injection	 	
4.7.4.2 Prophylaxis of Migraine		
Botulinum Toxin Type A		RESTRICTED Specialist use only in line with NICE
Red 	    	
Botox® injection		
Clonidine Hydrochloride		
tablets	 	
Erenumab		RESTRICTED Specialist use only NOT STOCKED
Red  	   	
injection		
Eptinezumab		RESTRICTED Specialist use only NOT STOCKED
Red  	   	
injection		
Fremanezumab		RESTRICTED Specialist use only NOT STOCKED
Red  	    	
injection		
Galcanezumab		RESTRICTED Specialist use only NOT STOCKED
Red  	   	
injection		
Pizotifen		
tablets	 	

4.8 Antiepileptic drugs Green		GMMMG
4.8.1 Control of the Epilepsies		NICE NG217
Carbamazepine Green tablets; M/R tablets; oral solution; suppositories NICE BNF emc		
MHRA Drug Safety Update (Dec-12): Carbamazepine, oxcarbazepine and eslicarbazepine: potential risk of serious skin reactions		
Phenobarbital Green CT tablets; oral solution; injection NICE BNF emc		
Phenytoin Sodium Green capsules; oral suspension; injection NICE BNF emc		
Sodium Valproate Green tablets; M/R tablets; oral solution; M/R granules; injection NICE BNF emc		
MHRA Drug Safety Update (Oct-23): Valproate: dispense full packs of valproate-containing medicines MHRA Drug Safety Update (Aug-23): Valproate: re-analysis of study on risks in children of men taking valproate MHRA Drug Safety Update (Dec-22): Valproate: reminder of current Pregnancy Prevention Programme requirements... MHRA Drug Safety Update (Jan-20): Valproate (Epilem ▼, Depakote ▼) pregnancy prevention programme: updated educational materials MHRA Drug Safety Update (Apr-19): Valproate medicines and serious harms in pregnancy: new Annual Risk Acknowledgement Form and clinical guidance... MHRA Drug Safety Update (Apr-18): Valproate medicines (Epilem ▼, Depakote ▼): contraindicated in women & girls of childbearing potential unless conditions of PPP met MHRA Drug Safety Update (May-10): Carbapenems: concomitant use with valproic acid not recommended		
Cenobamate Green Ontozry® tablets NICE MMC BNF emc		RESTRICTED Specialist use only in line with NICE NOT STOCKED
Clobazam Green tablets; oral suspension NICE BNF emc		RESTRICTED Specialist use only
Clonazepam Green tablets; oral solution; injection NICE BNF emc		RESTRICTED Specialist use only
Eslicarbazepine Green tablets; oral suspension NICE MMC BNF emc		RESTRICTED Specialist use only in line with NICE
MHRA Drug Safety Update (Dec-12): Carbamazepine, oxcarbazepine and eslicarbazepine: potential risk of serious skin reactions		
Ethosuximide Green capsules; oral solution NICE BNF emc		RESTRICTED Paediatrics only
Fenfluramine Hydrochloride Red Fintepla® oral solution NICE MMC BNF emc		RESTRICTED Specialist use only in line with NICE
Gabapentin Green CT capsules; oral suspension NICE BNF emc		RESTRICTED Specialist use only
MHRA Drug Safety Update (Apr-19): Pregabalin (Lyrica), gabapentin (Neurontin) and risk of abuse and dependence: new scheduling requirements from 1 April MHRA Drug Safety Update (Oct-17): Gabapentin (Neurontin): risk of severe respiratory depression Public Health England briefing (Dec-14): risk of misuse of gabapentin and pregabalin		
Lacosamide Green tablets; oral solution; infusion NICE MMC BNF emc		RESTRICTED Specialist use only
Lamotrigine Green tablets; dispersible tablets NICE BNF emc		RESTRICTED Specialist use only
MHRA Drug Safety Update (Jan-21): Antiepileptic drugs in pregnancy: updated advice following comprehensive safety review		
Levetiracetam Green tablets; oral solution; infusion; granules NICE MMC BNF emc		RESTRICTED Specialist use only
MHRA Drug Safety Update (Jan-21): Antiepileptic drugs in pregnancy: updated advice following comprehensive safety review		
Oxcarbazepine Green tablets; oral suspension NICE BNF emc		RESTRICTED Specialist use only
MHRA Drug Safety Update (Dec-12): Carbamazepine, oxcarbazepine and eslicarbazepine: potential risk of serious skin reactions		
Perampanel Green tablets; oral suspension MMC BNF emc		RESTRICTED Specialist use only

<p>Pregabalin   capsules; oral solution    </p> <p>MHRA Drug Safety Update (Feb-21): Pregabalin (Lyrica): reports of severe respiratory depression MHRA Drug Safety Update (Apr-19): Pregabalin (Lyrica), gabapentin (Neurontin) and risk of abuse and dependence: new scheduling requirements from 1 April Public Health England briefing (Dec-14): risk of misuse of gabapentin and pregabalin</p>	<p>RESTRICTED Specialist use only</p>
<p>Primidone  tablets  </p>	<p>RESTRICTED Specialist use only</p>
<p>Rufinamide  tablets    </p>	<p>RESTRICTED Specialist use only Lennox-Gastaut Syndrome</p>
<p>Stiripentol  capsules; sachets    </p>	<p>RESTRICTED Specialist use only</p>
<p>Tiagabine  tablets    </p>	<p>RESTRICTED Specialist use only</p>
<p>Topiramate  tablets; capsules    </p>	<p>RESTRICTED Specialist use only</p>
<p>Vigabatrin  tablets; sachets   </p>	<p>RESTRICTED Specialist use only</p>
<p>Zonisamide  capsules    </p>	<p>RESTRICTED Specialist use only</p>
<p>Cannabidiol (CBD)   Epidyolex®    </p>	<p>RESTRICTED Specialist use only in line with NICE TA614 / 615</p>
<p>4.8.2 Drugs Used in Status Epilepticus</p>	
<p>Lorazepam tablets; injection  </p>	
<p>MHRA Drug Safety Update (Mar-20): Benzodiazepines and opioids: reminder of risk of potentially fatal respiratory depression</p>	
<p>Diazepam tablets; liquid; injection; rectal tube  </p>	
<p>MHRA Drug Safety Update (Mar-20): Benzodiazepines and opioids: reminder of risk of potentially fatal respiratory depression</p>	
<p>Clonazepam  tablets; oral solution; injection  </p>	
<p>MHRA Drug Safety Update (Mar-20): Benzodiazepines and opioids: reminder of risk of potentially fatal respiratory depression</p>	
<p>Midazolam   oromucosal solution; injection; infusion  </p>	
<p>MHRA Drug Safety Update (Mar-20): Benzodiazepines and opioids: reminder of risk of potentially fatal respiratory depression</p>	
<p>Paraldehyde injection; rectal solution  </p>	
<p>Phenytoin Sodium  capsules; oral suspension; injection  </p>	
<p>Sulthiame  Ospolot® 50mg tablets   </p>	<p>RESTRICTED Consultant Neurologist use only</p>

4.9 Drugs used in Parkinsonism & related disorders		GMMMG
4.9.1 Dopaminergic Drugs Used in Parkinsonism		NICE NG71
Amantadine Hydrochloride Green capsules; oral solution	  	RESTRICTED Specialist use only
Apomorphine Hydrochloride Amber injection; infusion	   	RESTRICTED Specialist use only
MHRA Drug Safety Update (Apr-16): Apomorphine with domperidone: minimising risk of cardiac side effects		
Cabergoline Green tablets	   	RESTRICTED Specialist use only
Co-beneldopa Green capsules; M/R capsules; dispersible tablets	  	RESTRICTED Specialist use only
Co-careldopa Green tablets; M/R tablets	   	RESTRICTED Specialist use only
Entacapone Green tablets	  	RESTRICTED Specialist use only
Opicapone Green capsules	  	RESTRICTED 2nd line Specialist use only
Pramipexole Green tablets; M/R tablets	  	RESTRICTED 3rd line add-on use Specialist use only
Rasagiline Green tablets	  	RESTRICTED patients with end of dose fluctuations
Ropinirole Green tablets; M/R tablets	 	RESTRICTED Specialist use only
Rotigotine Green transdermal patches	   	RESTRICTED Specialist use only. NBM patients
Safinamide Green tablets	  	RESTRICTED Specialist use only
Selegiline Green tablets	 	RESTRICTED Specialist use only
4.9.2 Antimuscarinic Drugs Used in Parkinsonism		
Orphenadrine Hydrochloride oral solution	 	
Procyclidine (Oral & IM) tablets; oral solution; injection	 	
Trihexyphenidyl Hydrochloride (Benzhexol Hydrochloride) tablet; syrup	  	

4.9.3 Drugs Used in Essential Tremor, Chorea, Tics & Related Disorders**Propranolol**

tablets; M/R capsules; oral solution; injection

**Haloperidol**

Green

tablets; capsules; oral solution



MHRA Drug Safety Update (Dec-21): Haloperidol (Haldol): reminder of risks when used in elderly patients for the acute treatment of delirium

Piracetam

tablets; oral solution

**Tetrabenazine**

tablets

**Torsion Dystonias & Other Involuntary Movements**

The dose of botulinum toxin is specific to each individual preparation and is **NOT** interchangeable. The doses for different indications vary - consult product literature & specialist guidance

Botulinum Toxin Type A

Red

Botox® injection

**Botulinum Toxin Type A**

Red

Dysport® injection

**Botulinum Toxin Type A**

Red

Xeomin® injection



RESTRICTED
Specialist use only
see decision tables

RESTRICTED
Specialist use only

RESTRICTED
Specialist use only
see decision tables

4.10 Drugs used in substance dependence		GMMMG
4.10.1 Alcohol dependence		
Nalmefene Green	   	RESTRICTED - Specialist use only in line with NICE TA325 NOT STOCKED
4.10.2 Nicotine dependence		
Nicotine Replacement Therapy patches, lozenges, inhalator, microtabs	 	NICE NG92 1 st line use
Bupropion Hydrochloride tablets	  	
MHRA Drug Safety Update (Nov-20): Bupropion (Zyban): risk of serotonin syndrome with use with other serotonergic drugs		
Varenicline tablets	   	
4.10.3 Opioid Dependence		
MHRA Drug Safety Update (Sep-20): Opioids: risk of dependence and addiction		
Buprenorphine Green 	  	RESTRICTED Initiation by substance misuse specialist
Methadone Hydrochloride 	  	RESTRICTED Initiation by substance misuse specialist
Naltrexone Hydrochloride Red 	   	RESTRICTED Gastro Consultant - cholestatic itch

4.11 Drugs for dementia		GMMMG
4.11 Drugs for Dementia		NICE NG97
Donepezil Hydrochloride Green tablets; orodispersible tablets	   	RESTRICTED Specialist use only
Galantamine Green M/R capsules; tablets	  	RESTRICTED Specialist use only
MHRA Drug Safety Update (Dec-15): Letters sent to healthcare professionals		
Memantine Hydrochloride Green tablets; oral solution	   	RESTRICTED Specialist use only
Rivastigmine Green capsules; oral solution; transdermal patches	   	RESTRICTED Specialist use only
Dementia - as per NICE TA217 & NG97 Green (following specialist initiation)		Green

Section 5: Infections

Supported by the
formulary ([click here](#))



5.1 Antibacterial drugs

- 5.1.1 Penicillins
- 5.1.2 Cephalosporins, Carbapenems & other Beta-Lactams
- 5.1.3 Tetracyclines
- 5.1.4 Aminoglycosides
- 5.1.5 Macrolides
- 5.1.6 Clindamycin
- 5.1.7 Some other Antibacterials
- 5.1.8 Sulphonamides & Trimethoprim
- 5.1.9 Antituberculosis Drugs
- 5.1.10 Antileprotic Drugs
- 5.1.11 Metronidazole & Tinidazole
- 5.1.12 Quinolones
- 5.1.13 Urinary-tract Infections

5.2 Antifungal drugs

- 5.2.1 Triazole Antifungals
- 5.2.3 Polyene Antifungals
- 5.2.4 Echinocandin Antifungals
- 5.2.5 Other Antifungals

5.3 Antiviral drugs

- 5.3.1 HIV Infection
- 5.3.2 Herpesvirus Infection
- 5.3.3 Viral Hepatitis
- 5.3.4 Influenza
- 5.3.5 Respiratory Syncytial Virus (RSV)

5.4 Antiprotozoal drugs

- 5.4.1 Antimalarials
- 5.4.2 Amoebicides
- 5.4.3 Trichomonacides
- 5.4.4 Antigiardial drugs
- 5.4.5 Leishmaniacides
- 5.4.7 Drugs for toxoplasmosis
- 5.4.8 Drugs for pneumocystis pneumonia

5.5 Anthelmintics

- 5.5.1 Drugs for Threadworms (pinworms, *Enterobius vermicularis*)
- 5.5.2 Ascaricides
- 5.5.5 Schistosomicides (bilharziasis)
- 5.5.6 Filaricides

Trust Guidelines

[Adult medicines and prescribing guidelines](#)
[MFT Adult Antimicrobial guidelines](#)
[Paediatric medicines and prescribing guidelines](#)
[MFT Paediatric Antimicrobial guidelines](#)
[Neonatal guidelines \(link to Staffnet site\)](#)
[Non-formulary Conversion Table](#)

NICE Guidance

[Prophylaxis against infective endocarditis \(CG64\)](#)
[Bacterial meningitis and meningococcal septicaemia \(CG102\)](#)
[Infection: Prevention & control of healthcare-associated infections in primary & community care \(CG139\)](#)
[Hepatitis B \(Chronic\) \(CG165\)](#)
[Tuberculosis \(NG33\)](#)
[Sinusitis \(acute\): antimicrobial prescribing \(NG79\)](#)
[Sore throat \(acute\): antimicrobial prescribing \(NG84\)](#)
[Otitis media \(acute\): antimicrobial prescribing \(NG91\)](#)
[Cough \(acute\): antimicrobial prescribing \(NG120\)](#)
[Surgical site infections: prevention and treatment \(NG125\)](#)
[Hepatitis C: Chronic \(TA75\) \(extended by TA106 - partially updated by TA200 & TA300\)](#)
[Hepatitis B: Chronic \(TA96\) \(partially updated by CG165\)](#)
[Hepatitis C: Peginterferon & Ribavirin \(TA106\) \(partially updated by TA200 & TA300\)](#)
[Hepatitis B: Entecavir \(TA153\)](#)
[Hepatitis B: Telbivudine \(TA154\)](#)
[Oseltamivir, Amantadine & Zanamivir for prophylaxis of Influenza \(TA158\)](#)
[Oseltamivir, Amantadine & Zanamivir for treatment of Influenza \(TA168\)](#)
[Hepatitis B: Tenofovir disoproxil \(TA173\)](#)
[Hepatitis C - peginterferon alfa and ribavirin \(TA200\) \(read in conjunction with TA75 & TA106\)](#)
[Cystic fibrosis \(pseudomonas lung infection\) - colistimethate sodium and tobramycin \(TA276\)](#)
[Hepatitis C \(children and young people\) - peginterferon alfa & ribavirin \(TA300\)](#)
[Sofosbuvir for treating chronic hepatitis C \(TA330\)](#)
[Rifaximin for preventing episodes of overt hepatic encephalopathy \(TA337\)](#)
[Ledipasvir–sofosbuvir for treating chronic hepatitis C \(TA363\)](#)
[Ombitasvir–paritaprevir–ritonavir with or without dasabuvir for treating chronic hepatitis C \(TA365\)](#)
[Elbasvir–grazoprevir for treating chronic hepatitis C \(TA413\)](#)
[Sofosbuvir–velpatasvir for treating chronic hepatitis C \(TA430\)](#)
[Glecaprevir–pibrentasvir for treating chronic hepatitis C \(TA499\)](#)
[Sofosbuvir–velpatasvir–voxilaprevir for treating chronic hepatitis C \(TA507\)](#)
[Letermovir for preventing cytomegalovirus disease after a stem cell transplant \(TA591\)](#)
[Cabotegravir with rilpivirine for treating HIV-1 \(TA757\)](#)
[Maribavir for treating refractory cytomegalovirus infection after transplant \(TA860\)](#)
[Casirivimab plus imdevimab, nirmatrelvir plus ritonavir, sotrovimab and tocilizumab for treating COVID-19 \(TA878\)](#)
[Bulevirtide for treating chronic hepatitis D \(TA896\)](#)

GMMM Formulary

[Formulary Homepage](#)
[Chapter 5: Infections \(Complete\)](#)
[GMMM Adult **Red/Amber/Green**; DNP and Grey Drug List](#)
[GMMM Paediatric **Red/Amber/Green** Drug List](#)

RESTRICTED USE ANTIBIOTICS

1. Must be recommended / approved for use by consultant medical microbiologist
2. The name of the microbiologist must be documented on the prescription chart. The indication must be documented.
3. Only available from Pharmacy

RESERVED USE ANTIBIOTICS

1. Can be used only in accordance with the restrictions outlined below.
2. Indication must be clearly documented on the prescription chart.
3. If being used outside of guidelines Microbiology approval must be sought as above.

UNRESTRICTED USE ANTIBIOTICS

1. Can be used according to CMFT Trust guidelines, (those drugs not marked Restricted or Reserved)

5.1 Antibacterial drugs**5.1.1 Penicillins****5.1.1.1 Benzylpenicillin & Phenoxymethylpenicillin****Benzylpenicillin Sodium (Penicillin G)**

600mg injection

**Phenoxymethylpenicillin (Penicillin V)**

tablets

**Benzathine Benzylpenicillin**

injection

**RESTRICTED**
unlicensed treatment for syphilis**5.1.1.2 Penicillinase-Resistant Penicillins****Flucloxacillin**

capsules; injection; oral solution

**Temocillin**

1g injection

**RESTRICTED** infection caused by
multi-resistant coliforms.
Micro only**5.1.1.3 Broad Spectrum Penicillins****Amoxicillin**

capsules; oral suspension; injection

**Co-amoxiclav**

tablets; oral suspension; injection

**5.1.1.4 Antipseudomonal Penicillins****Piperacillin with Tazobactam**

injection

**RESERVED**
serious / resistant infections**Ticarcillin with Clavulanic Acid**

Timentin® 3.2g injection

**RESERVED**
serious / resistant infections**5.1.1.5 Mecillinams****Pivmecillinam Hydrochloride**

200mg tablets

**RESTRICTED** UTIs caused by resistant
coliforms**5.1.2 Cephalosporins, Carbapenems & other Beta-Lactams****5.1.2.1 Cephalosporins****Cefalexin**

capsules; tablets; oral suspension

**Cefazolin**

injection

**RESTRICTED**
on Micro. advice only**Cefotaxime**

injection

**RESERVED**
as per guidelines for children**Ceftriaxone**

injection

**RESERVED**
as per guidelines for children**Cefuroxime**

injection

**RESERVED**
as per guidelines for children

Cefixime		RESERVED GU infections only
tablets	  	
Ceftazidime		RESERVED pseudomonas infection in CF
injection	  	
Cetazidime / Avibactam		RESERVED for gram negative organisms Micro. Consultant only
Zavicefta® infusion	  	
Ceftolozane sulfate / Tazobactam sodium		RESERVED for gram negative organisms Micro. Consultant only
Zerbaxa® infusion	  	
Ceftaroline Fosamil		RESERVED CAP & cSSTI treatment. Micro. Consultant only
Zinforo® infusion	  	
Cefoxitin		RESERVED for treatment of mycobacterium abscessus in CF. Micro. Consultant only
injection	  	
Cefiderocol		RESERVED for gram negative organisms Micro. Consultant only
Fetroja® infusion	  	
5.1.2.2 Carbapenems		
Ertapenem		RESTRICTED Outpatient therapy only
infusion	  	
Imipenem with Cilastatin		RESTRICTED Non-Tuberculous Mycobacteria in CF
infusion	  	
Imipenem / Cilastatin / Relebactam		RESTRICTED Micro. Consultant only
 Recarbrio® infusion	  	
Meropenem		RESERVED as per guidelines
injection	  	
Meropenem with Vaboractam		RESTRICTED Micro. Consultant only
Vaborem® infusion	  	
5.1.2.3 Other Beta-Lactam antibiotics		
Aztreonam		RESTRICTED gram negative organisms
injection	 	
Aztreonam lysine		RESTRICTED 3rd line CF patients with chronic pulmonary infection
  Cayston® nebuliser solution	  	
5.1.3 Tetracyclines		
Doxycycline		
capsules; tablets; dispersible tablets	  	
Oxytetracycline		
tablets	 	
Demeclocycline Hydrochloride		RESTRICTED SIADH only
capsules	  	
Lymecycline		RESTRICTED Non-Formulary MMC approved for GP referral
capsules	  	
Minocycline		
capsules; tablets	  	
Tigecycline		RESERVED as per guidelines
infusion	  	

5.1.4 Aminoglycosides		
MHRA Drug Safety Update (Jan-21): Aminoglycosides (gentamicin, amikacin, tobramycin & neomycin): increased risk of deafness in patients with mitochondrial mutations		
Amikacin		RESERVED as per guidelines
injection	 MMC  	
Gentamicin		
injection	 	
Tobramycin		RESERVED as per guidelines
  		
injection; inhalation powder; nebuliser liquid	 MMC  	
Neomycin Sulfate		RESTRICTED Gastro team only - op prep
oral solution	 	
5.1.5 Macrolides		
Clarithromycin		
tablets; oral suspension; infusion	 	
Azithromycin		RESERVED GU only or specialist use
tablets; oral suspension	 	
Erythromycin		RESERVED in pregnancy or neonates
tablets; oral suspension; injection	 	
MHRA Drug Safety Update (Dec-20): Erythromycin: caution required due to cardiac risks (QT interval prolongation); drug interaction with rivaroxaban		
MHRA Drug Safety Update (Dec-20): Erythromycin: update on known risk of infantile hypertrophic pyloric stenosis		
5.1.6 Clindamycin		
Clindamycin		RESERVED as per guidelines
capsules; oral suspension; injection; 2% vaginal cream	 	
5.1.7 Some other Antibacterials		
Chloramphenicol		RESERVED as per guidelines
capsules; injection	 	
MHRA Drug Safety Update (Jul-21): Chloramphenicol eye drops containing borax or boric acid buffers: use in children younger than 2 years		
Dalbavancin		RESTRICTED Consultant only Micro. approval required
500mg infusion	MMC  	
Fidaxomicin		RESTRICTED <i>clostridium difficile</i> associated diarrhoea Micro. only
 		
200mg tablets; 40mg/mL granules for oral suspension	MMC  	
Fusidic Acid		
Sodium Fusidate		RESERVED as per guidelines
		
tablets; oral suspension; 2% cream	 	
MHRA Drug Safety Update (Sep-11): Systemic fusidic acid and interaction with statins		
Glycopeptides		
Vancomycin		
		
injection; capsules; oral suspension	MMC  	
Teicoplanin		RESERVED as per guidelines
injection	 	
Daptomycin		
Daptomycin		RESTRICTED as per guidelines
		
infusion	MMC  	
Linezolid		
Linezolid		RESTRICTED as per guidelines
		
tablets; infusion	MMC  	
Quinupristin with Dalfopristin		
Synercid®		RESTRICTED as per guidelines. Non-formulary
injection	MMC  	

Polymyxins			
Colistimethate Sodium   injection  		RESTRICTED as per guidelines	
Colistimethate Sodium (DPI)   Colobreathe® inhalation powder    		RESTRICTED as per guidelines	
MHRA Drug Safety Update (Nov-14): Colobreathe (colistimethate sodium dry powder for inhalation): risk of capsule breakage - new instructions for use			
Pristinamycin			
Pristinamycin   500mg tablets   		RESTRICTED as per BASHH guidelines for <i>Mycoplasma genitalium</i>	
Rifaximin			
Rifaximin  550mg tablets    		RESTRICTED as per guidelines	
Spectinomycin			
Spectinomycin  Kirin® injection  		RESTRICTED cephalosporin resistant gonorrhoea	
Taurolidine			
Taurolidine citrate 4% TauroLock® 4% ampoules  		RESTRICTED as per CVC guidelines	
5.1.8 Sulphonamides & Trimethoprim			
Trimethoprim			
tablets; oral suspension  			
Co-trimoxazole			
 tablets; oral suspension; infusion  		RESERVED as per guidelines	
Sulfadiazine			
tablets  		RESTRICTED	
5.1.9 Antituberculosis Drugs		 until patient stabilised then  	NICE NG33
Bedaquiline			
 tablets     		RESTRICTED MDR TB only	
Ethambutol Hydrochloride			
 tablets    			
Isoniazid			
 tablets; oral solution; injection    			
Prothionamide			
 tablets   		RESTRICTED MDR TB only	
Pyrazinamide			
 tablets   			
Rifampicin			
 capsules; oral solution; infusion   			
Rifabutin			
 caspules  		2nd line where rifampicin not suitable	
Rifater®			
 Rifampicin / Isoniazid / Pyrazinamide tablets   			
Rifinah®			
 Rifampicin / Isoniazid tablets   			
Voractiv®			
 Rifampicin / Isoniazid / Pyrazinamide / Ethambutol Hydrochloride tablets   			

Capreomycin			RESTRICTED MDR TB only Not stocked
injection	  		
Cycloserine			RESTRICTED MDR TB only Not stocked
capsules	 		
Delamanid			RESTRICTED MDR TB only
 tablets	  		
Streptomycin			RESTRICTED MDR TB only Not stocked
injection	  		
Moxifloxacin			RESTRICTED
tablets; injection	   		
Para aminosalicylic acid (PAS)			RESTRICTED MDR TB only Not stocked
granules	   		
5.1.10 Antitubercular Drugs			
Clofazimine			RESTRICTED MDR TB only
 capsules	  		
Dapsone			RESERVED
tablets	  		
5.1.11 Metronidazole & Tinidazole			
Metronidazole			
tablets; oral suspension; infusion; suppositories; vaginal gel	  		
Tinidazole			RESTRICTED
tablets	 		
5.1.12 Quinolones			
Ciprofloxacin			RESERVED as per guidelines
tablets; oral suspension; infusion (see also sections 11.3.1 & 12.1.1)	 		
Levofloxacin			RESTRICTED MDR TB only Not stocked
tablets; infusion (see also section 11.3.1)	  		
Moxifloxacin			RESTRICTED MDR TB only
tablets; infusion	  		
Nalidixic acid			RESTRICTED Urology use in children only
tablets	 		
Ofloxacin			RESTRICTED GU infections only
tablets (see also section 11.3.1)	 		
<p>MHRA Drug Safety Update (Sep-23): Fluoroquinolone antibiotics: suicidal thoughts and behaviour</p> <p>MHRA Drug Safety Update (Aug-23): Fluoroquinolone antibiotics: reminder of the risk of disabling and potentially long-lasting or irreversible side effects</p> <p>MHRA Drug Safety Update (Dec-20): Systemic & inhaled fluoroquinolones: small risk of heart valve regurgitation; consider other therapeutic options first in patients at risk</p> <p>MHRA Drug Safety Update (Jul-20): Systemically administered VEGF pathway inhibitors: risk of aneurysm and artery dissection</p> <p>MHRA Drug Safety Update (Mar-19): Fluoroquinolones: new restrictions / precautions for use due to reports of disabling & potentially long-lasting or irreversible side effects</p> <p>MHRA Drug Safety Update (Nov-18): Systemic & inhaled fluoroquinolones: small increased risk of aortic aneurysm & dissection; advice for prescribing in high-risk patients</p>			
5.1.13 Urinary-tract Infections			
Nitrofurantoin			
M/R capsules; capsules; tablets	 		
<p>MHRA Drug Safety Update (Apr-23): Nitrofurantoin: reminder of the risks of pulmonary and hepatic adverse drug reactions</p> <p>MHRA Drug Safety Update (Sep-14): Nitrofurantoin now contraindicated in most patients with an estimated glomerular filtration rate (eGFR) of less than 45 ml/min/1.73m²</p>			
Fosfomycin			RESTRICTED Micro recommendation only
sachets; infusion	  		
Methenamine Hippurate			RESTRICTED Urology Consultants only as part of ALTAR trial
tablets	  		

5.2 Antifungal drugs		GMMMG
5.2.1 Triazole Antifungals		
Fluconazole		
capsules; infusion; oral suspension.	 	
Isavuconazole		RESTRICTED micro / specialist use only
capsules; infusion	   	
Itraconazole		
capsules; oral solution; infusion	 	
Posaconazole		RESTRICTED micro / specialist use only
G/R tablets; oral suspension; infusion	   	
MHRA Drug Safety Update (Sep-16): Posaconazole (Noxafil): tablets and oral suspension are not directly interchangeable		
Voriconazole		RESTRICTED micro / specialist use only
tablets; oral suspension; infusion	   	
5.2.3 Polyene Antifungals		
Nystatin		
100,000 units/mL oral suspension	 	
Amphotericin (liposomal)		RESTRICTED micro / specialist use only
 <i>AmBisome</i> ® infusion (systemic use)	   	
Amphotericin		RESTRICTED micro / specialist use only
 <i>Fungizone</i> ®	   	
5.2.4 Echinocandin Antifungals		
Anidulafungin		1st line RESTRICTED micro / specialist use only
  <i>Ecalta</i> ® infusion	   	
Micafungin		RESTRICTED micro / specialist use only
  <i>Mycamine</i> ® infusion	   	
5.2.5 Other Antifungals		
Griseofulvin		2nd line following topical therapy
tablets	  	
Terbinafine		2nd line following topical therapy
tablets	 	
Flucytosine		RESTRICTED micro / Neonates only
infusion	 	
MHRA Drug Safety Update (Oct-20): Flucytosine (Ancotil): new contraindication in patients with DPD deficiency		

5.3 Antiviral drugs		GMMMG
Casirivimab with Imdevimab Red Ronapreve® infusion PbR X NICE MMC BNF		RESTRICTED
Molnupiravir Red Lagevrio® 200mg capsules PbR X MMC BNF		RESTRICTED CMDU see COVID-19 guidance
Nirmatrelvir with Ritonavir Red Paxlovid® 150mg/100mg tablets PbR X NICE MMC BNF		RESTRICTED see COVID-19 guidance
MHRA Drug Safety Update (Nov-23): Nirmatrelvir, ritonavir (Paxlovid▼): be alert to the risk of drug interactions with ritonavir		
Remdesivir Red Veklury® infusion PbR X NICE MMC BNF		RESTRICTED see COVID-19 guidance
Sotrovimab Red Veklury® infusion PbR X NICE MMC BNF		RESTRICTED see COVID-19 guidance
Tecovirimat monohydrate Red Tecovirimat SIGA® 200mg capsules PbR X MMC BNF		RESTRICTED patients hospitalised due to monkeypox
5.3.1 HIV Infection Red		BHIVA treatment guidelines
Nucleoside Reverse Transcriptase Inhibitors (NRTIs)		CHIVA PEP 2023
Abacavir Red tablets; oral solution PbR X MMC BNF		
Bictegravir / Emtricitabine / Tenofovir Alafenamide Red Biktarvy® tablets PbR X MMC BNF		
Emtricitabine Red capsules PbR X MMC BNF		
Lamivudine Red tablets; oral solution PbR X BNF		
Tenofovir Disoproxil Red tablets; granules PbR X NICE MMC BNF		
Tenofovir Alafenamide Red Descovy® / Odefsey® / Genvoya® tablets PbR X MMC BNF		RESTRICTED patients requiring new formulation
Tenofovir Disoproxil / Efavirenz / Emtricitabine Red Atripla® tablets PbR X MMC BNF		
Tenofovir / Cobicistat / Elvitegravir / Emtricitabine Red Stribild® tablets PbR X MMC BNF		
Tenofovir / Emtricitabine Red Truvada® tablets PbR X MMC BNF		
Emtricitabine / Rilpivirine / Tenofovir Red Eviplera® tablets PbR X MMC BNF		
Zidovudine / Lamivudine Red Combivir® tablets PbR X BNF		
Didanosine Red Videx® capsules (to be DISCONTINUED Q1 2020) PbR X MMC BNF		
Stavudine Red Zerit® capsules (to be DISCONTINUED Q1 2020) PbR X BNF		

Protease Inhibitors		BHIVA treatment guidelines
Atazanavir capsules 		
Atazanavir / Cobicistat Evotaz® tablets 		
Darunavir tablets; oral suspension 		
MHRA Drug Safety Update (Jul-18): Darunavir boosted with cobicistat: avoid use in pregnancy due to risk of treatment failure and maternal-to-child transmission of HIV-1		
Darunavir / Cobicistat RezoSta® tablets 		
MHRA Drug Safety Update (Jul-18): Darunavir boosted with cobicistat: avoid use in pregnancy due to risk of treatment failure and maternal-to-child transmission of HIV-1		
Darunavir / Cobicistat / Emtricitabine & Tenofovir Symtuza® tablets 		
MHRA Drug Safety Update (Jul-18): Darunavir boosted with cobicistat: avoid use in pregnancy due to risk of treatment failure and maternal-to-child transmission of HIV-1		
Fosamprenavir Telzir® tablets 		
Fostemsavir tromethamine Rukobia® tablets 		
Lopinavir / Ritonavir Kaletra® tablets; oral solution 		
MHRA Drug Safety Update (Oct-18): Ritonavir-containing products: reports of interaction with levothyroxine leading to reduced thyroxine levels		
Ritonavir tablets; powder for oral suspension 		
MHRA Drug Safety Update (Oct-18): Ritonavir-containing products: reports of interaction with levothyroxine leading to reduced thyroxine levels		
Saquinavir tablets 		
Tipranavir capsules 		
Non-Nucleoside Reverse Transcriptase Inhibitors (Non-NRTIs)		BHIVA treatment guidelines
Doravirine Pifeltro® tablets 		
Doravirine / Lamivudine / Tenofovir Disoproxil Fumarate Delstrigo® tablets 		
Efavirenz tablets; capsules 		
Etravirine Intelence® tablets 		
Nevirapine tablets; oral suspension; M/R tablets 		
Rilpivirine Edurant® tablets / Rekambys® injection 		
Other Antiretrovirals		BHIVA treatment guidelines
Cabotegravir Vocabria® injection 		
Dolutegravir Tivicay® tablets 		
MHRA Drug Safety Update (Oct-20): Dolutegravir (Tivicay▼, Triumeq▼, Juluca▼): updated advice on increased risk of neural tube defects		
MHRA Drug Safety Update (Jun-18): Dolutegravir (Tivicay▼, Triumeq▼, Juluca▼): increased risk of neural tube defects; DNP to women seeking to become pregnant...		

Dolutegravir / Abacavir / Lamivudine 		
Triumeq® tablets PbR X MMC BNF emc		
MHRA Drug Safety Update (Oct-20): Dolutegravir (Tivicay ▼, Triumeq ▼, Juluca ▼): updated advice on increased risk of neural tube defects		
Dolutegravir / Lamivudine 		
Dovato® tablets PbR X MMC BNF emc		
MHRA Drug Safety Update (Oct-20): Dolutegravir (Tivicay ▼, Triumeq ▼, Juluca ▼): updated advice on increased risk of neural tube defects		
Dolutegravir / Rilpivirine 		
Juluca® tablets PbR X MMC BNF emc		
MHRA Drug Safety Update (Oct-20): Dolutegravir (Tivicay ▼, Triumeq ▼, Juluca ▼): updated advice on increased risk of neural tube defects		
Enfuvirtide 		
Fuzeon® injection PbR X MMC BNF emc		
Maraviroc 		
Celsentri® tablets PbR X MMC BNF emc		
Raltegravir 		
tablets; chewable tablets; granules MMC BNF emc		
Pharmacokinetic enhancers of antiretrovirals		
Cobicistat 		
Tybost® tablets PbR X MMC BNF emc		
5.3.2 Herpesvirus Infection		
5.3.2.1 Herpes Simplex & Varicella-Zoster Infection		
Aciclovir tablets; oral suspension; infusion (see also section 13.10.3) BNF emc		
Valaciclovir tablets BNF emc		RESTRICTED Specialist use only Haematology / Renal
5.3.2.2 Cytomegalovirus (CMV) Infection		
Cidofovir infusion PbR X BNF emc		RESERVED Specialist use only
Foscarnet Sodium infusion PbR X MMC BNF emc		RESERVED Specialist use only; also for aggressive CMV retinitis
Ganciclovir infusion (see also eye gel section 11.3.3) PbR X BNF emc		RESERVED Specialist use only
Letermovir Prevmis® tablets PbR X NICE MMC BNF emc		RESERVED Specialist use only in line with NICE
Maribavir Livtency® tablets PbR X NICE MMC BNF emc blueiq		RESERVED Specialist use only in line with NICE
Valganciclovir tablets; oral solution PbR X BNF emc		RESERVED Specialist use only
5.3.3 Viral Hepatitis		
5.3.3.1 Chronic hepatitis B		
Adefovir Dipivoxil Hepsera® tablets PbR X NICE MMC BNF emc		NICE CG165
Entecavir Baraclude® tablets PbR X NICE MMC BNF emc		NHSE Hepatitis C
5.3.3.2 Chronic hepatitis C		
MHRA Drug Safety Update (Jan-17): Direct-acting antiviral interferon-free regimens to treat chronic hepatitis C: risk of hepatitis B reactivation		
MHRA Drug Safety Update (Jan-17): Direct-acting antivirals to treat chronic hepatitis C: risk of interaction with vitamin K antagonists and changes in INR		
Dasabuvir Exviera® tablets PbR X MMC BNF emc blueiq		RESTRICTED Specialist use only in line with NHSE Commissioning

<p>Elbasvir / Grazoprevir   Zepatier® tablets      </p>	<p>RESTRICTED Specialist use only in line with NICE TA413</p>
<p>Glecaprevir / Pibrentasvir   Maviret® tablets      </p>	<p>RESTRICTED Specialist use only in line with NHSE and NICE TA499</p>
<p>Ombitasvir / Paritaprevir / Ritonavir   Viekirax® tablets      </p>	<p>RESTRICTED Specialist use only in line NICE / NHSE Commissioning</p> 
<p>MHRA Drug Safety Update (Oct-18): Ritonavir-containing products: reports of interaction with levothyroxine leading to reduced thyroxine levels</p>	
<p>Sofosbuvir   Sovaldi® tablets      </p>	<p>RESTRICTED Specialist use only in line with NICE TA330</p> 
<p>MHRA Drug Safety Update (Aug-15): Simeprevir with sofosbuvir: risk of severe bradycardia and heart block when taken with amiodarone</p>	
<p>Sofosbuvir / Ledipasvir   Harvoni® tablets      </p>	<p>RESTRICTED Specialist use only in line NHSE Commissioning</p> 
<p>MHRA Drug Safety Update (May-15): Sofosbuvir with daclatasvir; sofosbuvir and ledipasvir: risks of severe bradycardia and heart block when taken with amiodarone</p>	
<p>Sofosbuvir / Velpatasvir   Epclusa® tablets      </p>	<p>RESTRICTED Specialist use only in line with NICE TA430</p>
<p>Sofosbuvir / Velpatasvir / Voxilaprevir   Vosevi® tablets      </p>	<p>RESTRICTED Specialist use only in line with NICE TA507</p>
<p>5.3.3.3 Hepatitis D</p>	
<p>Bulevirtide   Hepcludex® injection      </p>	<p>RESTRICTED Specialist use only in line with NICE TA896</p>
<p>5.3.4 Influenza</p>	
<p>Oseltamivir Tamiflu® capsules; oral suspension    </p>	<p>MHRA Drug Safety Update (Sep-12): Oseltamivir (Tamiflu): changed concentration and dosing dispenser of oral suspension</p>
<p>Zanamivir Relenza® inhalation powder    </p>	<p>RESTRICTED Virology approval only</p>
<p>Zanamivir  Dectova® 10mg/mL infusion    </p>	<p>RESTRICTED Specialist use only</p> 
<p>5.3.5 Respiratory Syncytial Virus (RSV)</p>	
<p>Palivizumab   Synagis® 100mg/mL injection     </p>	<p>RESTRICTED Specialist use only</p> 
<p>Ribavirin   capsules; tablets     </p>	<p>RESTRICTED Specialist use only</p>

5.4 Antiprotozoal drugs		GMMMG
Nitazoxanide    500mg tablets; 100mg/5mL oral suspension  MMC 		RESTRICTED Specialist use only
5.4.1 Antimalarials		
Artesunate  injection  		RESTRICTED Specialist use only
Artemether with Lumefantrine  tablets MMC  		RESTRICTED Specialist use only
Chloroquine  tablets  		RESTRICTED Specialist use only
MHRA Drug Safety Update (Feb-22): Hydroxychloroquine, chloroquine: increased risk of CV events when used with macrolide antibiotics; reminder of psychiatric reactions MHRA Drug Safety Update (Mar-20): Chloroquine and Hydroxychloroquine not licensed for coronavirus (COVID-19) treatment		
Mefloquine  tablets  		RESTRICTED Specialist use only
Primaquine  tablets  		RESTRICTED Specialist use only
Proguanil Hydrochloride  tablets  		RESTRICTED Specialist use only
Proguanil Hydrochloride / Atovaquone  Malarone® tablets  		RESTRICTED Specialist use only
Pyrimethamine  tablets MMC  		RESTRICTED Specialist use only
Pyrimethamine with Sulfadoxine  tablets  		RESTRICTED Specialist use only
Quinine Dihydrochloride   injection  		RESTRICTED Specialist use only
MHRA Drug Safety Update (Nov-17): Quinine: reminder of dose-dependent QT-prolonging effects; updated interactions		
Quinine Sulfate  tablets  		RESTRICTED Specialist use only
MHRA Drug Safety Update (Nov-17): Quinine: reminder of dose-dependent QT-prolonging effects; updated interactions		
5.4.2 Amoebicides		
Metronidazole (see also section 5.1.11)  		
Tinidazole Fasigyn® tablets  		RESERVED Specialist use only
Diloxanide Furoate tablets  		RESTRICTED Non-formulary micro. recommendation only
5.4.3 Trichomonacides		
Metronidazole (see also section 5.1.11)  		
5.4.4 Antigiardial drugs		
Metronidazole (see also section 5.1.11)  		

5.4.5 Leishmaniicides		
Paromomycin  tablets 		RESTRICTED treatment of Cryptosporidiosis
Sodium Stibogluconate  injection 		RESTRICTED treatment of Leishmaniicides
5.4.7 Drugs for toxoplasmosis		
Sulfadiazine  tablets 		RESTRICTED treatment of toxoplasmosis micro. recommendation only
5.4.8 Drugs for pneumocystis pneumonia		
Atovaquone  oral suspension 		RESTRICTED Specialist use only
Pentamidine Isethionate  injection 		RESTRICTED Specialist use only

5.5 Anthelmintics		GMMMG
5.5.1 Drugs for Threadworms (pinworms, <i>Enterobius vermicularis</i>)		
Albendazole  tablets   		RESTRICTED Specialist use only
Mebendazole chewable tablets; oral suspension  		
5.5.2 Ascaricides		
Levamisole  tablets   		RESTRICTED Specialist use only
5.5.5 Schistosomicides (bilharziasis)		
Praziquantel  tablets   		RESTRICTED Schistosomicides / tapeworm
5.5.6 Filaricides		
Diethylcarbamazine  tablets   		RESTRICTED Specialist use only

Section 6: Endocrine System

Supported by the
formulary (click here)



6.1 Drugs used in diabetes

6.1.1 Insulins

6.1.1.1 Short-acting insulins

6.1.1.2 Intermediate & long-acting insulins

Biphasic insulins

6.1.2 Antidiabetic drugs

6.1.2.1 Sulphonylureas

6.1.2.2 Biguanides

6.1.2.3 Other antidiabetic drugs

Alpha glucosidase inhibitors

Dipeptidyl peptidase-4 (DPP-4) inhibitors

Rapid acting insulin secretagogues (meglitinides)

Glucagon-like peptide-1 (GLP-1) receptor agonists

Sodium-glucose co-transporter 2 (SGLT2) inhibitors

Thiazolidinediones

6.1.4 Treatment of hypoglycaemia

6.2 Thyroid & antithyroid drugs

6.2.1 Thyroid hormones

6.2.2 Antithyroid drugs

6.3 Corticosteroids

6.3.1 Replacement therapy

6.3.2 Glucocorticoid therapy

6.4 Sex hormones

6.4.1 Female sex hormones and their modulators

6.4.1.1 Oestrogens & HRT

6.4.1.2 Progestogens and progesterone receptor modulators

6.4.2 Male sex hormones & antagonists

6.5 Hypothalamic and pituitary hormones & anti-oestrogens

6.5.1 Hypothalamic & anterior pituitary hormones & anti-oestrogens

6.5.2 Posterior pituitary hormones & antagonists

6.6 Drugs affecting bone metabolism

6.6.1 Calcitonin & parathyroid hormone

6.6.2 Bisphosphonates & other drugs affecting bone metabolism

6.7 Other endocrine drugs

6.7.1 Bromocriptine & other dopaminergic drugs

6.7.2 Drugs affecting gonadotrophins

6.7.3 Metyrapone

6.7.4 Somatomedins

Trust Guidelines

Adult medicines and prescribing guidelines
 Paediatric medicines and prescribing guidelines
 Neonatal guidelines (link to Staffnet site)
[Non-formulary Conversion Table](#)

NICE Guidance

Safer insulin prescribing (KTT20)
 Diabetes in pregnancy: management from preconception to the postnatal period (NG3)
 Type 1 diabetes in adults: diagnosis and management (NG17)
 Diabetes (type 1 and type 2) in children and young people: diagnosis and management (NG18)
 Diabetic foot problems: prevention and management (NG19)
 Type 2 diabetes in adults: management (NG28)
 Heavy menstrual bleeding: assessment and management (NG88)
 Burosumab for treating X-linked hypophosphataemia in children and young people (HST8)
 Human growth hormone - adults (TA64)
 Diabetes (type 1) - insulin pump therapy (TA151)
 Osteoporosis - Primary Prevention (TA160)
 Osteoporosis - Secondary Prevention (TA161)
 Human growth hormone (somatropin) for the treatment of growth failure in children (review) (TA188)
 Osteoporotic Fractures - denosumab (TA204)
 Bone metastases from solid tumours - denosumab (TA265)
 Type 2 diabetes - Dapagliflozin combination therapy (TA288)
 Diabetes (type 2) - canagliflozin (TA315)
 Tolvaptan for treating autosomal dominant polycystic kidney disease (TA358)
 Canagliflozin, dapagliflozin and empagliflozin as monotherapies for treating type 2 diabetes (TA390)
 Dapagliflozin in triple therapy for treating type 2 diabetes (TA418)
 Bisphosphonates for treating osteoporosis (TA464)
 Ertugliflozin as monotherapy or with metformin for treating type 2 diabetes (TA572)
 Ertugliflozin with metformin and a dipeptidyl peptidase-4 inhibitor for treating type 2 diabetes (TA583)
 Dapagliflozin with insulin for treating type 1 diabetes (TA597)
 Sotagliflozin with insulin for treating type 1 diabetes (TA622)
 Liraglutide for managing overweight and obesity (TA664)
 Dapagliflozin for treating chronic kidney disease (TA775)
 Romosozumab for treating severe osteoporosis (TA791)
 Relugolix-estradiol-norethisterone acetate for treating moderate to severe symptoms of uterine fibroids (TA832)
 Somatogron for treating growth disturbance in people 3 years and over (TA863)

GMMMG Formulary

Formulary Homepage
 Chapter 6: Endocrine system (Complete)
 GMMMG Adult [Red](#)/[Amber](#)/[Green](#); DNP and Grey Drug List
 GMMMG Paediatric [Red](#)/[Amber](#)/[Green](#) Drug List

6.1 Drugs used in diabetes		GMMMG
6.1.1 Insulins		
Insulins must ONLY be initiated by practitioners experienced in their use Insulins must be prescribed by BRAND NAME		
MHRA Drug Safety Update (Apr-15): High strength, fixed combination & biosimilar insulin products: minimising the risk of medication error		
		NICE NG3
		NICE NG17
		NICE NG18
		NICE NG19
		NICE NG28
6.1.1.1 Short-acting insulins		
Human		
Actrapid®		
Human Insulin	 	
apidra®		
Insulin Glulisine	 	
Fiasp®		
Insulin Aspart	  	
Humalog®		
Insulin Lispro	 	
Humulin R®		
 Human Insulin	  	
Humulin S®		
Human Insulin	 	
Insulin Lispro Sanofi®		
Insulin Lispro	  	
Lyumjev®		
 Insulin Lispro	  	
NovoRapid®		
Insulin Aspart	  	
Trurapi®		
 Insulin Aspart	  	
Animal		
Hypurin® Bovine Neutral		
Insulin Bovine	 	
Hypurin® Porcine Neutral		
Insulin Porcine	 	
6.1.1.2 Intermediate & long-acting insulins		
Human		
Humulin I® Insulin		
Isophane Insulin	 	
Insulatard®		
Isophane Insulin	 	
Animal		
Hypurin® Bovine Isophane		
Isophane Insulin	 	
Hypurin® Porcine Isophane		
Isophane Insulin	 	

Long-acting insulins		
Human		
Levemir®		
Insulin Detemir	 MMC BNF emc	
Lantus®		
Insulin Glargine	 MMC BNF emc	2nd line use in patients where normal basal insulins cause nocturnal hypoglycaemia
Abasaglar®		
Insulin Glargine biosimilar	 MMC BNF emc	
Toujeo®		
Insulin Glargine HIGH STRENGTH	 MMC BNF emc	
Tresiba®		
Insulin Degludec	 MMC BNF emc	RESTRICTED 3rd line after Levemir & Lantus Diabetes Consultant only
MHRA Drug Safety Update (Apr-13): Insulin degludec (Tresiba ▼): available in additional higher strength		
Animal		
Hypurin® Bovine Lente		
Insulin Zinc suspension	 BNF emc	
Biphasic insulins		
Human		
Humalog® Mix 25		
Biphasic Insulin Lispro	 BNF emc	
Humalog® Mix 50		
Biphasic Insulin Lispro	 BNF emc	
Humulin M3®		
Biphasic Isophane Insulin	 BNF emc	
Insuman® Comb 25		
Biphasic Isophane Insulin	 BNF emc	
NovoMix® 30		
Biphasic Insulin Aspart	 MMC BNF emc	
Animal		
Hypurin® Porcine 30/70 Mix Insulin		
Biphasic Isophane Insulin	 BNF emc	
6.1.2 Antidiabetic drugs		
6.1.2.1 Sulfonylureas		
Gliclazide		
tablets	 BNF emc	
Glipizide		
tablets	 BNF emc	RESTRICTED Not for initiation
6.1.2.2 Biguanides		
Metformin Hydrochloride		
 oral solution; tablets	 MMC BNF emc	
MHRA Drug Safety Update (Jun-22): Metformin and reduced vitamin B12 levels: new advice for monitoring patients at risk		
MHRA Drug Safety Update (Mar-22): Metformin in pregnancy: study shows no safety concerns		

6.1.2.3 Other antidiabetic drugs		NICE NG28
Alpha glucosidase inhibitors		
Acarbose		
tablets	 	
Dipeptidyl peptidase 4 (DPP 4) inhibitors		
MHRA Drug Safety Update (Sep-12): Dipeptidylpeptidase-4 inhibitors: risk of acute pancreatitis		
Alogliptin		
		
tablets	  	
Linagliptin		
		
tablets	  	
Saxagliptin		
		2nd line to improve glycaemic control in adults with metformin
tablets	  	
Sitagliptin		
		
tablets	  	
Rapid acting insulin secretagogues (meglitinides)		
Nateglinide		
tablets	  	2nd line
Repaglinide		
tablets	  	2nd line
Glucagon-like peptide-1 (GLP-1) receptor agonists		
MHRA Drug Safety Update (Jun-19): GLP-1 receptor agonists: reports of diabetic ketoacidosis when concomitant insulin was rapidly reduced or discontinued		
Dulaglutide		
		RESTRICTED 1st line weekly preparation Diabetes Consultants only
injection	  	
Exenatide		
		2nd line patients with poor glycaemic control
injection	   	
Bydureon®		
		3rd line after failure / inadequate response to oral therapy
Exenatide prolonged release (once weekly injection)	  	
Liraglutide (Victoza®)		
		2nd line to achieve glycaemic control with metformin or a sulphonylurea
6mg/mL pre-filled pen	   	PRESCRIBE BY BRAND NAME
Liraglutide (Saxenda®)		
		RESTRICTED in line with NICE TA664 PRESCRIBE BY BRAND NAME
6mg/mL pre-filled pen	   	
MHRA Drug Safety Update (Nov-23): Ozempic▼(semaglutide) and Saxenda (liraglutide): vigilance required due to potentially harmful falsified products		
GLP-1 receptor agonists (continued)		
Lixisenatide		
		RESTRICTED 3rd line as per by GMMMG & NICE Diabetes Consultants only
injection	  	
Semaglutide		
		1st line weekly preparation
Ozempic® injection	  	
MHRA Drug Safety Update (Nov-23): Ozempic▼(semaglutide) and Saxenda (liraglutide): vigilance required due to potentially harmful falsified products		
Semaglutide		
		RESTRICTED as per by GMMMG
Rybelsus® tablets	   	

Sodium-glucose co-transporter 2 (SGLT2) inhibitors	
MHRA Drug Safety Update (Mar-20): SGLT2 inhibitors: monitor ketones in blood during treatment interruption for surgical procedures or acute serious medical illness	
MHRA Drug Safety Update (Feb-19): SGLT2 inhibitors: reports of Fournier's gangrene (necrotising fasciitis of the genitalia or perineum)	
MHRA Drug Safety Update (Mar-17): SGLT2 inhibitors: updated advice on increased risk of lower-limb amputation (mainly toes)	
MHRA Drug Safety Update (Apr-16): SGLT2 inhibitors: updated advice on the risk of diabetic ketoacidosis	
Canagliflozin tablets    	RESTRICTED in line with NICE Diabetes Consultants only
MHRA Drug Safety Update (Jun-16): Canagliflozin (Invokana▼, Vokanamet▼): signal of increased risk of lower extremity amputations in trial in high CV risk patients	
Dapagliflozin Green tablets    	RESTRICTED in line with NICE
MHRA Drug Safety Update (Apr-16): Dapagliflozin (Forxiga): no longer authorised for treatment of type 1 diabetes mellitus	
Empagliflozin Green tablets    	RESTRICTED in line with NICE
Ertugliflozin tablets    	RESTRICTED in line with NICE Diabetes Consultants only
Sotagliflozin Zynquista® 200mg tablets    	RESTRICTED in line with NICE Diabetes Consultants only
Thiazolidinediones	
Pioglitazone tablets   	2nd line add-on with metformin or a sulphonylurea
MHRA Drug Safety Update (Aug-11): Pioglitazone: risk of bladder cancer	
6.1.4 Treatment of hypoglycaemia	
Glucagon 1mg injection  	
Glucose gel 40% oral gel  	
Diazoxide Green tablets   	Hyperinsulinaemic Hypoglycaemia

6.2 Thyroid & antithyroid drugs		GMMMG
6.2.1 Thyroid hormones		
Levothyroxine Sodium		
oral solution; tablets	 	
MHRA Drug Safety Update (May-21): Levothyroxine: new prescribing advice for patients who experience symptoms on switching between different levothyroxine products		
Liothyronine Sodium		2nd line use (I.V. RESTRICTED to hypothyroid coma)
 		
injection; tablets	 	
6.2.2 Antithyroid drugs		
Carbimazole		
tablets	 	
MHRA Drug Safety Update (Feb-19): Carbimazole: increased risk of congenital malformations; strengthened advice on contraception		
MHRA Drug Safety Update (Feb-19): Carbimazole: risk of acute pancreatitis		
Iodine (Aqueous Iodine Oral Solution)		
		
Lugol's Iodine	 	
Potassium Iodide		
tablets	 	
Propylthiouracil		
		
tablets	 	

6.3 Corticosteroids		GMMMG
MHRA Drug Safety Update (Aug-17): Corticosteroids: rare risk of central serous chorioretinopathy with local as well as systemic administration		
6.3.1 Replacement therapy		
Fludrocortisone		
tablets	 	
6.3.2 Glucocorticoid therapy		
Prednisolone		
	 	
Dexamethasone		
	 	
Hydrocortisone		
	 	
MHRA Drug Safety Update (Dec-18): Hydrocortisone muco-adhesive buccal tablets: should not be used off-label for adrenal insufficiency in children due to serious risks		
Hydrocortisone M/R		
5mg tablets	MMC  	RESTRICTED 2 nd line use in adrenal insufficiency
Hydrocortisone		
Green	MMC  	RESTRICTED 2 nd line use in adrenal insufficiency
Alkindi® granules in capsules		
MHRA Drug Safety Update (Feb-21): Alkindi (granules): risk of acute adrenal insufficiency in children when switching from hydrocortisone tablet formulations to granules		
Betamethasone		
	 	RESTRICTED Specialist use only
Methylprednisolone		
	 	
MHRA Drug Safety Update (Oct-17): Methylprednisolone injectable medicine containing lactose (Solu-Medrone 40 mg): do not use in patients with cows' milk allergy		
Triamcinolone		
(see also section 10.1.2.2)	 	RESTRICTED Specialist use only

6.4 Sex hormones		GMMMG
6.4.1 Female sex hormones and their modulators		
6.4.1.1 Oestrogens & HRT		
Conjugated oestrogens with progestogen		
Premique®		2nd line use oral (continuous combined HRT)
tablets	BNF emc	
Estradiol with Progestogen		
Elleste-Duet®		1st line use oral (sequential HRT)
tablets	BNF emc	
Femoston®		2nd line use oral (sequential HRT)
tablets	BNF emc	
Kliovance®		1st line use oral (continuous combined HRT)
tablets	MMC BNF emc	
Evorel Conti®		RESTRICTED (Continuous combined HRT) when oral contraindicated
patch	BNF emc	
Estradiol only		
Elleste Solo®		1st line use oral (oestrogen only HRT)
tablets	BNF emc	
Estradot®		RESTRICTED (Oestrogen only HRT) when oral contraindicated.
patch	BNF emc	
Evorel®		RESTRICTED Paed. Endocrine Consultants
patch	MMC BNF emc	
Ethinylestradiol, raloxifene & tibolone		
Ethinylestradiol		2 microgram tablets (unlicensed) for amenorrhoea
tablets	MMC BNF emc	
Raloxifene Hydrochloride		RESTRICTED Specialist Med. Consultant only
tablets	NICE MMC BNF emc	
Tibolone		3rd line use oral (continuous combined HRT)
tablets	BNF emc	
6.4.1.2 Progestogens and progesterone receptor modulators		
Dydrogesterone		
tablets	BNF emc	
Medroxyprogesterone Acetate		
<i>Depo-Provera®</i> 150mg/mL injection	BNF emc	
Medroxyprogesterone Acetate		
<i>Sayana Press®</i> 104mg/0.65 mL injection	MMC BNF emc	
Norethisterone		
tablets	BNF emc	
Progesterone		
Red (suppositories in IVF)		
pessaries; vaginal capsules; injection	MMC BNF emc	
Ulipristal Acetate		
Red		RESTRICTED Specialist use only uterine fibroids
<i>Esmya®</i> 5mg tablets	MMC BNF emc	
MHRA Drug Safety Update (Feb-21): Ulipristal acetate 5mg (Esmya): further restrictions due to risk of serious liver injury		
MHRA Drug Safety Update (Aug-18): Esmya - risk of serious liver injury: new restrictions to use, requirements for LFT monitoring before, during & after treatment		
MHRA Drug Safety Update (Mar-18): Esmya (ulipristal acetate) for uterine fibroids: do not initiate or re-start treatment; monitor LFT in current and recent users		

6.4.2 Male sex hormones & antagonists		
Testosterone & Esters		
Oral		
Testosterone Green Amber	 	RESTRICTED Specialist use only
injection & implants only		
Transdermal preparations		
Androstanolone (aka Dihydrotestosterone (DHT))	  	RESTRICTED Specialist use only - 3 rd line
Andractim® 2.5% gel		
MHRA Drug Safety Update (Jan-23): Topical testosterone (Testogel): risk of harm to children following accidental exposure		
Testosterone	  	RESTRICTED Specialist use only
Tostran® 2% gel		
MHRA Drug Safety Update (Jan-23): Topical testosterone (Testogel): risk of harm to children following accidental exposure		
Anti-androgens		
Cyproterone Acetate Green	 	RESTRICTED Specialist use only
tablets (see also section 8.3.4.2)		
Finasteride Amber	 	RESTRICTED Specialist use only
tablets		
MHRA Drug Safety Update (May-17): Finasteride: rare reports of depression and suicidal thoughts		

6.5 Hypothalamic & pituitary hormones & anti-oestrogens		GMMMG
6.5.1 Hypothalamic & anterior pituitary hormones & anti-oestrogens		
Anti-oestrogens		
Clomifene Citrate 		
tablets	 	
Anterior pituitary hormones (Corticotrophins)		
Tetracosactide 		RESTRICTED test for adrenocortical insufficiency
injection	 	
Corticotropin releasing hormone 		RESTRICTED Specialist use only
injection	 	
Anterior pituitary hormones (Gonadotrophins)		
Human Chorionic Gonadotrophin (hCG)  		RESTRICTED Specialist use only
Gonasi® injection	  	
Recombinant human follicle stimulating hormone (r-hFSH) 		RESTRICTED Specialist use only
Ovaleap® injection	  	
Anterior pituitary hormones (Growth Hormone)		
Somatropin   		RESTRICTED as per NICE
injection	    	
Somatogon  		RESTRICTED as per NICE
Ngenla® injection	    	
Growth hormone for children		
Growth hormone for primary and secondary hypopituitarism		
Growth hormone for adults except in proven primary and secondary hypopituitarism		
Anterior pituitary hormones (Growth Hormone receptor antagonists)		
Pegvisomant  		RESTRICTED acromegaly on named patient basis NOT STOCKED
injection	    	
Hypothalamic hormones		
Gonadorelin (GnRH; LHRH) 		RESTRICTED Specialist use only
injection	 	
Protirelin (TRH) 		RESTRICTED Specialist use only
injection	 	
6.5.2 Posterior pituitary hormones & antagonists		
Desmopressin		RESTRICTED Haematology Consultants only
injection; oral lyophilisates; nasal spray; solution; tablets (see also section 7.4.2)	  	
Terlipressin Acetate		RESTRICTED adjunct in oesophageal varices
injection	 	
MHRA Drug Safety Update (Mar-23): Terlipressin: new recommendations to reduce risks of respiratory failure & septic shock in patients with type 1 hepatorenal syndrome		
Tolvaptan  		RESTRICTED Adult. Endocrine / Renal Consultant only
tablets	    	
Vasopressin		RESTRICTED pituitary diabetes insipidus
injection	 	
Antidiuretic hormone antagonists		
Demeclocycline Hydrochloride 		RESTRICTED SIADH only
capsules (see also section 5.1.3)	  	

6.6 Drugs affecting bone metabolism		GMMMG
6.6.1 Calcitonin & parathyroid hormone		
Calcitonin (salmon) / Salcatonin (Miacalcic®)		RESTRICTED osteoporosis patients with acute fracture pain.
injection	MMC BNF emc	
MHRA Drug Safety Update (Aug-12): Calcitonin-containing medicines should no longer be used in treatment of osteoporosis.		
Parathyroid hormone		RESTRICTED postmenopausal osteoporosis if failure or non-compliance with bisphosphonates
Red  		
injection	PbR X MMC BNF emc	
Teriparatide (Forsteo®)		RESTRICTED as per NICE/NHSE
Red  		
250 micrograms / mL injection	PbR X NICE MMC BNF emc	Paeds. see decision tables
Teriparatide (Movymia®)		RESTRICTED as per forsteo for new patients
Red  		
250 micrograms / mL injection	PbR X NICE MMC BNF emc	
6.6.2 Bisphosphonates & other drugs affecting bone metabolism		
MHRA Guidance (Dec-14): Bisphosphonates: use and safety		
MHRA Drug Safety Update (Dec-15): Bisphosphonates: very rare reports of osteonecrosis of the external auditory canal		
MHRA Drug Safety Update (Jun-11): Bisphosphonates: atypical femoral fractures		
MHRA Drug Safety Update (Nov-09): Bisphosphonates: osteonecrosis of the jaw		
Alendronic Acid		1st line use
tablets	NICE MMC BNF emc	
Risedronate Sodium		2nd line Osteoporosis & Paget's disease
tablets	NICE MMC BNF emc	
Strontium Ranelate		3rd line osteoporosis patients unable to take bisphosphonates
Red 		
oral suspension	MMC BNF emc	
Ibandronic Acid		RESTRICTED monthly treatment when daily/weekly dosing contraindicated; NICE TA464
Red  injection  tablets		
tablets; injection	NICE MMC BNF emc	
Denosumab		RESTRICTED specialist use / NICE TA204
Amber 		
Prolia® injection	NICE MMC BNF emc	
MHRA Drug Safety Update (May-22): Denosumab 60mg (Prolia): should not be used in patients under 18 years due to the risk of serious hypercalcaemia		
MHRA Drug Safety Update (Aug-20): Denosumab 60mg (Prolia): increased risk of multiple vertebral fractures after stopping or delaying ongoing treatment		
MHRA Drug Safety Update (Jun-17): Denosumab (Xgeva ▼, Prolia): reports of osteonecrosis of the external auditory canal		
MHRA Drug Safety Update (Jul-15): Denosumab (Xgeva ▼, Prolia); intravenous bisphosphonates: osteonecrosis of the jaw—further measures to minimise risk		
Denosumab		RESTRICTED specialist use / NICE TA265
Red 		
Xgeva® injection	NICE MMC BNF emc	
MHRA Drug Safety Update (Jun-18): Denosumab (Xgeva ▼) for advanced malignancies involving bone: study data show new 1ry malignancies reported more frequently...		
MHRA Drug Safety Update (Jun-18): Denosumab (Xgeva ▼) for giant cell tumour of bone: risk of clinically significant hypercalcaemia following discontinuation		
MHRA Drug Safety Update (Jun-17): Denosumab (Xgeva ▼, Prolia): reports of osteonecrosis of the external auditory canal		
MHRA Drug Safety Update (Jul-15): Denosumab (Xgeva ▼, Prolia); intravenous bisphosphonates: osteonecrosis of the jaw—further measures to minimise risk		
Zoledronic Acid		RESTRICTED see decision tables; also NICE TA464
Red 		
infusion	NICE MMC BNF emc	
Burosumab		RESTRICTED specialist use only XLH / TIO
Red 		
infusion	NICE MMC BNF emc	
Romosozumab		RESTRICTED specialist use NICE TA791
Red 		
Evenity® injection	NICE MMC BNF emc	

6.7 Other endocrine drugs		GMMMG
6.7.1 Bromocriptine & other dopaminergic drugs		
Bromocriptine		
1mg; 2.5mg tablets	MMC BNF emc	
Cabergoline		
500 microgram tablets	BNF emc	RESTRICTED Hyperprolactinaemia
6.7.2 Drugs affecting gonadotrophins		
Danazol		
capsules	BNF emc	
Buserelin		
Red		RESTRICTED IVF
injection (see also section 8.3.4.2)	MMC BNF emc	
Buserelin Acetate		
Red		RESTRICTED adult haem-oncology patients
Suprecur® nasal spray	MMC BNF emc	
Goserelin		
Amber Red		
implant (also section 8.3.4.2)	BNF emc	
Leuprorelin Acetate		
Amber Red		
injection (also section 8.3.4.2)	MMC BNF emc	
Triptorelin		
Amber Red		RESTRICTED
injection (also section 8.3.4.2)	MMC BNF emc	
Cetrorelix acetate		
Red		RESTRICTED IVF
injection	MMC BNF emc	
Ganirelix		
Red		RESTRICTED IVF
injection	MMC BNF emc	
Relugolix with estradiol & norethisterone acetate		
Green		RESTRICTED specialist use NICE TA832
Ryeqo® 40mg/1mg/0.5mg tablets	NICE MMC BNF emc	
Goserelin/Leuprorelin - Licensed Indications (Pre-op management prior to endometrial ablation/fibroid surgery)		Amber
Goserelin/Leuprorelin/Triptorelin - Licensed Indications (Prostate cancer for all and breast cancer for Goserelin)		Amber
Goserelin/Leuprorelin/Triptorelin - Precocious puberty and for testosterone castration in sex offenders (unlicensed in goserelin and leuprorelin)		Red
Goserelin/Leuprorelin/Triptorelin - For all other unlicensed indications (including long term use > 6 months)		Red
6.7.3 Metyrapone		
Metyrapone		
Red		RESTRICTED Specialist use only
250mg capsules	BNF emc	
6.7.4 Somatomedins		
Mecasermin		
££		RESTRICTED Specialist use only
10mg/mL injection	PbR X BNF emc	
MHRA Drug Safety Update (Jan-20): Mecasermin (Increlex ▼): risk of benign and malignant neoplasia		

Section 7: Obstetrics, gynaecology & urinary tract disorders

Supported by the
formulary ([click here](#))



7.1 Drugs used in Obstetrics

7.1.1 Prostaglandins & oxytocics

7.1.1.1 Ductus arteriosus

7.1.2 Mifepristone

7.1.3 Myometrial relaxants

7.2 Treatment of vaginal & vulval conditions

7.2.1 Preparations for vaginal & vulval changes

7.2.2 Vaginal & vulval infections

7.3 Contraceptives

7.3.1 Combined hormonal contraceptives

Ethinylestradiol with Desogestrel

Ethinylestradiol with Gestodene

Ethinylestradiol with Levonorgestrel

Ethinylestradiol with Norelgestromin

Ethinylestradiol with Norethisterone

Ethinylestradiol with Norgestimate

Mestranol with Norethisterone

7.3.2 Progestogen-only contraceptives

7.3.2.1 Oral progestogen-only contraceptives

7.3.2.2 Parenteral progestogen-only contraceptives

7.3.2.3 Intra-uterine progestogen-only device

7.3.5 Emergency contraception

7.4 Drugs for genito-urinary disorders

7.4.1 Drugs for urinary retention

7.4.2 Drugs for urinary, enuresis & incontinence

7.4.3 Drugs used in urological pain

7.4.4 Bladder instillations & urological surgery

7.4.5 Drugs for erectile dysfunction

7.4.6 Drugs for premature ejaculation

Trust Guidelines

Adult medicines and prescribing guidelines
Paediatric medicines and prescribing guidelines
Neonatal guidelines (link to Staffnet site)
[Non-formulary Conversion Table](#)

NICE Guidance

Long-acting reversible contraception (CG30)
Lower urinary tract symptoms (CG97)
Nocturnal enuresis - the management of bedwetting in children and young people (CG111)
Antenatal and postnatal mental health: clinical management and service guidance (CG192)
Heavy menstrual bleeding: assessment and management (NG88)
Urinary incontinence and pelvic organ prolapse in women: management (NG123)
Caesarean birth (NG192)
Antenatal care for uncomplicated pregnancies (NG201)
Inducing labour (NG207)
Intrapartum care for healthy women and babies (NG235)
Overactive bladder - mirabegron (TA290)
Pentosan polysulfate sodium for treating bladder pain syndrome (TA610)

GMMMG Formulary

Formulary Homepage
Chapter 7: Obstetrics, gynaecology & urinary tract disorders (Complete)
GMMMG Adult [Red](#)/[Amber](#)/[Green](#); DNP and Grey Drug List
GMMMG Paediatric [Red](#)/[Amber](#)/[Green](#) Drug List

7.1 Drugs used in Obstetrics		GMMMG
7.1.1 Prostaglandins & oxytocics		NICE NG207
Carbetocin <small>Red</small>		RESTRICTED Obs & Gynae Consultants only
<i>Pabal</i> ® injection	MMC BNF emc	
Carboprost <small>Red</small>		
injection	BNF emc	
Ergometrine Maleate <small>Red</small>		
injection	BNF emc	
Gemeprost <small>Red</small>		
pessaries	BNF emc	
Oxytocin <small>Red</small>		
injection	BNF emc	
Dinoprostone <small>Red</small>		RESTRICTED Obs & Gynae Consultants only
injection; pessaries; vaginal gel; vaginal tablet	MMC BNF emc	
7.1.1.1 Drugs affecting the ductus arteriosus		(see also BNFC)
Maintenance of patency		
Alprostadil <small>Red</small>		
<i>Prostin VR</i> ® infusion	MMC BNF emc	
Closure of the ductus arteriosus		
Indometacin <small>Red</small>		
injection	BNF emc	
7.1.2 Mifepristone		
Mifepristone <small>Red</small>		
tablets	BNF emc	
7.1.3 Myometrial relaxants		
Atosiban		
Atosiban <small>Red</small>		RESTRICTED Obs & Gynae Consultants only
infusion; injection	MMC BNF emc	
Beta₂ agonists		
Salbutamol <small>Red</small>		
injection (see also section 3.1.1.1)	BNF emc	
Terbutaline Sulfate <small>Red</small>		
injection (see also section 3.1.1.1)	BNF emc	

7.2 Treatment of vaginal & vulval conditions		GMMMG
7.2.1 Preparations for vaginal & vulval changes		
Oestrogens, topical		
Estradiol		
Vagifem® 10 microgram pessaries	BNF emc	
Estriol		
0.01% cream	BNF emc	
Estradiol vaginal ring		RESTRICTED Obs & Gynae Consultants only
Estring® 7.5 microgram / 24 hours ring	BNF emc	
7.2.2 Vaginal & vulval infections		
Preparations for vaginal & vulval candidiasis		
Clotrimazole		
cream; pessaries	BNF emc	
Miconazole		
vaginal cream	BNF emc	
Preparations for other vaginal infections		
Clindamycin		
2% vaginal cream	BNF emc	
Nystatin		
vaginal cream; pessaries	BNF emc	
Metronidazole		RESTRICTED Obs & Gynae Consultants only
Zidoval® 0.75% vaginal gel	MMC BNF emc	
Boric acid		RESTRICTED specialist use only for vulvovaginal candidiasis
Red U vaginal pessary	MMC emc	

7.3 Contraceptives		GMMMG
MHRA Drug Safety Update (Mar-19): Medicines with teratogenic potential: what is effective contraception and how often is pregnancy testing needed?		
7.3.1 Combined hormonal contraceptives		NICE CG30
MHRA Drug Safety Update (Mar-14): Combined hormonal contraceptives: risk of venous thromboembolism		
Ethinylestradiol with Desogestrel		
Munalea®		2nd line due to increased risk of VTE
tablets	 	
Mercilon®		2nd line due to increased risk of VTE
tablets	 	
Ethinylestradiol with Gestodene		
Femodene®		2nd line due to increased risk of VTE
tablets	 	
Aidulan®		2nd line due to increased risk of VTE
20microgram / 75 microgram tablets	 	
Ethinylestradiol with Levonorgestrel		NICE NG88
TriRegol®		
tablets	 	
Microgynon 30®		
tablets	 	
Ovranette®		
tablets	 	
Ethinylestradiol with Norelgestromin		
Evra®		RESTRICTED in line with GMMMG and SmPC
patch	  	
Ethinylestradiol with Norethisterone		
Loestrin 20®		
tablets	 	
Loestrin 30®		
tablets	 	
Norimin®		
tablets	 	
Ethinylestradiol with Norgestimate		
Cilest®		
tablets	 	
Mestranol with Norethisterone		
Norinyl-1®		2nd line due to increased risk of VTE
tablets	 	
7.3.2 Progestogen-only contraceptives		
7.3.2.1 Oral progestogen-only contraceptives		
Desogestrel		
Cerazette® 75 microgram tablets	 	
Levonorgestrel		
Norgeston® 35 microgram tablets	 	
Norethisterone		
Noriday® 350 microgram tablets	 	

7.3.2.2 Parenteral progestogen-only contraceptives	
Injectable preparations	
Medroxyprogesterone Acetate	
<i>Depo-Provera</i> ® 150mg/mL intramuscular injection	 
Medroxyprogesterone Acetate	
<i>Sayana Press</i> ® 160mg/mL subcutaneous injection	  
Implants	
Etonogestrel	2nd line as per MMC
<i>Nexplanon</i> ® 68mg subdermal implant	  
MHRA Drug Safety Update (Feb-20): Nexplanon (etonogestrel) contraceptive implants: new insertion site to reduce rare risk of neurovascular injury & implant migration	
MHRA Drug Safety Update (Jun-16): Nexplanon (etonogestrel) contraceptive implants: reports of device in vasculature and lung	
7.3.2.3 Intra-uterine progestogen-only device	
Levonorgestrel	
<i>Mirena</i> ® 20micrograms/24 hours IUD	 
MHRA Drug Safety Update (Jan-16): Levonorgestrel-releasing intrauterine systems: prescribe by brand name	
Levonorgestrel	RESTRICTED Specialist use Tertiary Services only
<i>Jaydess</i> ® 13.5mg IUD	  
MHRA Drug Safety Update (Jan-16): Levonorgestrel-releasing intrauterine systems: prescribe by brand name	
Levonorgestrel	RESTRICTED Specialist use Tertiary Services only
<i>Kyleena</i> ® 19.5mg IUD	  
MHRA Drug Safety Update (Jan-16): Levonorgestrel-releasing intrauterine systems: prescribe by brand name	
7.3.5 Emergency contraception	
Levonorgestrel	
<i>Levonelle</i> ® 1500 microgram tablets	 
MHRA Drug Safety Update (Sep-16): Levonorgestrel-containing emergency hormonal contraception: advice on interactions with hepatic enzyme inducers...	
MHRA Drug Safety Update (Aug-14): Levonorgestrel and ulipristal remain suitable emergency contraceptives for all women	
Ulipristal Acetate	RESTRICTED emergency contraception (SARC)
<i>ellaOne</i> ® 30mg tablets	  
MHRA Drug Safety Update (Aug-14): Levonorgestrel and ulipristal remain suitable emergency contraceptives for all women	
Assisted Reproductive Technology (ART) cycles	
Progesterone	RESTRICTED ART cycles 2nd line
<i>Utrogestan</i> ® 100mg; 200mg vaginal capsules	  

7.4 Drugs for genito-urinary disorders		GMMMG
7.4.1 Drugs for urinary retention		NICE CG97
Alpha blockers		NICE CG111
		NICE NG123
Alfuzosin Hydrochloride		
tablets	BNF emc	
Tamsulosin Hydrochloride		
capsules, tablets	MMC BNF emc	1 st line
7.4.2 Drugs for urinary, enuresis & incontinence		
Urinary incontinence		NICE NG123
Oxybutynin Hydrochloride		
oral solution; patch; tablets	NICE MMC BNF emc	1 st line in OAB
Darifenacin Hydrobromide		
tablets	NICE MMC BNF emc	1 st line in OAB
Tolterodine Tartrate		
capsules, tablets	NICE MMC BNF emc	1 st line in OAB
Solifenacin Succinate		
tablets	MMC BNF emc	2 nd line in OAB patients failed / intolerant to oxybutynin
Duloxetine		
capsules	MMC BNF emc	
Tropium Chloride		
capsules; tablets	MMC BNF emc	RESTRICTED 1 ^{RY} Care referral only
Mirabegron		
tablets	NICE MMC BNF emc	RESTRICTED in line with TA290 / Paeds 3 rd line
MHRA Drug Safety Update (Oct-15): Mirabegron (Betmiga ▼): risk of severe hypertension and associated cerebrovascular and cardiac events		
Nocturnal enuresis		
Amitriptyline		
oral solution; tablets (see also section 4.3.1)	BNF emc	
Desmopressin		
injection; nasal spray; tablets (see also section 6.5.2)	MMC BNF emc	RESTRICTED Haematology Consultants only
7.4.3 Drugs used in urological pain		
Methionine		
tablets	BNF emc	RESTRICTED resistant calcium phosphate lithiasis eau European Association of Urology
Pentosan polysulfate sodium		
capsules	NICE MMC BNF emc	RESTRICTED Urology Cons. in line with NICE
MHRA Drug Safety Update (Sep-19): Elmiron (pentosan polysulfate sodium): rare risk of pigmentary maculopathy		
Potassium Citrate		
tablets	BNF emc	

7.4.4 Bladder instillations & urological surgery		
Chlorhexidine 0.02% irrigation solution	 	
Dimethyl Sulfoxide  50% solution	 	
Glycine 1.5% irrigation solution	 	
Sodium Chloride 0.9% irrigation solution	 	
Sodium Citrate 3% irrigation solution	 	
Sodium Hyaluronate  Cystistat® 40mg/50mL bladder instillation	 	RESTRICTED Urology Consultants only
Sodium Hyaluronate with sodium chondroitin sulfate  iAluRil® 800mg/50mL (1.6% w/v) / 1g/50mL (2% w/v) bladder instillation	 	RESTRICTED Urology Consultants only

7.4.5 Drugs for erectile dysfunction		
Alprostadil Green	   	RESTRICTED Urology Consultants only
cream; injection; urethral sticks		
Aviptadil with Phentolamine Green	   	RESTRICTED Urology Consultants only
<i>Invicorp</i> ® injection		
Sildenafil Green or Red PAH	   	RESTRICTED 1 ^{RY} Care referral only
injection; oral suspension; tablets (see also section 2.5.1)		
MHRA Drug Safety Update (Nov-18): Sildenafil (Revatio & Viagra): reports of PPHN following in-utero exposure in a clinical trial on intrauterine growth restriction		
Tadalafil Green or Red PAH	   	RESTRICTED 1 ^{RY} Care referral only
tablets (see also section 2.5.1)		
Vardenafil	   	RESTRICTED 1 ^{RY} Care referral only
tablets		
7.4.6 Drugs for premature ejaculation		
NOT STOCKED		NOT STOCKED

Section 8: Malignant disease & immunosuppression

Supported by the
formulary ([click here](#))



8.1 Cytotoxic drugs

- 8.1.1 Alkylating drugs
- 8.1.2 Anthracyclines & other cytotoxic antibiotics
- 8.1.3 Antimetabolites
- 8.1.4 Vinca alkaloids & etoposide
- 8.1.5 Other antineoplastic drugs

8.2 Drugs affecting the immune response

- 8.2.1 Antiproliferative immunosuppressants
- 8.2.2 Corticosteroids & other immunosuppressants
- 8.2.3 Anti-lymphocyte monoclonal antibodies
- 8.2.4 Other immunomodulating drugs

8.3 Sex hormones & hormone antagonists in malignant disease

- 8.3.1 Oestrogens
- 8.3.2 Progestogens
- 8.3.3 Androgens
- 8.3.4 Hormone Antagonists
 - 8.3.4.1 Breast Cancer
 - 8.3.4.2 Gonadorelin analogues & gonadotrophin-releasing hormone antagonists
 - 8.3.4.3 Somatostatin analogues

8.4 Miscellaneous preparations

Trust Guidelines

Adult medicines and prescribing guidelines
 Paediatric medicines and prescribing guidelines
 Neonatal guidelines (link to Staffnet site)
[Non-formulary Conversion Table](#)

NICE Guidance

Advanced breast cancer (CG81)
 Familial breast cancer (CG164)
 Hepatitis B (chronic) (CG165)
 Burosumab for treating X-linked hypophosphataemia in children and young people (HST8)
 Selumetinib for treating symptomatic & inoperable plexiform neurofibromas associated with type 1 neurofibromatosis (HST20)
 Early and locally advanced breast cancer: diagnosis and management (NG101)
 Lung cancer: diagnosis and management (NG122)
 Prostate cancer: diagnosis and management (NG131)
 Colorectal cancer (NG151)
 Temozolomide for malignant glioma (TA23)
 Leukaemia (lymphocytic) - fludarabine (TA29)
 Trastuzumab for advanced breast cancer (TA34)
 Paclitaxel for ovarian cancer (TA55)
 Capecitabine and Tegafur Uracil for Colorectal Cancer (TA61)
 Imatinib for chronic myeloid leukaemia (TA70) (partially updated by TA425 & TA426)
 Hepatitis C: Chronic (TA75) (extended by TA106 - partially updated by TA200 & TA300)
 Gastrointestinal stromal tumours - imatinib (TA86) (partially updated by TA209)
 Hepatitis B: Chronic (TA96) (partially updated by CG165)
 Colon cancer (adjuvant) - capecitabine and oxaliplatin (TA100)
 Docetaxel for prostate cancer (hormone-refractory) (TA101)
 Hepatitis C: Peginterferon & Ribavirin (TA106) (partially updated by TA200 & TA300)
 Paclitaxel for early breast cancer (TA108)
 Docetaxel for early breast cancer (TA109)
 Gemcitabine for Breast Cancer (TA116)
 Bevacizumab & Cetuximab in metastatic colorectal cancer (TA118) (partially updated by TA242)
 Leukaemia (lymphocytic) - fludarabine (TA119)
 Carmustine implants and temozolomide for glioma (newly diagnosed & high grade) (TA121)
 Pemetrexed for lung cancer (non small cell) (TA124)
 Multiple sclerosis - natalizumab (TA127)
 Bortezomib for relapsed multiple myeloma (TA129)
 Pemetrexed for mesothelioma (TA135)
 Rituximab for follicular non-Hodgkin's lymphoma (TA137)
 Head and neck cancer - cetuximab (TA145)
 Renal cell carcinoma - sunitinib (TA169)
 Lenalidomide - multiple myeloma (TA171)
 Rituximab for the first-line treatment of chronic lymphocytic leukaemia (TA174)
 Cetuximab for the first-line treatment of metastatic colorectal cancer (TA176)
 Renal Cell Carcinoma (TA178)
 Sunitinib for gastrointestinal stromal tumours (TA179)
 Pemetrexed for lung cancer (non-small cell) - first line treatment (TA181)
 Cervical cancer (recurrent) - topotecan (TA183)
 Lung cancer (small cell) - topotecan (TA184)
 Soft tissue sarcoma - trabectedin (TA185)
 Lung cancer (non-small-cell) - pemetrexed (maintenance) (TA190)
 Gastric cancer (advanced) - capecitabine (TA191)
 Lung cancer (non-small-cell, first line) - gefitinib (TA192)
 Leukaemia (chronic lymphocytic, relapsed) - rituximab (TA193)
 Gastrointestinal stromal tumours - imatinib (adjuvant) (TA196)
 Hepatitis C - peginterferon alfa and ribavirin (TA200) (read in conjunction with TA75 & TA106)
 Gastric cancer (HER2-positive metastatic) - trastuzumab (TA208)
 Gastrointestinal stromal tumours (unresectable/metastatic) - imatinib (TA209) (part review of TA86)
 Colorectal cancer (metastatic) - bevacizumab (TA212)
 Breast cancer - bevacizumab (in combination with a taxane) (TA214) (replaces TA147)
 Renal cell carcinoma (1st line metastatic) - pazopanib (TA215)
 Bendamustine for the first-line treatment of chronic lymphocytic leukaemia (TA216)
 Myelodysplastic syndrome - azacitidine (TA218)
 Lymphoma (follicular non-Hodgkin's) - rituximab (TA226)
 Multiple myeloma (1st line) - bortezomib and thalidomide (TA228)
 Osteosarcoma - mifamurtide (TA235)
 Follicular lymphoma - rituximab (review TA110) (TA243)
 Multiple sclerosis (relapsing-remitting) - fingolimod (TA254)
 Melanoma (stage III or IV) - ipilimumab (TA268)
 Melanoma (BRAF V600 mutation positive, unresectable metastatic) - vemurafenib (TA269)
 Urothelial tract carcinoma (transitional cell, advanced, metastatic) - vinflunine (TA272)
 Bevacizumab in combination with paclitaxel & carboplatin for 1st line treatment of advanced ovarian cancer (TA284)
 Ovarian, fallopian tube & primary peritoneal cancer - bevacizumab (TA285)
 Hepatitis C (children and young people) - peginterferon alfa & ribavirin (TA300)
 Multiple sclerosis (relapsing) - teriflunomide (TA303)
 Lymphoma (non Hodgkin's, relapsed, refractory) - pixantrone monotherapy (TA306)
 Vasculitis (anti-neutrophil cytoplasmic antibody-associated) - rituximab (with glucocorticoids) (TA308)
 Multiple myeloma - bortezomib (induction therapy) (TA311)

Multiple sclerosis (relapsing-remitting) - alemtuzumab (TA312)
 Ipilimumab for previously untreated advanced (unresectable or metastatic) melanoma (TA319)
 Dimethyl fumarate for treating relapsing-remitting multiple sclerosis (TA320)
 Dabrafenib for treating unresectable or metastatic BRAF V600 mutation-positive melanoma (TA321)
 Lenalidomide for treating myelodysplastic syndromes associated with an isolated deletion 5q cytogenetic abnormality (TA322)
 Imatinib for the adjuvant treatment of gastrointestinal stromal tumours (review of TA196) (TA326)
 Axitinib for treating advanced renal cell carcinoma after failure of prior systemic treatment (TA333)
 Obinutuzumab in combination with chlorambucil for untreated chronic lymphocytic leukaemia (TA343)
 Nintedanib for previously treated locally advanced, metastatic, or locally recurrent non small cell lung cancer (TA347)
 Pembrolizumab for treating advanced melanoma after disease progression with ipilimumab (TA357)
 Idelalisib for treating chronic lymphocytic leukaemia (TA359)
 Pembrolizumab for advanced melanoma not previously treated with ipilimumab (TA366)
 Bortezomib for previously untreated mantle cell lymphoma (TA370)
 Erlotinib and gefitinib for treating non-small-cell lung cancer that has progressed after prior chemotherapy (TA374)
 Enzalutamide for treating metastatic hormone-relapsed prostate cancer before chemotherapy is indicated (TA377)
 Nintedanib for treating idiopathic pulmonary fibrosis (TA379)
 Panobinostat for treating multiple myeloma after at least 2 previous treatments (TA380)
 Olaparib for ovarian, fallopian tube and peritoneal cancer (TA381)
 Nivolumab for treating advanced (unresectable or metastatic) melanoma (TA384)
 Ruxolitinib for treating disease-related splenomegaly or symptoms in adults with myelofibrosis (TA386)
 Abiraterone for treating metastatic hormone-relapsed prostate cancer before chemotherapy is indicated (TA387)
 Topotecan, PLDH, paclitaxel, trabectedin & gemcitabine for recurrent ovarian cancer (TA389)
 Cabazitaxel for hormone-relapsed metastatic prostate cancer treated with docetaxel (TA391)
 Ceritinib for previously treated anaplastic lymphoma kinase positive non-small-cell lung cancer (TA395)
 Trametinib in combination with dabrafenib for treating unresectable or metastatic melanoma (TA396)
 Nivolumab in combination with ipilimumab for treating advanced melanoma (TA400)
 Bosutinib for previously treated chronic myeloid leukaemia (TA401)
 Pemetrexed maintenance treatment for non-squamous non-small-cell lung cancer after pemetrexed and cisplatin (TA402)
 Degarelix for treating advanced hormone-dependent prostate cancer (TA404)
 Trifluridine–tipiracil for previously treated metastatic colorectal cancer (TA405)
 Crizotinib for untreated anaplastic lymphoma kinase-positive advanced non-small-cell lung cancer (TA406)
 Pegaspargase for treating acute lymphoblastic leukaemia (TA408)
 Talimogene laherparepvec for treating unresectable metastatic melanoma (TA410)
 Radium-223 dichloride for treating hormone-relapsed prostate cancer with bone metastases (TA412)
 Nivolumab for previously treated advanced renal cell carcinoma (TA417)
 Everolimus with exemestane for treating advanced breast cancer after endocrine therapy (TA421)
 Crizotinib for previously treated anaplastic lymphoma kinase-positive advanced non-small-cell lung cancer (TA422)
 Eribulin for treating locally advanced or metastatic breast cancer after 2 or more chemotherapy regimens (TA423)
 Pertuzumab for the neoadjuvant treatment of HER2-positive breast cancer (TA424)
 Dasatinib, nilotinib and high-dose imatinib for treating imatinib-resistant or intolerant chronic myeloid leukaemia (TA425)
 Dasatinib, nilotinib and imatinib for untreated chronic myeloid leukaemia (TA426)
 Pomalidomide for multiple myeloma previously treated with lenalidomide and bortezomib (TA427)
 Pembrolizumab for treating PD-L1-positive non-small-cell lung cancer after chemotherapy (TA428)
 Everolimus for advanced renal cell carcinoma after previous treatment (TA432)
 Cetuximab and panitumumab for previously untreated metastatic colorectal cancer (TA439)
 Everolimus & sunitinib for treating unresectable or metastatic neuroendocrine tumours (TA449)
 Blinatumomab for previously treated Philadelphia-chromosome-negative acute lymphoblastic leukaemia (TA450)
 Ponatinib for treating chronic myeloid leukaemia and acute lymphoblastic leukaemia (TA451)
 Trastuzumab emtansine for treating HER2-positive advanced breast cancer after trastuzumab and a taxane (TA458)
 Nivolumab for treating relapsed or refractory classical Hodgkin lymphoma (TA462)
 Cabozantinib for previously treated advanced renal cell carcinoma (TA463)
 Cetuximab for treating recurrent or metastatic squamous cell cancer of the head and neck (replaces TA172) (TA473)
 Sorafenib for treating advanced hepatocellular carcinoma (replaces TA189) (TA474)
 Paclitaxel with gemcitabine for untreated metastatic pancreatic cancer (replaces TA360) (TA476)
 Brentuximab vedotin for treating relapsed or refractory systemic anaplastic large cell lymphoma (TA478)
 Immunosuppressive therapy for kidney transplant in adults (replaces TA85) (TA481)
 Immunosuppressive therapy for kidney transplant in children and young people (replaces TA99) (TA482)
 Nivolumab for previously treated squamous non-small-cell lung cancer (TA483)
 Nivolumab for previously treated non-squamous non-small-cell lung cancer (TA484)
 Regorafenib for previously treated unresectable or metastatic gastrointestinal stromal tumours (TA488)
 Nivolumab for treating squamous cell carcinoma of the head and neck after platinum-based chemotherapy (TA490)
 Ibrutinib for treating Waldenstrom's macroglobulinaemia (TA491)
 Atezolizumab for untreated locally advanced or metastatic urothelial cancer when cisplatin is unsuitable (TA492)
 Cladribine tablets for treating relapsing–remitting multiple sclerosis (TA493)
 Palbociclib for previously untreated, locally advanced or metastatic breast cancer (TA495)
 Ribociclib for previously untreated, locally advanced or metastatic breast cancer (TA496)
 Lenvatinib with everolimus for previously treated advanced renal cell carcinoma (TA498)
 Ceritinib for untreated ALK-positive non-small-cell lung cancer (TA500)
 Intrabeam radiotherapy system for adjuvant treatment of early breast cancer (TA501)
 Ibrutinib for treating relapsed or refractory mantle cell lymphoma (TA502)
 Fulvestrant for untreated locally advanced or metastatic oestrogen-receptor positive breast cancer (TA503)
 Pertuzumab with trastuzumab and docetaxel for treating HER2-positive breast cancer (TA509)
 Tivozanib for treating advanced renal cell carcinoma (TA512)
 Obinutuzumab for untreated advanced follicular lymphoma (TA513)
 Regorafenib for previously treated advanced hepatocellular carcinoma (TA514)
 Eribulin for treating locally advanced or metastatic breast cancer after 1 chemotherapy regimen (replaces TA250) (TA515)
 Cabozantinib for treating medullary thyroid cancer (TA516)
 Avelumab for treating metastatic Merkel cell carcinoma (TA517)
 Pembrolizumab for treating locally advanced or metastatic urothelial carcinoma (TA519)

Atezolizumab for treating locally advanced or metastatic non-small-cell lung cancer after chemotherapy (TA520)
 Pembrolizumab for untreated locally advanced or metastatic urothelial cancer when cisplatin is unsuitable (TA522)
 Midostaurin for untreated acute myeloid leukaemia (TA523)
 Brentuximab vedotin for treating CD30-positive Hodgkin lymphoma (replaces TA446) (TA524)
 Atezolizumab for treating locally advanced or metastatic urothelial carcinoma (TA525)
 Arsenic trioxide for treating acute promyelocytic leukaemia (TA526)
 Beta interferons and glatiramer acetate for treating multiple sclerosis (replaces TA32) (TA527)
 Niraparib for maintenance treatment of relapsed, platinum-sensitive ovarian, fallopian tube and peritoneal cancer (TA528)
 Crizotinib for treating ROS1-positive advanced non-small-cell lung cancer (TA529)
 Nivolumab for treating locally advanced unresectable or metastatic urothelial cancer (TA530)
 Pembrolizumab for untreated PD-L1-positive metastatic non-small-cell lung cancer (TA531)
 Ocrelizumab for treating relapsing–remitting multiple sclerosis (TA533)
 Lenvatinib and sorafenib for treating differentiated thyroid cancer after radioactive iodine (TA535)
 Alectinib for untreated ALK-positive advanced non-small-cell lung cancer (TA536)
 Dinutuximab beta for treating neuroblastoma (TA538)
 Lutetium (177Lu) oxodotreotide for treating unresectable or metastatic neuroendocrine tumours (TA539)
 Pembrolizumab for treating relapsed or refractory classical Hodgkin lymphoma (TA540)
 Inotuzumab ozogamicin for treating relapsed or refractory B-cell acute lymphoblastic leukaemia (TA541)
 Cabozantinib for untreated advanced renal cell carcinoma (TA542)
 Dabrafenib with trametinib for adjuvant treatment of resected BRAF V600 mutation-positive melanoma (TA544)
 Gemtuzumab ozogamicin for untreated acute myeloid leukaemia (TA545)
 Padeliporfin for untreated localised prostate cancer (TA546)
 Vandetanib for treating medullary thyroid cancer (TA550)
 Lenvatinib for untreated advanced hepatocellular carcinoma (TA551)
 Liposomal cytarabine–daunorubicin for untreated acute myeloid leukaemia (TA552)
 Pembrolizumab for adjuvant treatment of resected melanoma with high risk of recurrence (TA553)
 Tisagenlecleucel for treating relapsed or refractory B-cell acute lymphoblastic leukaemia in people aged up to 25 years (TA554)
 Regorafenib for previously treated advanced hepatocellular carcinoma (TA555)
 Axicabtagene ciloleucel for treating diffuse large B-cell lymphoma and primary mediastinal large B-cell lymphoma (TA559)
 Venetoclax with rituximab for previously treated chronic lymphocytic leukaemia (TA561)
 Encorafenib with binimetinib for unresectable or metastatic BRAF V600 mutation-positive melanoma (TA562)
 Abemaciclib for previously untreated, locally advanced or metastatic breast cancer (TA563)
 Tisagenlecleucel for treating relapsed or refractory diffuse large B-cell lymphoma after 2 or more systemic therapies (TA567)
 Pertuzumab for adjuvant treatment of HER2-positive early stage breast cancer (TA569)
 Brigatinib for treating ALK-positive advanced non-small-cell lung cancer after crizotinib (TA571)
 Brentuximab vedotin for treating CD30-positive cutaneous T-cell lymphoma (TA577)
 Abemaciclib with fulvestrant for treating hormone receptor-positive, HER2-negative advanced breast cancer (TA579)
 Enzalutamide for hormone-relapsed non-metastatic prostate cancer (TA580)
 Atezolizumab in combination for treating metastatic non-squamous non-small-cell lung cancer (TA584)
 Ocrelizumab for treating primary progressive multiple sclerosis (TA585)
 Lenalidomide plus dexamethasone for multiple myeloma after 1 treatment with bortezomib (TA586)
 Lenalidomide plus dexamethasone for previously untreated multiple myeloma (TA587)
 Blinatumomab for treating acute lymphoblastic leukaemia in remission with minimal residual disease activity (TA589)
 Ribociclib with fulvestrant for treating hormone receptor-positive, HER2-negative, advanced breast cancer (TA593)
 Dacomitinib for untreated EGFR mutation-positive non-small-cell lung cancer (TA595)
 Olaparib for maintenance treatment of BRCA mutation-positive advanced ovarian, fallopian tube or peritoneal cancer (TA598)
 Pembrolizumab with carboplatin and paclitaxel for untreated metastatic squamous non-small-cell lung cancer (TA600)
 Rucaparib for maintenance treatment of relapsed platinum-sensitive ovarian, fallopian tube or peritoneal cancer (TA611)
 Neratinib for extended adjuvant treatment of hormone receptor-positive, HER2-positive early stage breast cancer (TA612)
 Cladribine for treating relapsing–remitting multiple sclerosis (TA616)
 Palbociclib with fulvestrant for treating hormone receptor-positive, HER2-negative, advanced breast cancer (TA619)
 Peginterferon beta-1a for treating relapsing–remitting multiple sclerosis (TA624)
 Lenalidomide with rituximab for previously treated follicular lymphoma (TA627)
 Lorlatinib for previously treated ALK-positive advanced non-small-cell lung cancer (TA628)
 Obinutuzumab with bendamustine for treating follicular lymphoma after rituximab (replacing TA472) (TA629)
 Larotrectinib for treating NTRK fusion-positive solid tumours (TA630)
 Trastuzumab emtansine for adjuvant treatment of HER2-positive early breast cancer (TA632)
 Atezolizumab with carboplatin and etoposide for untreated extensive-stage small-cell lung cancer (TA638)
 Atezolizumab for untreated PD-L1-positive, locally advanced or metastatic, triple-negative breast cancer (TA639)
 Treosulfan with fludarabine for malignant disease before allogeneic stem cell transplant (TA640)
 Brentuximab vedotin in combination for untreated systemic anaplastic large cell lymphoma (TA641)
 Gilteritinib for treating relapsed or refractory acute myeloid leukaemia (TA642)
 Entrectinib for treating ROS1-positive advanced non-small-cell lung cancer (TA643)
 Entrectinib for treating NTRK fusion-positive solid tumours (TA644)
 Avelumab with axitinib for untreated advanced renal cell carcinoma (TA645)
 Polatuzumab vedotin with rituximab and bendamustine for treating relapsed or refractory diffuse large B-cell lymphoma (TA649)
 Pembrolizumab with axitinib for untreated advanced renal cell carcinoma (TA650)
 Osimertinib for treating EGFR T790M mutation-positive advanced non-small-cell lung cancer (replacing TA416) (TA653)
 Osimertinib for untreated EGFR mutation-positive NSCLC (replacing TA621) (TA654)
 Nivolumab for advanced squamous non-small-cell lung cancer after chemotherapy (TA655)
 Carfilzomib for previously treated multiple myeloma (replacing TA457) (TA657)
 Darolutamide with androgen deprivation therapy for treating hormone-relapsed non-metastatic prostate cancer (TA660)
 Pembrolizumab for untreated metastatic or unresectable recurrent head and neck squamous cell carcinoma (TA661)
 Venetoclax with obinutuzumab for untreated chronic lymphocytic leukaemia (TA663)
 Atezolizumab with bevacizumab for treating advanced or unresectable hepatocellular carcinoma (TA666)
 Encorafenib plus cetuximab for previously treated BRAF V600E mutation-positive metastatic colorectal cancer (TA668)
 Brigatinib for ALK-positive advanced NSCLC that has not been previously treated with an ALK inhibitor (TA670)
 Autologous anti-CD19-transduced CD3+ cells for treating relapsed or refractory mantle cell lymphoma (TA677)
 Lenalidomide maintenance treatment after an autologous stem cell transplant for newly diagnosed multiple myeloma (TA680)

Pembrolizumab with pemtrexed for untreated, metastatic, non-squamous NSCLC (replacing TA557) (TA683)
 Nivolumab for adjuvant treatment of completely resected melanoma (replacing TA558) (TA684)
 Ribociclib with fulvestrant for treating hormone receptor-positive, HER2-negative advanced breast cancer (TA687)
 Acalabrutinib for treating chronic lymphocytic leukaemia (TA689)
 Avelumab for untreated metastatic Merkel cell carcinoma (TA691)
 Olaparib plus bevacizumab for maintenance treatment of advanced ovarian, fallopian tube or primary peritoneal cancer (TA693)
 Carfilzomib with dexamethasone and lenalidomide for previously treated multiple myeloma (TA695)
 Ofatumumab for treating relapsing multiple sclerosis (TA699)
 Trastuzumab deruxtecan for treating HER2-positive unresectable or metastatic breast cancer (TA704)
 Atezolizumab monotherapy for untreated advanced non-small-cell lung cancer (TA705)
 Nivolumab for previously treated unresectable advanced or recurrent oesophageal cancer (TA707)
 Pembrolizumab for untreated metastatic colorectal cancer with high microsatellite instability or mismatch repair deficiency (TA709)
 Enzalutamide for treating hormone-sensitive metastatic prostate cancer (TA712)
 Nivolumab for advanced non-squamous non-small-cell lung cancer after chemotherapy (TA713)
 Nivolumab with ipilimumab for previously treated metastatic colorectal cancer with ... (TA716)
 Chlormethine gel for treating mycosis fungoides-type cutaneous T-cell lymphoma (TA720)
 Abiraterone for treating newly diagnosed high-risk hormone-sensitive metastatic prostate cancer (TA721)
 Pemigatinib for treating relapsed or refractory advanced cholangiocarcinoma with FGFR2 fusion or rearrangement (TA722)
 Abemaciclib for treating hormone receptor-positive, HER2-negative advanced breast cancer (updates & replaces TA579) (TA725)
 Midostaurin for treating advanced systemic mastocytosis (TA728)
 Nivolumab for treating recurrent or metastatic squamous cell carcinoma of the head and neck (TA736)
 Pembrolizumab for untreated advanced oesophageal & gastro-oesophageal junction cancer (TA737)
 Atezolizumab for untreated PD-L1-positive advanced urothelial cancer when cisplatin is unsuitable (TA739)
 Apalutamide with androgen deprivation therapy for treating high-risk hormone-relapsed non-metastatic prostate cancer (TA740)
 Apalutamide with androgen deprivation therapy for treating hormone-sensitive metastatic prostate cancer (TA741)
 Selpercatinib for treating advanced thyroid cancer with RET alterations (TA742)
 Nivolumab for adjuvant treatment of resected oesophageal or gastro-oesophageal junction cancer (TA746)
 Nintedanib for treating progressive fibrosing interstitial lung diseases (TA747)
 Mogamulizumab for previously treated mycosis fungoides and Sézary syndrome (TA754)
 Fedratinib for treating disease-related splenomegaly or symptoms in myelofibrosis (TA756)
 Selpercatinib for previously treated RET fusion-positive advanced non-small-cell lung cancer (TA760)
 Osimertinib for adjuvant treatment of EGFR mutation-positive non-small-cell lung cancer after complete tumour resection (TA761)
 Daratumumab in combination for untreated multiple myeloma when a stem cell transplant is suitable (TA763)
 Venetoclax with azacitidine for untreated acute myeloid leukaemia when intensive chemotherapy is unsuitable (TA765)
 Pembrolizumab for adjuvant treatment of completely resected stage 3 melanoma (TA766)
 Ponesimod for treating relapsing–remitting multiple sclerosis (TA767)
 Pembrolizumab with carboplatin and paclitaxel for untreated metastatic squamous non-small-cell lung cancer (TA770)
 Pembrolizumab for relapsed or refractory classical Hodgkin lymphoma after SCT or at least 2 previous therapies (TA772)
 Dostarlimab for previously treated advanced or recurrent endometrial cancer.... (TA779)
 Nivolumab with ipilimumab for untreated advanced renal cell carcinoma (TA780)
 Sotorasib for previously treated KRAS G12C mutation-positive advanced non-small-cell lung cancer (TA781)
 Daratumumab monotherapy for treating relapsed and refractory multiple myeloma (TA783)
 Niraparib for maintenance treatment of relapsed, platinum-sensitive ovarian, fallopian tube and peritoneal cancer (TA784)
 Tucatinib with trastuzumab & capecitabine for treating HER2-positive advanced breast cancer.... (TA786)
 Venetoclax with low dose cytarabine for untreated acute myeloid leukaemia when intensive chemotherapy is unsuitable (TA787)
 Avelumab for maintenance treatment of locally advanced or metastatic urothelial cancer.... (TA788)
 Tepotinib for treating advanced non-small-cell lung cancer with MET gene alterations (TA789)
 Diroximel fumarate for treating relapsing–remitting multiple sclerosis (TA794)
 Ibrutinib for treating Waldenstrom's macroglobulinaemia (replacing TA491) (TA795)
 Venetoclax for treating chronic lymphocytic leukaemia (replacing TA487) (TA796)
 Durvalumab for maintenance treatment of unresectable NSCLC after platinum-based chemoradiation (replacing TA578) (TA798)
 Pembrolizumab (plus chemo) for untreated, triple-negative, locally recurrent unresectable or metastatic breast cancer (TA801)
 Cemiplimab for treating advanced cutaneous squamous cell carcinoma (updates & replaces TA592) (TA802)
 Imlifidase for desensitisation treatment before kidney transplant in people with chronic kidney disease (TA809)
 Abemaciclib for adjuvant treatment of hormone receptor-positive, HER2-negative, node-positive early breast cancer (TA810)
 Pralsetinib for treating RET fusion-positive advanced non-small-cell lung cancer (TA812)
 Asciminib for treating chronic myeloid leukaemia after 2 or more tyrosine kinase inhibitors (TA813)
 Alpelisib with fulvestrant for treating hormone receptor-positive, HER2-negative, PIK3CA-mutated advanced breast cancer (TA816)
 Nivolumab for adjuvant treatment of invasive urothelial cancer at high risk of recurrence (TA817)
 Nivolumab with ipilimumab for untreated unresectable malignant pleural mesothelioma (TA818)
 Sacituzumab govitecan for treating unresectable triple-negative advanced breast cancer after 2 or more therapies (TA819)
 Atezolizumab for adjuvant treatment of resected non-small-cell lung cancer (TA823)
 Avacopan for treating severe active granulomatosis with polyangiitis or microscopic polyangiitis (TA825)
 Oral azacitidine for maintenance treatment of acute myeloid leukaemia after induction therapy (TA827)
 Pembrolizumab for adjuvant treatment of renal cell carcinoma (TA830)
 Zanubrutinib for treating Waldenstrom's macroglobulinaemia (TA833)
 Palbociclib with fulvestrant for treating hormone receptor-positive, HER2-negative advanced breast cancer (TA836)
 Pembrolizumab for adjuvant treatment of resected stage 2B or 2C melanoma (TA837)
 Cabozantinib for previously treated advanced hepatocellular carcinoma (TA849)
 Pembrolizumab for neoadjuvant and adjuvant treatment of triple-negative early or locally advanced breast cancer (TA851)
 Trifluridine–tipiracil for metastatic gastric cancer or gastro-oesophageal junction adenocarcinoma (replacing TA669) (TA852)
 Mobocertinib for treating EGFR exon 20 insertion mutation-positive advanced NSCLC after platinum-based chemotherapy (TA855)
 Nivolumab for untreated HER2-negative advanced gastric, gastro-oesophageal junction or oesophageal adenocarcinoma (TA857)
 Lenvatinib with pembrolizumab for untreated advanced renal cell carcinoma (TA858)
 Trastuzumab deruxtecan for treating HER2-positive unresectable or metastatic breast cancer (TA862)
 Nintedanib for treating idiopathic pulmonary fibrosis when FVC is above 80% predicted (partially replaces TA379) (TA864)
 Nivolumab for untreated unresectable advanced, recurrent, or metastatic oesophageal squamous cell carcinoma (TA865)
 Regorafenib for previously treated metastatic colorectal cancer (TA866)
 Ixazomib with lenalidomide & dexamethasone for treating relapsed or refractory multiple myeloma (replacing TA505) (TA870)

Axicabtagene ciloleucel for treating diffuse large B-cell lymphoma (replacing TA559) (TA872)
Polatuzumab vedotin in combination for untreated diffuse large B-cell lymphoma (TA874)
Nivolumab with chemotherapy for neoadjuvant treatment of resectable non-small-cell lung cancer (TA876)
Voclosporin with mycophenolate mofetil for treating lupus nephritis (TA882)
Pembrolizumab plus chemotherapy with or without bevacizumab for persistent, recurrent or metastatic cervical cancer (TA885)
Olaparib for adjuvant treatment of BRCA mutation-positive HER2-negative high-risk early breast cancer after chemotherapy (TA886)
Olaparib for previously treated BRCA mutation-positive hormone-relapsed metastatic prostate cancer (TA887)
Ibrutinib with venetoclax for untreated chronic lymphocytic leukaemia (TA891)
Brexucabtagene autoleucel for treating relapsed or refractory B-cell acute lymphoblastic leukaemia... (TA893)
Axicabtagene ciloleucel for treating relapsed or refractory diffuse large B-cell lymphoma... (TA895)
Daratumumab with bortezomib and dexamethasone for previously treated multiple myeloma (updates & replaces TA573) (TA897)
Dabrafenib plus trametinib for treating BRAF V600 mutation-positive advanced non-small-cell lung cancer (TA898)
Darolutamide with androgen deprivation therapy and docetaxel for treating hormone-sensitive metastatic prostate cancer (TA903)
Pembrolizumab with lenvatinib for previously treated advanced or recurrent endometrial cancer (TA904)
Olaparib for maintenance treatment of relapsed, platinum-sensitive ovarian, fallopian tube or peritoneal cancer (TA908)
Selpercatinib for untreated RET fusion-positive advanced non-small-cell lung cancer (TA911)
Pembrolizumab For treating tumours with high microsatellite instability (MSI) or mismatch repair (MMR) deficiency (TA914)
Daratumumab with lenalidomide and dexamethasone for untreated multiple myeloma when a SCT is unsuitable (TA917)
Ruxolitinib for treating polycythaemia vera (TA921)
Glofitamab for treating relapsed or refractory diffuse large B-cell lymphoma after 2 or more systemic treatments (TA927)

GMMMG Formulary

Formulary Homepage

Chapter 8: Malignant disease & immunosuppression (Complete)

GMMMG Adult [Red](#)/[Amber](#)/[Green](#); DNP and [Grey](#) Drug List

GMMMG Paediatric [Red](#)/[Amber](#)/[Green](#) Drug List

8.1 Cytotoxic drugs		GMMMG
8.1 Cytotoxic drugs		
Dexrazoxane   infusion	 MMC  	RESTRICTED Haematology Consultants only 
Folinic Acid (as calcium folinate)  tablets; injection	 	RESTRICTED Haematology Consultants only
Mesna  tablets; injection	 	RESTRICTED Haematology Consultants only
Palifermin  injection	MMC  	RESTRICTED Haematology Consultants only
8.1.1 Alkylating drugs		
Busulfan  infusion	MMC  	RESTRICTED Haematology Consultants only
Bendamustine   infusion	  MMC   	RESTRICTED Haematology Consultants only
MHRA Drug Safety Update (Mar-21): Bendamustine (Levact): increased risk of non-melanoma skin cancer and progressive multifocal encephalopathy (PML) MHRA Drug Safety Update (Jul-17): Bendamustine: increased mortality in recent clinical studies in off-label use; monitor for opportunistic infections, HBV reactivation		
Carmustine  infusion	  	RESTRICTED Haematology Consultants only
Chlorambucil  tablets	  	RESTRICTED Haematology Consultants only
Cyclophosphamide  injection; tablets; oral suspension	MMC  	RESTRICTED Haematology Consultants only
Ifosfamide  injection	 	RESTRICTED Haematology Consultants only
Lomustine  capsules	 	RESTRICTED Haematology Consultants only
Melphalan  injection; tablets	 	RESTRICTED Haematology Consultants only
Treosulfan  injection	 MMC  	RESTRICTED Adult Haematology / Paediatric Haematology / Oncology
8.1.2 Anthracyclines & other cytotoxic antibiotics		
Bleomycin  injection	 	RESTRICTED Haematology Consultants only
Daunorubicin  injection	 	RESTRICTED Haematology Consultants only
Doxorubicin Hydrochloride   infusion; injection	  MMC   	RESTRICTED Haematology Consultants only
Idarubicin  capsules; injection	 	RESTRICTED Haematology Consultants only
Mitomycin  injection	MMC  	RESTRICTED Consultants only
Mitoxantrone  infusion	 	RESTRICTED Haematology Consultants only
Pixantrone   infusion	  MMC  	RESTRICTED Haematology Consultants only

8.1.3 Antimetabolites		NICE CG81
		NICE NG151
Azacitidine   injection     		RESTRICTED Haematology Consultants only
Capecitabine  tablets    		
MHRA Drug Safety Update (Oct-20): 5-fluorouracil (IV), capecitabine, tegafur: DPD testing recommended before initiation to identify patients at risk of severe & fatal toxicity		
MHRA Drug Safety Update (Dec-14): Capecitabine: risk of severe skin reactions - discontinue treatment		
Cladribine   infusion; injection      		RESTRICTED Haematology Consultants only
MHRA Drug Safety Update (Mar-22): Cladribine (Mavenclad): new advice to minimise risk of serious liver injury		
MHRA Drug Safety Update (Dec-17): Cladribine (Litak, Leustat) for leukaemia: reports of PML; stop treatment if PML is suspected		
Clofarabine   infusion    		RESTRICTED Haematology Consultants only
Cytarabine  injection   		RESTRICTED Haematology Consultants only
Cytarabine / Daunorubicin   Vyxeos® 100mg/44mg infusion      		RESTRICTED Haematology Consultants only
Fludarabine  injection; tablets   		RESTRICTED Haematology Consultants only
Fluorouracil  injection    		RESTRICTED Haematology Consultants only
MHRA Drug Safety Update (Oct-20): 5-fluorouracil (IV), capecitabine, tegafur: DPD testing recommended before initiation to identify patients at risk of severe & fatal toxicity		
Gemcitabine  infusion    		RESTRICTED Haematology Consultants only
Mercaptopurine  oral suspension; tablets (see also section 1.5.3)  		
Methotrexate  infusion; injection; oral solution; tablets (see sections 1.5.3, 10.1.3 & 13.5.3)   		
MHRA Drug Safety Update (Aug-23): Methotrexate: advise patients to take precautions in the sun to avoid photosensitivity reactions		
Pemetrexed   injection      		RESTRICTED Respiratory Consultants only in line with TA402
8.1.4 Vinca alkaloids & etoposide		
Etoposide  capsules; infusion  		RESTRICTED Haematology Consultants only
Vinblastine Sulfate  injection  		RESTRICTED Haematology Consultants only
Vincristine Sulfate  injection  		RESTRICTED Haematology Consultants only
8.1.5 Other antineoplastic drugs		
Acalabrutinib   infusion      		RESTRICTED Haematology Consultants only
Arsenic Trioxide   infusion      		RESTRICTED Haem. Consultants only / also in line with NICE TA526
Asciminib   Scemblix® 20mg/40mg tablets      		RESTRICTED Haem. Consultants in line with NICE TA813
Asparaginase e-coli  infusion   		RESTRICTED Haematology Consultants only

Autologous anti-CD19-transduced CD3+ cells   Tecartus® infusion      	RESTRICTED Haem. Consultants in line with NICE TA677
Axicabtagene ciloleucel   Yescarta® infusion      	RESTRICTED in line with NICE TA872
Bevacizumab   Avastin® 100mg in 4mL vial     	RESTRICTED Haematology Consultants only
Bortezomib   injection      	RESTRICTED Haematology Consultants only
Brentuximab Vedotin   infusion      	RESTRICTED Haematology Consultants only
Brexucabtagene autoleucel   Tecartus® infusion     	RESTRICTED Haem. Consultants only in line with CDF
Cabozantinib   tablets; capsules      	RESTRICTED Specialist Consultant use only in line with NICE NOT STOCKED
Carfilzomib   infusion      	RESTRICTED Haematology Consultants only in line with NICE
Ceritinib   capsules      	RESTRICTED Respiratory Consultants only in line with NICE NOT STOCKED
Cetuximab   infusion      	RESTRICTED Haematology Consultants only in line with NICE
Crisantaspase   injection  	RESTRICTED Haematology Consultants only
Dacarbazine  injection  	RESTRICTED Haematology Consultants only
Durvalumab   infusion      	RESTRICTED Respiratory Consultants only in line with NICE NOT STOCKED
Entrectinib   injection      	RESTRICTED Specialist Consultant use only in line with NICE
Eribulin   injection      	RESTRICTED Specialist Consultant use only in line with NICE NOT STOCKED
Erlotinib   tablets      	RESTRICTED Respiratory Consultants only in line with NICE NOT STOCKED
Everolimus   tablets      	RESTRICTED Specialist Consultant use only in line with NICE NOT STOCKED
Hydroxycarbamide  capsules; tablets (see below)  	RESTRICTED Haematology Consultants only
Ipilimumab   infusion      	RESTRICTED Dermatology Consultants only in line with NICE NOT STOCKED
MHRA Drug Safety Update (Jan-19): Ipilimumab (Yervoy): reports of cytomegalovirus (CMV) gastrointestinal infection or reactivation	
Ixazomib   capsules      	RESTRICTED Haematology Consultants only in line with NICE
Lorlatinib   Lorviqua® tablets      	RESTRICTED Respiratory Consultants only in line with NICE
Midostaurin   Rydapt® capsules      	RESTRICTED Haematology Consultants only in line with NICE

<p>Nintedanib esilate   Ofev® capsules      </p>	<p>RESTRICTED Respiratory Consultants only in line with NICE</p>
<p>Nintedanib esilate   Vargatef® capsules      </p>	<p>RESTRICTED Respiratory Consultants only in line with NICE NOT STOCKED</p>
<p>Niraparib   Zejula® capsules      </p>	<p>RESTRICTED Gynaecology Consultants only in line with NICE NOT STOCKED</p>
<p>MHRA Drug Safety Update (Oct-20): Niraparib (Zejula▼): reports of severe hypertension & PRES, particularly in early treatment</p>	
<p>Panitumumab   infusion      </p>	<p>RESTRICTED Haematology Consultants only in line with NICE NOT STOCKED</p>
<p>Panobinostat   capsules     </p>	<p>RESTRICTED Haematology Consultants only in line with TA380</p>
<p>Pegaspargase   Oncaspar® injection     </p>	<p>RESTRICTED Haematology Consultants only</p>
<p>Pembrolizumab   infusion      </p>	<p>RESTRICTED Specialist use only in line with NICE / NHSE</p>
<p>MHRA Drug Safety Update (Jul-17): Nivolumab (Opdivo▼), pembrolizumab (Keytruda▼): reports of organ transplant rejection</p>	
<p>Pentostatin   infusion  </p>	<p>RESTRICTED Haematology Consultants only</p>
<p>Pertuzumab   infusion      </p>	<p>RESTRICTED Specialist Consultant use only in line with NICE NOT STOCKED</p>
<p>Procarbazine   capsules  </p>	<p>RESTRICTED Haematology Consultants only</p>
<p>Sacituzumab govitecan   Trodelvy® infusion      </p>	<p>RESTRICTED Specialist Consultant use only in line with NICE NOT STOCKED</p>
<p>Sorafenib   tablets      </p>	<p>RESTRICTED Haematology Consultants only in line with NICE</p>
<p>MHRA Drug Safety Update (Jul-20): Systemically administered VEGF pathway inhibitors: risk of aneurysm and artery dissection</p>	
<p>Sotorasib   Lumykras® tablets      </p>	<p>RESTRICTED PulmonaryOnc Consultants only in line with NICE TA781</p>
<p>Talimogene Laherparepvec   injection      </p>	<p>RESTRICTED Dermatology Consultants only in line with TA410</p>
<p>Tisagenlecleucel   Kymriah® infusion      </p>	<p>RESTRICTED in line with CDF criteria and NICE TA554 / TA567</p>
<p>Trastuzumab   infusion; injection      </p>	<p>RESTRICTED Specialist use only in line with NICE</p>
<p>Venetoclax   tablets      </p>	<p>RESTRICTED Specialist use only in line with NICE / NHSE</p>
<p>MHRA Drug Safety Update (Dec-21): Venetoclax (Venclyxto▼): updated recommendations on tumour lysis syndrome (TLS)</p>	
Hydroxycarbamide - Essential thrombocythaemia or polycythaemia with high risk of complications	
Hydroxycarbamide - Sickle Cell Disease	
Hydroxycarbamide - Chemotherapy	
<p>Platinum compounds</p>	
<p>Cisplatin  injection  </p>	<p>RESTRICTED Haematology Consultants only</p>

Protein kinase inhibitors		
Abemaciclib   Verzenios® tablets      		RESTRICTED Specialist use only in line with NICE NOT STOCKED
MHRA Drug Safety Update (Jun-21): CDK4/6 inhibitors (abemaciclib ▼, palbociclib ▼, ribociclib ▼): reports of ILD & pneumonitis, including severe cases		
Alectinib   Alecensa® capsules      		RESTRICTED Specialist use only in line with NICE TA536 NOT STOCKED
Alpelisib   Piqray® tablets      		RESTRICTED Specialist use only in line with NICE TA816 NOT STOCKED
Axitinib   Inlyta® tablets      		RESTRICTED Haematology Consultants only in line with NICE NOT STOCKED
Bosutinib   Bosulif® tablets      		RESTRICTED Haematology Consultants only in line with TA401
MHRA Drug Safety Update (May-16): BCR-ABL tyrosine kinase inhibitors: risk of hepatitis B reactivation		
Brigatinib   Alunbrig® tablets      		RESTRICTED Specialist use only in line with NICE
Crizotinib   Xalkori® capsules      		RESTRICTED Specialist use only in line with NICE NOT STOCKED
Dabrafenib   Tafinlar® capsules      		RESTRICTED Specialist use only in line with NICE
Dacomitinib   Vizimpro® tablets      		RESTRICTED Specialist use only in line with NICE NOT STOCKED
Dasatinib   Sprycel® tablets; powder for oral suspension      		RESTRICTED Haematology Consultants only
MHRA Drug Safety Update (May-16): BCR-ABL tyrosine kinase inhibitors: risk of hepatitis B reactivation		
Encorafenib   Braftovi® capsules      		RESTRICTED Specialist use only in line with NICE NOT STOCKED
Fedratinib   Inrebic® capsules      		RESTRICTED Haematology Consultants only
Gefitinib   tablets      		RESTRICTED Specialist use only in line with NICE NOT STOCKED
Gemtuzumab ozogamicin   Mylotarg® injection      		RESTRICTED Haematology Consultants only
Gilteritinib fumarate   Xospata® tablets      		RESTRICTED Haematology Consultants only
Ibrutinib   Imbruvica® capsules; tablets      		RESTRICTED Haem. Consultants only / also in line with NICE
MHRA Drug Safety Update (Nov-22): Imbruvica (ibrutinib): New risk minimisation measures, including dose modification recommendations		
MHRA Drug Safety Update (Aug-17): Ibrutinib (Imbruvica ▼): reports of ventricular tachyarrhythmia; risk of HBV B reactivation & opportunistic infections		
Idelalisib   Zydelig® tablets      		RESTRICTED Specialist use only in line with NICE TA359
MHRA Drug Safety Update (Sep-16): Idelalisib (Zydelig ▼): updated indications and advice on minimising the risk of infection		
Imatinib   tablets      		RESTRICTED Haematology Consultants only
MHRA Drug Safety Update (May-16): BCR-ABL tyrosine kinase inhibitors: risk of hepatitis B reactivation		
Inotuzumab ozogamicin   Besponsa® 1mg solution for infusion      		RESTRICTED Haematology Consultants only
Larotrectinib sulfate   Vitravivi® 20mg/mL oral solution      		RESTRICTED Consultants only in line with NICE

Lenvatinib   Kisplyx® capsules      	RESTRICTED Specialist use only in line with NICE TA498 / 858 NOT STOCKED
Lenvatinib   Lenvima® capsules      	RESTRICTED Specialist use only in line with NICE TA535 / 551 NOT STOCKED
MHRA Drug Safety Update (Jul-20): Systemically administered VEGF pathway inhibitors: risk of aneurysm and artery dissection	
Mobocertinib   Exkivity® capsules      	RESTRICTED Specialist use only
Neratinib   Nerlynx® tablets      	RESTRICTED Specialist use only in line with NICE TA612 NOT STOCKED
Nilotinib   Tassigna® capsules      	RESTRICTED Haematology Consultants only
MHRA Drug Safety Update (May-16): BCR-ABL tyrosine kinase inhibitors: risk of hepatitis B reactivation	
Osimertinib   Tagrisso® tablets      	RESTRICTED Specialist use only in line with NICE
Palbociclib   Ibrance® capsules      	RESTRICTED Specialist use only in line with NICE NOT STOCKED
MHRA Drug Safety Update (Jun-21): CDK4/6 inhibitors (abemaciclib ▼, palbociclib ▼, ribociclib ▼): reports of ILD & pneumonitis, including severe cases	
Ponatinib   Iclusig® tablets      	RESTRICTED Specialist use only in line with NICE TA451
MHRA Drug Safety Update (Jul-20): Systemically administered VEGF pathway inhibitors: risk of aneurysm and artery dissection	
MHRA Drug Safety Update (Oct-18): Ponatinib (Iclusig ▼): reports of posterior reversible encephalopathy syndrome	
MHRA Drug Safety Update (May-16): BCR-ABL tyrosine kinase inhibitors: risk of hepatitis B reactivation	
MHRA Drug Safety Update (Nov-14): Ponatinib (Iclusig ▼): risk of vascular occlusive events	
Regorafenib   Stivarga® 40mg tablets      	RESTRICTED Specialist use only in line with NICE TA488 / TA555 NOT STOCKED
MHRA Drug Safety Update (Jul-20): Systemically administered VEGF pathway inhibitors: risk of aneurysm and artery dissection	
Ribociclib   Kisqali® 200mg tablets      	RESTRICTED Specialist use only in line with NICE NOT STOCKED
MHRA Drug Safety Update (Jun-21): CDK4/6 inhibitors (abemaciclib ▼, palbociclib ▼, ribociclib ▼): reports of ILD & pneumonitis, including severe cases	
Ruxolitinib   Jakavi® tablets      	RESTRICTED Specialist use only in line with NICE / NHSE
Selpercatinib   Retsevmo® capsules      	RESTRICTED Specialist use only in line with NICE
Selumetinib   Koselugo® capsules      	RESTRICTED Specialist use only for NF1 in line with NICE HST20
Sunitinib   Sutent® capsules      	RESTRICTED Specialist use only in line with NICE NOT STOCKED
MHRA Drug Safety Update (Jul-20): Systemically administered VEGF pathway inhibitors: risk of aneurysm and artery dissection	
Tepotinib   Tepmetko® 225mg tablets      	RESTRICTED Specialist use in line with NICE / NHSE
Tivozanib   Fotivda® capsules      	RESTRICTED Specialist use only in line with NICE NOT STOCKED
Trametinib   Mekinist® tablets      	RESTRICTED Specialist use only in line with NICE TA396 NOT STOCKED
Zanubrutinib   Brukinsa® 80mg hard capsules      	RESTRICTED Specialist use in line with NICE / NHSE
Topoisomerase I inhibitors	
Tretinoin  capsules  	RESTRICTED Haematology Consultants only

Taxanes	
<p>Paclitaxel</p> <p> Red</p> <p>Infusion</p> <p>     </p>	<p>RESTRICTED</p> <p>Haematology Consultants only</p>
<p>MHRA Drug Safety Update (Jan-22): Paclitaxel formulations (conventional and nab-paclitaxel): caution required due to potential for medication error</p>	
<p>Cabazitaxel</p> <p> Red </p> <p>Jevtana® Infusion</p> <p>     </p>	<p>RESTRICTED</p> <p>Haematology Consultants only</p>

8.2 Drugs affecting the immune response		GMMMG
8.2.1 Antiproliferative immunosuppressants		
Azathioprine Amber tablets; oral solution; injection (see also sections 1.5.3; 10.1.3 & 13.5.3)	PbR X NICE MMC BNF emc	
Mycophenolate Mofetil Amber capsules; tablets; oral suspension; infusion MHRA Drug Safety Update (Feb-18): Mycophenolate mofetil, mycophenolic acid: updated contraception advice for male patients MHRA Drug Safety Update (Dec-15): Mycophenolate mofetil, mycophenolic acid: new pregnancy-prevention advice for women and men MHRA Drug Safety Update (Jan-15): Mycophenolate mofetil (CellCept) and mycophenolic acid: risk of hypogammaglobulinaemia and risk of bronchiectasis	PbR X NICE MMC BNF emc	
Belatacept U ££ Nulojix® 25mg/mL injection	PbR X NICE MMC BNF emc	RESTRICTED Renal Transplant Consultants only NOT STOCKED
8.2.2 Corticosteroids & other immunosuppressants		
Antithymocyte immunoglobulin (Rabbit) ££ injection	PbR X NICE BNF emc	
Basiliximab Red ££ Simlect® injection	PbR X NICE MMC BNF emc	RESTRICTED Renal Consultants only
Ciclosporin (Deximune®) & I.V. (Sandimmun®) Amber ££ capsules; oral solution; injection	PbR X NICE MMC BNF emc	
Sirolimus Amber ££ oral solution; tablets	PbR X NICE MMC BNF emc	RESTRICTED Renal Consultants only
Tacrolimus Amber capsules; tablets; ointment; oral suspension; infusion; sachets	PbR X NICE MMC BNF emc	
Voclosporin Red ££ capsules	PbR X NICE MMC BNF emc blueiq	RESTRICTED Specialist use only in line with NICE
Immunosuppressants - e.g. ciclosporin, tacrolimus, sirolimus Amber Red if no SCP		
8.2.3 Anti-lymphocyte monoclonal antibodies		
Alemtuzumab Red ££ Lemtrada® infusion MHRA Drug Safety Update (Feb-20): Alemtuzumab: updated restrictions & monitoring requirements following review of serious CV & immune-mediated reactions MHRA Drug Safety Update (May-19): Alemtuzumab and serious CV & immune-mediated adverse reactions: new restrictions to use & strengthened monitoring requirements	PbR X NICE MMC BNF emc blueiq	RESTRICTED Renal Consultants only under Patient Access Scheme
Atezolizumab Red ££ Tecentriq® infusion; solution for injection MHRA Drug Safety Update (Jun-21): Atezolizumab (Tecentriq ▼) and other immune-stimulatory anti-cancer drugs: risk of severe cutaneous adverse reactions (SCARs)	PbR X NICE MMC BNF emc blueiq	RESTRICTED Specialist Consultants in line with NICE / NHSE
Avacopan Red ££ Tavneos® capsules	PbR X NICE MMC BNF emc blueiq	RESTRICTED Specialist Consultants in line with NICE
Avelumab Red ££ Bavencio® infusion	PbR X NICE MMC BNF emc blueiq	RESTRICTED Specialist Consultants in line with NICE
Blinatumomab Red ££ Blincyto® infusion	PbR X NICE MMC BNF emc blueiq	RESTRICTED Haematology Consultants only in line with NICE
Burosumab Red ££ Crysvida® injection	PbR X NICE MMC BNF emc blueiq	RESTRICTED X-linked hypophosphatemia
Daratumumab Red ££ Darzalex® infusion MHRA Drug Safety Update (Aug-19): Daratumumab (Darzalex ▼): risk of reactivation of hepatitis B virus	PbR X NICE MMC BNF emc blueiq	RESTRICTED Haematology Consultants only in line with NICE / NHSE
Glofitamab Red ££ Columvi® infusion	PbR X NICE MMC BNF emc blueiq	RESTRICTED Haematology Consultants only in line with NICE
Isatuximab Red ££ infusion	PbR X NICE MMC BNF emc blueiq	RESTRICTED Haematology Consultants only in line with EAMS

Mogamulizumab   Poteligeo® infusion      	RESTRICTED Haematology Consultants only in line with NICE NOT STOCKED
Obinutuzumab   Gazyvaro® infusion      	RESTRICTED Haematology Consultants only in line with NICE
Ofatumumab   Kesimpta® injection      	RESTRICTED Consultants only in line with NICE
MHRA Drug Safety Update (Aug-14): Ofatumumab▼: reminder of risk of serious and fatal infusion reactions MHRA Drug Safety Update (Jan-14): Ofatumumab: screen for hepatitis B virus before treatment	
Pertuzumab   Perjeta® infusion      	RESTRICTED Haematology Consultants only in line with NICE
Polatuzumab vedotin   Polivy® infusion      	RESTRICTED Haematology Consultants only in line with NICE
Rituximab   injection; infusion (see also section 10.1.3)      	RESTRICTED Consultants only in line with NICE / NHSE 
MHRA Drug Safety Update (Dec-13): Rituximab: screen for hepatitis B virus before treatment	
8.2.4 Other immunomodulating drugs	
Interferon alfa	
Interferon alfa-2a   Roferon-A® injection   	
Interferon alfa-2b   IntronA®   	
Peginterferon alfa-2a   Pegasys®     	RESTRICTED Gastro Consultants only
Peginterferon alfa-2b   ViraferonPeg®    	RESTRICTED Gastro Consultants only
Interferon beta	
MHRA Drug Safety Update (Oct-14): Interferon-beta: risk of thrombotic microangiopathy and risk of nephrotic syndrome	
Interferon beta-1a   injection      	RESTRICTED Specialist use only in line with NICE TA527 NOT STOCKED
Interferon beta-1b   injection      	RESTRICTED Specialist use only in line with NICE TA527 NOT STOCKED
BCG bladder instillation	
BCG bladder instillation  OncoTICE®  	RESTRICTED Specialist use only

Other Agents		
Canakinumab   <i>Ilaris</i> ® 150mg/mL injection     		RESTRICTED Specialist use in line with NHSE 
Cemiplimab   <i>Libtayo</i> ® 50mg/mL injection      		RESTRICTED Specialist use in line with CDF & NICE
Dimethyl Fumarate   <i>Tecfidera</i> ® capsules      		RESTRICTED Specialist use only in line with NICE TA320
<p>MHRA Drug Safety Update (Jan-21): Dimethyl fumarate (Tecfidera): updated advice on the risk of PML associated with mild lymphopenia MHRA Drug Safety Update (Apr-16): Dimethyl fumarate (Tecfidera): updated advice on risk of progressive multifocal leukoencephalopathy MHRA Drug Safety Update (Mar-15): Dimethyl fumarate (Tecfidera): fatal PML in an MS patient with severe, prolonged lymphopenia</p>		
Dinutuximab beta   <i>Qarziba</i> ® 4.5mg/mL injection      		RESTRICTED Specialist use in line with CDF & NICE
Diroximel Fumarate   <i>Vumerity</i> ® 231mg capsules      		RESTRICTED Specialist use in line with NICE TA794 NOT STOCKED
Fingolimod Hydrochloride   <i>Gilenya</i> ® capsules      		RESTRICTED Specialist use only in line with NICE TA254
<p>MHRA Drug Safety Update (Jan-21): Fingolimod (Gilenya ▼): updated advice about the risks of serious liver injury and herpes meningoencephalitis</p>		
Glatiramer acetate   injection      		RESTRICTED Specialist use only in line with NICE TA527 NOT STOCKED
Imlifidase   infusion      		RESTRICTED Specialist use only in line with NICE TA809
Lenalidomide   <i>Revlimid</i> ® capsules      		RESTRICTED Haematology Consultants only
<p>MHRA Drug Safety Update (May-20): Immunomodulatory drugs and pregnancy prevention: temporary advice for management during coronavirus (COVID-19) MHRA Drug Safety Update (Jan-13): Lenalidomide (Revlimid): risk of serious hepatic adverse drug reactions</p>		
Mifamurtide   <i>Mepact</i> ® Intravenous infusion      		RESTRICTED Specialist use only in line with NICE TA235 NOT STOCKED
Natalizumab   <i>Tysabri</i> ® infusion      		RESTRICTED Specialist use only in line with NICE TA127 NOT STOCKED
<p>MHRA Drug Safety Update (Apr-16): Natalizumab (Tysabri ▼): progressive multifocal leukoencephalopathy—updated advice to support early detection</p>		
Nivolumab   <i>Opdivo</i> ® 10mg/mL infusion      		RESTRICTED Specialist use only in line with NICE
<p>MHRA Drug Safety Update (Oct-19): Nivolumab (Opdivo): reports of cytomegalovirus (CMV) gastrointestinal infection or reactivation MHRA Drug Safety Update (Jul-17): Nivolumab (Opdivo ▼), pembrolizumab (Keytruda ▼): reports of organ transplant rejection</p>		
Ocrelizumab   <i>Ocrevus</i> ® 30mg/mL infusion      		RESTRICTED Specialist use only in line with NICE TA533 / TA585 NOT STOCKED
Olaparib   <i>Lynparza</i> ® tablets      		RESTRICTED Specialist use only in line with NICE NOT STOCKED
Pomalidomide   capsules      		RESTRICTED Haematology only / also in line with NICE
<p>MHRA Drug Safety Update (May-20): Immunomodulatory drugs and pregnancy prevention: temporary advice for management during coronavirus (COVID-19) MHRA Drug Safety Update (May-16): Pomalidomide (Imnovid ▼): risk of hepatitis B reactivation MHRA Drug Safety Update (May-15): Pomalidomide (Imnovid ▼): risks of cardiac failure, interstitial lung disease and hepatotoxicity</p>		
Ponesimod   <i>Ponvory</i> ® tablets      		RESTRICTED Specialist use only in line with NICE TA767 NOT STOCKED
Rucaparib   tablets      		RESTRICTED Specialist use only in line with NICE TA611 NOT STOCKED
<p>MHRA Drug Safety Update (Sep-22): Rucaparib (Rubraca ▼): withdrawal of third-line treatment indication</p>		
Teriflunomide   tablets      		RESTRICTED Specialist use only in line with NICE TA303 NOT STOCKED

Thalidomide

Red

££

**RESTRICTED Haematology
Consultants only**

capsules

PbR X

NICE

MMC

BNF

emc

MHRA Drug Safety Update (May-20): Immunomodulatory drugs and pregnancy prevention: temporary advice for management during coronavirus (COVID-19)

MHRA Drug Safety Update (Dec-15): Thalidomide: reduced starting dose in patients older than age 75 years

MHRA Drug Safety Update (May-13): Thalidomide: risk of second primary malignancies

8.3 Sex hormones & hormone antagonists in malignant disease		GMMMG
8.3.1 Oestrogens		
Diethylstilbestrol		RESTRICTED Specialist use only
tablets	BNF emc	
8.3.2 Progestogens		
Medroxyprogesterone Acetate		RESTRICTED Specialist use only
tablets	BNF emc	
Megestrol Acetate		RESTRICTED Specialist use only
tablets	BNF emc	
8.3.3 Androgens		
Testolactone		RESTRICTED Specialist use only
tablets	BNF emc	
8.3.4 Hormone Antagonists		
8.3.4.1 Breast Cancer		
Aminoglutethimide		NICE NG101 RESTRICTED Specialist use only
tablets	BNF emc	
Anastrozole Green		RESTRICTED Specialist use only
tablets	NICE MMC BNF emc	
Exemestane Green		RESTRICTED Specialist use only
tablets	NICE MMC BNF emc	
Letrozole Green		RESTRICTED Specialist use only
tablets	NICE BNF emc	
Tamoxifen Green		RESTRICTED Specialist use only
tablets; oral solution	NICE BNF emc	
8.3.4.2 Gonadorelin analogues & gonadotrophin-releasing hormone antagonists		
Gonadorelin analogues		
Buserelin Red		RESTRICTED Specialist use only
injection (see also section 6.7.2)	BNF emc	
Goserelin Amber Red		RESTRICTED Specialist use only
implant (also section 6.7.2)	BNF emc	
Leuprorelin Acetate Amber Red		RESTRICTED Specialist use only
injection (also section 6.7.2)	MMC BNF emc	
Triptorelin Amber Red		RESTRICTED Specialist use only
injection (also section 6.7.2)	MMC BNF emc	
Goserelin/Leuprorelin - Licensed Indications (pre-op management prior to endometrial ablation/fibroid surgery)		Amber
Goserelin/Leuprorelin/Triptorelin - Licensed Indications (prostate cancer (all), breast cancer (goserelin))		Amber
Goserelin/Leuprorelin/Triptorelin - Precocious puberty and for testosterone castration in sex offenders (unlicensed in goserelin and leuprorelin)		Red
Goserelin/Leuprorelin/Triptorelin - For all other unlicensed indications (including long term use > 6 months)		Red

Anti-androgens		
Bicalutamide Green tablets  		RESTRICTED Specialist use only
Cyproterone Acetate Amber tablets (see also section 6.4.2) MHRA Drug Safety Update (Jun-20): Cyproterone acetate: new advice to minimise risk of meningioma MHRA Drug Safety Update (Apr-20): Cyproterone acetate: restrictions in use of due to risk of meningioma  		RESTRICTED Specialist use only
Darolutamide Red ££ 300mg tablets      		RESTRICTED Specialist use only in line with NICE
Flutamide tablets  		RESTRICTED Specialist use only
Enzalutamide Red ££ tablets      		RESTRICTED Specialist use only NOT STOCKED
Abiraterone Red ££ Zytiga® tablets      		RESTRICTED Specialist use only NOT STOCKED
Gonadotrophin-releasing hormone antagonists		
Degarelix Amber Firmagon® 80mg; 120mg injection    		RESTRICTED Specialist use only in line with NICE
Other		
Radium-223 dichloride Red ££ Xofigo® 1,100 kBq/mL injection      		RESTRICTED Specialist use only in line with NICE
MHRA Drug Safety Update (Sep-18): Xofigo ▼: new restrictions on use due to increased risk of fracture and trend for increased mortality seen in clinical trial MHRA Drug Safety Update (Dec-17): ▼ Xofigo: Increased risk of death and fractures in RCT with abiraterone acetate & prednisolone/prednisone		
8.3.4.3 Somatostatin analogues		
Lanreotide Red ££ injection    		RESTRICTED Consultant only - acromegaly
Octreotide Red ££ injection    		RESTRICTED 3 rd line use Gastro. Consultant only
Lutetium (¹⁷⁷Lu) oxodotretotide Red ££ Lutathera® injection      		RESTRICTED Specialist use only in line with NICE NOT STOCKED

8.4 Miscellaneous preparations		GMMMG
<p>Glucarpidase</p> <p> </p> <p>Voraxaze® 1,000 unit injection (see also sections 1.10, 10.4 & 13.14)</p>	<p>  </p>	<p>RESTRICTED 2nd line rescue therapy</p>
<p>Trifluridine / Tipiracil hydrochloride</p> <p> </p> <p>tablets</p>	<p>     </p>	<p>RESTRICTED Specialist use only in line with NICE NOT STOCKED</p>

Section 9: Nutrition & blood

Supported by the
formulary ([click here](#))



9.1 Anaemias and some other blood disorders

- 9.1.1 Iron deficiency anaemias
- 9.1.2 Drugs used in megaoblastic anaemias
- 9.1.3 Drugs used in hypoplastic, haemolytic & renal anaemias
- 9.1.4 Drugs used in autoimmune thrombocytopenic purpura
- 9.1.6 Drugs used in neutropenia
- 9.1.7 Drugs used to mobilise stem cells

9.2 Fluids and electrolytes

- 9.2.1 Oral preparations for fluid & electrolyte imbalance
- 9.2.2 Parenteral preparations for fluid & electrolyte imbalance

9.3 Intravenous nutrition

9.4 Oral nutrition

- 9.4.1 Nutrition in special diets

9.5 Minerals

- 9.5.1 Calcium and magnesium
- 9.5.2 Phosphorus
- 9.5.3 Fluoride
- 9.5.4 Zinc

9.6 Vitamins

- 9.6.1 Vitamin A
- 9.6.2 Vitamin B group
- 9.6.3 Vitamin C (Ascorbic acid)
- 9.6.4 Vitamin D
- 9.6.5 Vitamin E (Tocopherols)
- 9.6.6 Vitamin K
- 9.6.7 Multivitamin preparations

9.7 Bitters & tonics

9.8 Metabolic disorders

- 9.8.1 Drugs used in metabolic disorders
- 9.8.2 Acute porphyrias

Trust Guidelines

Adult medicines and prescribing guidelines
 Paediatric medicines and prescribing guidelines
 Neonatal guidelines (link to Staffnet site)
[Non-formulary Conversion Table](#)

NICE Guidance

Preventing recurrent hypomagnesaemia: oral magnesium glycerophosphate (ESUOM4)
 Nutrition support in adults (CG32)
 Coeliac disease: recognition, assessment and management (NG20)
 Chronic kidney disease: assessment and management (NG203)
 Eculizumab for treating atypical haemolytic uraemic syndrome (HST1)
 Migalastat for treating Fabry disease (HST4)
 Eliglustat for treating type 1 Gaucher disease (HST5)
 Cerliponase alfa for treating neuronal ceroid lipofuscinosis type 2 (HST12)
 Elosulfase alfa for treating mucopolysaccharidosis type 4A (HST19)
 Asfotase alfa for treating paediatric-onset hypophosphatasia (replacing HST6) (HST23)
 Hyperparathyroidism - cinacalcet (TA117)
 Thrombocytopenic purpura - romiplostim (TA221)
 Thrombocytopenic purpura - eltrombopag (TA293)
 Erythropoiesis-stimulating agents (epoetin & darbepoetin) for treating anaemia in chemotherapy (TA323)
 Etelcalcetide for treating secondary hyperparathyroidism (TA448)
 Sodium zirconium cyclosilicate for treating hyperkalaemia (TA599)
 Lusutrombopag for treating thrombocytopenia in people with chronic liver disease needing a planned invasive procedure (TA617)
 Patisiran for treating hyperkalaemia (TA623)
 Avatrombopag for treating thrombocytopenia in people with chronic liver disease needing a planned invasive procedure (TA626)
 Caplacizumab for treating acute acquired thrombotic thrombocytopenic purpura (TA667)
 Ravulizumab for treating paroxysmal nocturnal haemoglobinuria (TA698)
 Ravulizumab for treating atypical haemolytic uraemic syndrome (TA710)
 Sapropterin for treating hyperphenylalaninaemia in phenylketonuria (TA729)
 Crizanlizumab for preventing sickle cell crises in sickle cell disease (TA743)
 Pegcetacoplan for treating paroxysmal nocturnal haemoglobinuria (TA778)
 Roxadustat for treating symptomatic anaemia in chronic kidney disease (TA807)
 Avalglucosidase alfa for treating Pompe disease (TA821)
 Fostamatinib for treating refractory chronic immune thrombocytopenia (TA835)
 Avatrombopag for treating primary chronic immune thrombocytopenia (TA853)

GMMM Formulary

Formulary Homepage
 Chapter 9: Nutrition & Blood (Complete)
 GMMM Adult [Red/Amber/Green](#); DNP and Grey Drug List
 GMMM Paediatric [Red/Amber/Green](#) Drug List

9.1 Anaemias and some other blood disorders		GMMMG
9.1.1 Iron deficiency anaemias		
9.1.1.1 Oral iron		
Ferrous Sulfate		1st line use
tablets	 	STANDARD PREPARATIONS ONLY
Ferrous Fumarate		
tablets; oral solution	 	
Ferric Maltol		
capsules	  	
Sodium Feredetate		LIQUID PREPARATIONS ONLY
oral solution	 	
Iron & folic acid		
Ferrous Sulfate		
M/R tablets	 	
Ferrous Fumarate		
capsules; tablets	 	
9.1.1.2 Parenteral iron		
Ferric Carboxymaltose		RESTRICTED
 Ferinject® injection	  	
MHRA Drug Safety Update (Nov-20): Ferric carboxymaltose (Ferinject▼): risk of symptomatic hypophosphataemia leading to osteomalacia and fractures		
Ferric Derisomaltose		RESTRICTED
 Monofer® injection	  	
MHRA: Monofer and Diafer name change (Nov-20)		
MHRA Drug Safety Update (Sep-13): Intravenous iron and serious hypersensitivity reactions		
Iron Sucrose		RESTRICTED
 Venofer® injection	  	
9.1.2 Drugs used in megaloblastic anaemias		
Hydroxocobalamin		1st line use
Intramuscular injection; sachets	  	
Cyanocobalamin		See BSH guidance
 50microgram; 1mg tablets	  	
9.1.3 Drugs used in hypoplastic, haemolytic & renal anaemias		
Erythropoietins		
MHRA Drug Safety Update (Jan-18): Recombinant human erythropoietins: very rare risk of severe cutaneous adverse reactions (SCARs)		
Darbepoetin alfa		RESTRICTED Renal Consultants only
 injection	    	
Epoetin Alfa		RESTRICTED Renal Consultants only
 injection	   	
Epoetin Beta		RESTRICTED Renal Consultants only
 injection	   	
MHRA Drug Safety Update (May-15): Epoetin beta (NeoRecormon): increased risk of retinopathy in preterm infants cannot be excluded		
Sickle-cell disease		
Hydroxycarbamide		RESTRICTED Haematology Consultants only
 oral solution; capsules	 	
Crizanlizumab		RESTRICTED Haematology Consultants only in line with NICE / NHSE
  Adakveo® infusion	     	
Voxelotor		RESTRICTED Haematology Consultants only in line with EAMS / NHSE SSC2339
  Oxbryta® 500mg tablets	    	

Iron overload		
Deferasirox   tablets    	RESTRICTED Haematology Consultants only	
Deferiprone   tablets    	RESTRICTED Haematology Consultants only	
Desferrioxamine Mesilate   injection   	RESTRICTED Haematology Consultants only	
Hypoxia-inducible factor, prolyl hydroxylase inhibitor (HIF-PHI)		
Roxadustat   Evrenzo® tablets      	RESTRICTED Specialist use only in line with NICE	
Paroxysmal nocturnal haemoglobinuria & atypical haemolytic uraemic syndrome		
Eculizumab   infusion       	RESTRICTED Haematology Consultants only	
Ravulizumab   infusion      	RESTRICTED Specialist use only in line with NICE	
9.1.4 Drugs used in autoimmune thrombocytopenic purpura		
Anagrelide   capsules   	RESTRICTED Haematology Consultants only	
Avatrombopag   Doptelet® tablets      	RESTRICTED Specialist use only in line with NICE	
Caplacizumab   Cablivi® injection      	RESTRICTED Specialist use only in line with NICE NOT STOCKED	
Eltrombopag   Revolade® tablets      	RESTRICTED Haematology Consultants only	
MHRA Drug Safety Update (Jul-18): Eltrombopag (Revolade): reports of interference with bilirubin and creatinine test results		
Fostamatinib   Tavesse® tablets      	RESTRICTED Specialist use only	
Lusutrombopag   Mulpleo® tablets      	RESTRICTED Specialist use only	
Romiplostim   Nplate® injection      	RESTRICTED Haematology Consultants only	
9.1.6 Drugs used in neutropenia		
Filgrastim   injection    	RESTRICTED Haematology Consultants only	
MHRA Drug Safety Update (Sep-13): Filgrastim and pegfilgrastim: risk of capillary leak syndrome		
Lenograstim   injection   	RESTRICTED Haematology Consultants only	
Pegfilgrastim   injection    	RESTRICTED Haematology Consultants only	
MHRA Drug Safety Update (Sep-13): Filgrastim and pegfilgrastim: risk of capillary leak syndrome		
9.1.7 Drugs used to mobilise stem cells		
Plerixafor   injection      	RESTRICTED - initiation on advice of Haematology Consultant only	

9.2 Fluids and electrolytes		GMMMG
9.2.1 Oral preparations for fluid & electrolyte imbalance		
9.2.1.1 Oral potassium		
Potassium Chloride		
Sando-K® effervescent tablets; Kay-Cee-L® syrup	 	
Potassium removal		
Calcium Polystyrene Sulfonate		
Calcium Resonium® powder; enema (unlicensed)	 	
Sodium Zirconium Cyclosilicate		
Red Lokelma® powder sachets	   	
9.2.1.2 Oral sodium and water		
Sodium Chloride (Slow Sodium®)		
600mg M/R tablets	 	
Oral Rehydration Therapy (ORT)		
Oral Rehydration Salts (ORS)		
oral powder	 	
9.2.1.3 Oral bicarbonate		
Sodium Bicarbonate		
500mg capsules; 8.4% (1mmol/mL) oral solution	 	
Sodium Hydrogen Carbonate		
Nephrotrans® 50mg gastro-resistant capsules	  	RESTRICTED 2 nd line patients with severe GI side effects
9.2.2 Parenteral preparations for fluid & electrolyte imbalance		
9.2.2.1 Electrolytes & water		
Intravenous sodium		
Sodium Chloride		
infusion; injection	 	
Sodium chloride with other ingredients		
Sodium Chloride & Glucose		
infusion	 	
Sodium Chloride, Calcium Chloride & Potassium Chloride (Ringer's solution)		
infusion	 	
Sodium Chloride, Calcium Chloride, Potassium Chloride & Sodium Lactate		
infusion	 	
Intravenous glucose		
Glucose		
infusion	 	
MHRA Drug Safety Update (May-23): Glucose solutions: recommendations to minimise the risks associated with the accidental use instead of saline solutions in arterial lines MHRA Drug Safety Update (Jul-12): Glucose solutions: false blood glucose readings when used to flush arterial lines		
Intravenous potassium		
Potassium Chloride and Glucose		
infusion	 	
Potassium Chloride and Sodium Chloride		
infusion	 	
Potassium Chloride, Sodium Chloride & Glucose		
infusion	 	

Bicarbonate and lactate	
Sodium Bicarbonate	
1.26%, 2.74%, 4.2% & 8.4% injection; infusion	 
Water	
Water for Injections	
injection	 
9.2.2.2 Plasma & plasma substitutes	
Dextran	
<i>Dextran 40</i> - 10% in sodium chloride 0.9% infusion	
Dextrose Acid Citrate ACDA	
solution	
Gelatin	
<i>Gelofusine</i> ® infusion	 

9.3 Intravenous nutrition



Prescribers should seek advice from the MFT Nutrician Support Team (pager service 07659 526240) or the Dietetic Support Teams (General x64668; Renal x64478; Gastro x65781)

NICE CG32

9.4 Oral nutrition		
Prescribers should seek advice from the MFT Nutrician Support Team (pager service 07659 526240) or the Dietetic Support Teams (General x64668; Renal x64478; Gastro x65781)		NICE CG32
9.4.1 Nutrition in special diets		
Sapropterin dihydrochloride   <i>Kuvan</i> ® 100mg soluble tablets     	RESTRICTED Tetrahydrobiopterin deficiency 	
LaBiNIC® probiotic drops  <i>LaBiNIC</i> ® probiotic drops   	RESTRICTED prevention of NEC	

9.5 Minerals		GMMMG
9.5.1 Calcium and magnesium		
9.5.1.1 Calcium supplements		
Oral preparations		
Calcium Carbonate Green		
<i>Cacit</i> ® effervescent tablets; <i>Calcichew</i> ® chewable tablets	 	
Calcium Carbonate & Calcium Lactate Gluconate Green		
<i>Sandocal</i> ® 1000 effervescent tablets	 	
Parenteral preparations		
Calcium Gluconate		
10% injection	 	
MHRA Drug Safety Update (Jun-23): Calcium chloride, calcium gluconate: potential risk of underdosing with calcium gluconate in severe hyperkalaemia		
Calcium Chloride		
10% injection	 	
MHRA Drug Safety Update (Jun-23): Calcium chloride, calcium gluconate: potential risk of underdosing with calcium gluconate in severe hyperkalaemia		
with vitamin D		
see section 9.6.4	 	
with risedronate sodium & colecalciferol		
see section 6.6.2	 	
9.5.1.2 Hypercalcaemia & hypercalciuria		
Cinacalce Red 2 ^{yr} HPT Amber 1 ^{yr} HPT ££		RESTRICTED as per NICE TA117
tablets	    	
Etelcalcetide Red ££		RESTRICTED as per NICE TA448
injection	     	
9.5.1.3 Magnesium		
Magnesium Aspartate Dihydrate		NICE ESUOM4 1st line use
<i>Magnaspartate</i> ® sachets	  	
Magnesium Glycerophosphate		
chewable tablets; capsules; oral solution; tablets	  	
Magnesium Sulfate		
injection; infusion	 	
MHRA Drug Safety Update (May-19): Magnesium sulfate: risk of skeletal adverse effects in the neonate following prolonged or repeated use in pregnancy		
9.5.2 Phosphorus		
9.5.2.1 Phosphate supplements		
Phosphate supplements (<i>Phosphate-Sandoz</i>®)		Effervescent tabs
effervescent tablets	 	
Phosphates (<i>Polyfusor</i>®) Red		I.V. preparation
infusion	 	
9.5.2.2 Phosphate-binding agents		
Aluminium Hydroxide Green		NICE NG203
capsules	 	
Calcium Carbonate Green		
tablets (see also section 9.5.1.1)	 	
Calcium Acetate Green		
tablets	  	
Calcium Acetate / Magnesium Carbonate Green		RESTRICTED Renal Consultants only
<i>Osvaren</i> ® 435mg/235mg tablets	  	

<p>Lanthanum   chewable tablets; oral powder   </p>	<p>RESTRICTED Renal Consultants only</p>
<p>Patiromer Calcium   Veltassa® oral powder    </p>	<p>RESTRICTED Consultants only in line with NICE TA623</p>
<p>Sevelamer Carbonate   tablets     </p>	<p>RESTRICTED Renal Consultants only</p>
<p>Sucroferric Oxyhydroxide   chewable tablets   </p>	<p>RESTRICTED Renal Consultants only - 3rd line</p>
<p>9.5.3 Fluoride</p>	
<p>Sodium Fluoride tablets, paediatric drops, dental rinse  </p>	
<p>9.5.4 Zinc</p>	
<p>Zinc Sulfate Solvazinc® 125mg effervescent tabs; Zincomed® 220mg capsules  </p>	

9.6 Vitamins		GMMMG
9.6.1 Vitamin A		
Vitamin A		
150,000units/mL drops	 	
Vitamin A Palmitate		
100,000units/2mL injection	 	
Vitamins A & D		
capsules	 	
9.6.2 Vitamin B group		
Pyridoxine Hydrochloride		
tablets	 	
Thiamine		
tablets	 	
Vitamin B Compound		
	 	
Vitamin B Compound Strong		
tablets	 	
Vitamins B & C		
<i>Pabrinex</i> ® Intramuscular (IM) & Intravenous (IV) injection	 	
9.6.3 Vitamin C (Ascorbic acid)		
Ascorbic acid		
tablets	 	
9.6.4 Vitamin D		
Alfacalcidol		
 capsules; injection; oral drops	 	
Calcitriol		
capsules; oral solution	 	
Vitamin D and calcium		
Colecalciferol		1 st line use
Calcichew D3® Forte tablets / Adcal D3® chewable tablets	  	
Calcium & Ergocalciferol		
calcium 97mg/vitamin D 400units	 	
Colecalciferol		
<i>Cacif</i> ® D3 effervescent granules; 800 IU capsules	  	
9.6.5 Vitamin E (Tocopherols)		
Alpha Tocopheryl Acetate (Vitamin E)		
500mg/5mL liquid	 	
Alpha Tocopheryl Acetate (Vitamin E)		
75 unit capsules	 	

9.6.6 Vitamin K		
Phytomenadione		
<i>Konakion® MM & Konakion® MM Paediatric</i> injection	 MMC BNF emc	
Menadiol Sodium Phosphate		
oral solution; tablets	 MMC BNF emc	
9.6.7 Multivitamin preparations		
Vitamins B,C		RESTRICTED
<i>Renavit®</i> tablets	MMC BNF emc	
Vitamins A,D,E,K		RESTRICTED Paediatric CF patients
<i>Paravit-CF®</i> capsules; liquid	MMC BNF emc	

9.7 Bitters & tonics



Mixtures containing simple and aromatic bitters are traditional remedies for loss of appetite; there is no evidence to support their use

9.8 Metabolic disorders		GMMMG
9.8.1 Drugs used in metabolic disorders		
Serine deficiency		
L-Serine		RESTRICTED Specialist use only
(Nutricia L-Serine) powder	MMC	
Wilson's Disease		
Penicillamine 		
tablets (see also section 10.1.3)		
Trientine Dihydrochloride 		3rd line use
capsules		
Carnitine Deficiency		
Levocarnitine 		RESTRICTED Specialist use only
injection; oral solution		
Fabry's disease		
Agalsidase alfa 		RESTRICTED Specialist use only NOT STOCKED
Replagal® infusion		
Migalastat 		RESTRICTED Specialist use only (NICE HST4)
Galafold® capsules		
Mucopolysaccharidosis		
Elosulfase alfa 		RESTRICTED Specialist use only (NICE HST19)
Vimizim® infusion		
Galsulfase 		RESTRICTED Specialist use only NOT STOCKED
Naglazyme® infusion		
Idursulfase 		RESTRICTED Specialist use only
Elaprase® infusion		
Laronidase 		RESTRICTED Specialist use only NOT STOCKED
Aldurazyme® infusion		
Vestronidase alfa 		RESTRICTED Specialist use only
Mepsevii® infusion		
Nephropathic cystinosis		
Cystagon® (Mercaptamine) 		RESTRICTED Specialist use only
capsules (NB: prescribe as CYSTAGON®)		
Pompe disease		
Avalglucosidase alfa 		RESTRICTED Specialist use only (NICE TA821)
Nexviadyme® infusion		
Tyrosinemia type I		
Nitisinone 		RESTRICTED Specialist use only
capsules; oral suspension		
Urea cycle disorders		
BIMDG		
Arginine 		RESTRICTED Specialist use only
infusion; oral solution		
Carglumic acid 		RESTRICTED Specialist use only
dispersible tablets		
Citrulline 		RESTRICTED Specialist use only
powder		
Glycerol Phenylbutyrate 		RESTRICTED Specialist use only
Ravicti® 1.1g/mL oral liquid		

Sodium Phenylbutyrate   tablets; injection; oral liquid; granules (discontinued)	  	RESTRICTED Specialist use only
Homocystinuria		
Betaine   tablets; oral powder	  	RESTRICTED Specialist use only
Sodium Benzoate injection; oral solution; tablets; powder	  	RESTRICTED Specialist use only
Uridine	  	RESTRICTED Specialist use only
Other metabolic disorders		
Asfotase alfa   <i>Strensiq</i> ® injection	     	RESTRICTED Specialist use only (NICE HST23)
Cerliponase alfa   <i>Brineura</i> ® 150mg solution for infusion	     	RESTRICTED Specialist use only (NICE HST12)
Eliglustat   <i>Cerdelga</i> ® 84mg capsules	     	RESTRICTED Specialist use only (NICE HST5)
Miglustat   100mg capsules	   	RESTRICTED Specialist use only
Sodium dichloroacetate    50 mg/mL powder for reconstitution for oral solution (200 mL)	  	RESTRICTED Specialist use only Primary lactic acidosis / PDHC deficiency
Velaglucerase alfa   <i>VPRIV</i> ® 400 units vial	   	RESTRICTED Specialist use only
9.8.2 Acute porphyrias		
Haem Arginate   infusion	  	

Section 10: Musculoskeletal & Joint Diseases

Supported by the
formulary ([click here](#))



10.1 Drugs used in rheumatic diseases & gout

- 10.1.1 Non-steroidal anti-inflammatory drugs
- 10.1.2 Corticosteroids
- 10.1.3 Drugs that suppress the rheumatic disease process
 - Gold
 - Penicillamine
 - Antimalarials
 - Drugs affecting the immune response
 - Cytokine modulators
- 10.1.4 Gout and cytotoxic induced hyperuricaemia
- 10.1.5 Other drugs for rheumatic diseases

10.2 Drugs used in neuromuscular disorders

- 10.2.1 Drugs that enhance neuromuscular transmission
- 10.2.2 Skeletal muscle relaxants
 - Nocturnal leg cramps
- 10.2.3 Drugs used in neuromuscular disorders

10.3 Drugs for the relief of soft-tissue inflammation

- 10.3.1 Enzymes
- 10.3.2 Rubefacients & other topical antirheumatics

10.4 Miscellaneous preparations

Trust Guidelines

Adult medicines and prescribing guidelines
 Paediatric medicines and prescribing guidelines
 Neonatal guidelines (link to Staffnet site)
[Non-formulary Conversion Table](#)

NICE Guidance

Biosimilar Medicines (KTT15)
 Rheumatoid arthritis in adults: management (NG100)
 Osteoarthritis in over 16s: diagnosis and management (NG226)
 Onasemnogene abeparvovec for treating spinal muscular atrophy (HST15)
 Atidarsagene autotemcel for treating metachromatic leukodystrophy (HST18)
 Ataluren for treating Duchenne muscular dystrophy with a nonsense mutation in the dystrophin gene (replacing HST3) (HST22)
 Onasemnogene abeparvovec for treating presymptomatic spinal muscular atrophy (partial update of HST15) (HST24)
 Hyperuricaemia - febuxostat (TA164)
 Psoriasis - ustekinumab (TA180)
 Rheumatoid arthritis - drugs for treatment after failure of a TNF inhibitor (TA195)
 Psoriatic arthritis - etanercept, infliximab and adalimumab (TA199)
 Psoriatic arthritis - golimumab (TA220)
 Rheumatoid arthritis (after the failure of previous DMARDs) - golimumab (TA225)
 Arthritis (juvenile idiopathic, systemic) - tocilizumab (TA238)
 Rheumatoid arthritis - tocilizumab (rapid review TA198) (TA247)
 Vasculitis (anti-neutrophil cytoplasmic antibody-associated) - rituximab (with glucocorticoids) (TA308)
 Ustekinumab for treating active psoriatic arthritis (rapid review of TA313) (TA340)
 Abatacept, adalimumab, etanercept and tocilizumab for treating juvenile idiopathic arthritis (TA373)
 Adalimumab, etanercept, infliximab, certolizumab, golimumab, tocilizumab & abatacept for rheumatoid arthritis (TA375)
 TNF-alpha inhibitors for ankylosing spondylitis and non-radiographic axial spondyloarthritis (TA383)
 Certolizumab pegol for treating rheumatoid arthritis after inadequate response to a TNF-alpha inhibitor (TA415)
 Apremilast for treating active psoriatic arthritis (TA433)
 Certolizumab pegol and secukinumab for treating active psoriatic arthritis after inadequate response to DMARDs (TA445)
 Collagenase clostridium histolyticum for treating Dupuytren's contracture (TA459)
 Adalimumab and dexamethasone for treating non-infectious uveitis (TA460)
 Baricitinib for moderate to severe rheumatoid arthritis (TA466)
 Autologous chondrocyte implantation for treating symptomatic articular cartilage defects of the knee (replaces TA89) (TA477)
 Tofacitinib for moderate to severe rheumatoid arthritis (TA480)
 Sarilumab for moderate to severe rheumatoid arthritis (TA485)
 Lesinurad for treating chronic hyperuricaemia in people with gout (TA506)
 Autologous chondrocyte implantation using chondrosphere for symptomatic articular cartilage defects of the knee (TA508)
 Tocilizumab for treating giant cell arteritis (TA518)
 Ixekizumab for treating active psoriatic arthritis after inadequate response to DMARDs (TA537)
 Tofacitinib for treating active psoriatic arthritis after inadequate response to DMARDs (TA543)
 Tofacitinib for moderately to severely active ulcerative colitis (TA547)
 Nusinersen for treating spinal muscular atrophy (TA588)
 Upadacitinib for treating severe rheumatoid arthritis (TA665)
 Filgotinib for treating moderate to severe rheumatoid arthritis (TA676)
 Anakinra for treating Still's disease (TA685)
 Adalimumab, etanercept, infliximab & abatacept for treating moderate RA after conventional DMARDs have failed (TA715)
 Ixekizumab for treating axial spondyloarthritis in adults (TA718)
 Secukinumab for treating non-radiographic axial spondyloarthritis in adults (TA719)
 Tofacitinib for treating juvenile idiopathic arthritis (TA735)
 Upadacitinib for treating moderate rheumatoid arthritis (TA744)
 Belimumab for treating active autoantibody-positive systemic lupus erythematosus (replaces TA397) (TA752)
 Risdiplam for treating spinal muscular atrophy (TA755)
 Upadacitinib for treating active psoriatic arthritis after inadequate response to DMARDs (TA768)
 Guselkumab for treating active psoriatic arthritis after inadequate response to DMARDs (replacing TA711) (TA815)
 Upadacitinib for treating active ankylosing spondylitis (TA829)
 Upadacitinib for treating active non-radiographic axial spondyloarthritis (TA861)
 Bimekizumab for treating axial spondyloarthritis (TA918)
 Tofacitinib for treating active ankylosing spondylitis (TA920)

GMMMG Formulary

Formulary Homepage
 Chapter 10: Musculoskeletal & Joint Diseases (Complete)
 GMMMG Adult [Red/Amber/Green](#); DNP and [Grey](#) Drug List
 GMMMG Paediatric [Red/Amber/Green](#) Drug List

10.1 Drugs used in rheumatic diseases & gout		GMMMG
10.1 Drugs used in rheumatic diseases & gout		NICE CG177
10.1.1 Non-steroidal anti-inflammatory drugs (NSAIDs)		NICE NG100
MHRA Drug Safety Update (Oct-12): Non-steroidal anti-inflammatory drugs (NSAIDs): cardiovascular risks		
MHRA Drug Safety Update (May-09): Non-steroidal anti-inflammatory drugs (NSAIDs): reminder on renal failure and impairment		
MHRA Drug Safety Update (Dec-07): NSAIDs and coxibs: balancing of cardiovascular and gastrointestinal risks		
Ibuprofen		1st line use
200mg; 400mg; 600mg tablets; 5% gel	MMC  	
MHRA Drug Safety Update (Jun-23): Non-steroidal anti-inflammatory drugs (NSAIDs): potential risks following prolonged use after 20 weeks of pregnancy		
MHRA Drug Safety Update (Jun-15): High-dose ibuprofen (≥2400mg/day): small increase in cardiovascular risk		
Naproxen		
250mg; 500mg tablets	 	
MHRA Drug Safety Update (Jun-23): Non-steroidal anti-inflammatory drugs (NSAIDs): potential risks following prolonged use after 20 weeks of pregnancy		
Celecoxib		RESTRICTED - osteoarthritis in line with NICE NG226
100mg; 200mg capsules	MMC  	
MHRA Drug Safety Update (Dec-07): NSAIDs and coxibs: balancing of cardiovascular and gastrointestinal risks		
Diclofenac Sodium		RESTRICTED - acute post-operative pain
50mg tablets	MMC  	
MHRA Drug Safety Update (Jun-23): Non-steroidal anti-inflammatory drugs (NSAIDs): potential risks following prolonged use after 20 weeks of pregnancy		
MHRA Drug Safety Update (Jan-15): Oral diclofenac no longer available without prescription		
MHRA Drug Safety Update (Dec-14): Diclofenac: new contraindications and warnings		
Flurbiprofen		
50mg tablets	 	
Mefenamic Acid		
250mg; 500mg tablets	 	
Meloxicam		
7.5mg; 15mg tablets	 	
Sulindac		
100mg; 200mg tablets	MMC  	
Etodolac		RESTRICTED Consultant Anaesthetist use only
600mg tablets	MMC  	
Phenylbutazone		RESTRICTED Specialist use only, ankylosing spondylitis
100mg; 200mg tablets	 	
10.1.2 Corticosteroids		
MHRA Drug Safety Update (Aug-17): Corticosteroids: rare risk of central serous chorioretinopathy with local as well as systemic administration		
10.1.2.1 Systemic corticosteroids		NICE NG100
Prednisolone		
	 	
10.1.2.2 Local corticosteroid injections		NICE NG100
Hydrocortisone Acetate		
25mg/mL injection	 	
Methylprednisolone Acetate		
40mg/mL injection	 	
Triamcinolone Acetonide		
10mg/mL; 40mg/mL injection	 	
Triamcinolone Hexacetonide		RESTRICTED Paediatric Rheumatology Consultants only
20mg/mL injection	MMC  	

10.1.3 Drugs that suppress the rheumatic disease process		
Gold		NICE NG100
Auranofin Amber		RESTRICTED Rheumatology Consultants only
tablets	BNF emc	
Sodium Aurothiomalate Amber		RESTRICTED Rheumatology Consultants only
injection	BNF emc	
Penicillamine		
Penicillamine Amber		RESTRICTED Rheumatology Consultants only
tablets	BNF emc	
Antimalarials		
Hydroxychloroquine Amber		RESTRICTED Rheumatology Consultants only
tablets	MMC BNF emc	
MHRA Drug Safety Update (Feb-22): Hydroxychloroquine, chloroquine: increased risk of CV events when used with macrolide antibiotics; reminder of psychiatric reactions		
MHRA Drug Safety Update (Mar-20): Chloroquine and Hydroxychloroquine not licensed for coronavirus (COVID-19) treatment		
Mepacrine hydrochloride Red		RESTRICTED Rheumatology Consultants only
100mg tablets	MMC BNF emc	
Drugs affecting the immune response		NICE NG100
Azathioprine Amber		RESTRICTED Rheumatology Consultants only
tablets; injection; oral solution (see also sections 1.5.3, 8.2.1 & 13.5.3)	PbR X BNF emc	
Ciclosporin Amber		RESTRICTED Consultants only
capsules; oral solution; injection (see also sections 8.2.2 & 13.5.3)	PbR X MMC BNF emc	
Leflunomide Amber		RESTRICTED Rheumatology Consultants only
tablets	MMC BNF emc	
Methotrexate Amber oral Red parenteral		RESTRICTED Consultants only
tablets; injections (see also sections 1.5.3, 8.1.3 & 13.5.3)	MMC BNF emc	
MHRA Drug Safety Update (Aug-23): Methotrexate: advise patients to take precautions in the sun to avoid photosensitivity reactions		
MHRA Drug Safety Update (Sep-20): Methotrexate once-weekly for autoimmune diseases: new measures to reduce risk of fatal overdose		
Cytokine modulators		
Abatacept Red ££		RESTRICTED Rheum. Consultants only in line with NICE / NHSE
injection; infusion	PbR X NICE MMC BNF emc blueTEQ NHS England NHS England	
Adalimumab Red ££		RESTRICTED Consultants only in line with NICE
injection (see also sections 1.5.3, 11.4.2 & 13.5.3)	PbR X NICE MMC BNF emc blueTEQ	
MHRA Drug Safety Update (Apr-14): TNF alpha inhibitors -risk of TB - screen all patients before starting treatment and monitor them closely		
Anakinra Red ££		RESTRICTED Consultants only in line with NICE / NHSE
injection	PbR X NICE MMC BNF emc blueTEQ NHS England NHS England	
Apremilast Red ££		RESTRICTED 3rd / 4th line as per NICE/GMMMG
10mg; 20mg; 30mg tablets	PbR X NICE MMC BNF emc	
Baricitinib Red ££		RESTRICTED Rheumatology Consultants only in line with NICE
2mg; 4mg tablets	PbR X NICE MMC BNF emc blueTEQ NHS England	
MHRA Drug Safety Update (Apr-23): JAK inhibitors: new measures to reduce risks of major CV events, malignancy, VTE, serious infections & increased mortality		
MHRA Drug Safety Update (Aug-20): Baricitinib (Olmiant▼): increased risk of diverticulitis, particularly in patients with risk factors		
MHRA Drug Safety Update (Mar-20): Baricitinib (Olmiant▼): risk of venous thromboembolism		
Belimumab Red ££		RESTRICTED Consultants only
infusion	PbR X NICE MMC BNF emc blueTEQ	
MHRA Drug Safety Update (Apr-19): Belimumab (Benlysta▼): increased risk of serious psychiatric events seen in clinical trials		
Bimekizumab Red ££		RESTRICTED in line with NICE
injection (see also section 13.5.3)	PbR X NICE MMC BNF emc blueTEQ	
Certolizumab Red ££		RESTRICTED Rheumatology Consultants in line with NICE
injection (see also section 13.5.3)	PbR X NICE MMC BNF emc	
MHRA Drug Safety Update (Apr-14): TNF alpha inhibitors -risk of TB - screen all patients before starting treatment and monitor them closely		

Etanercept   injection      	RESTRICTED Consultants only; in line with NICE
MHRA Drug Safety Update (Apr-14): TNF alpha inhibitors -risk of TB - screen all patients before starting treatment and monitor them closely	
Filgotinib   tablets      	RESTRICTED Consultants only in line with NICE
MHRA Drug Safety Update (Apr-23): JAK inhibitors: new measures to reduce risks of major CV events, malignancy, VTE, serious infections & increased mortality	
Golimumab   injection      	RESTRICTED Consultants only in line with NICE
MHRA Drug Safety Update (Apr-14): TNF alpha inhibitors -risk of TB - screen all patients before starting treatment and monitor them closely	
Guselkumab   100mg/mL injection     	RESTRICTED in line with NICE
Infliximab   <i>Remicade</i> ® infusion; <i>Remsima</i> ® infusion      	RESTRICTED Consultants only MMC Remsima
MHRA Drug Safety Update (Apr-14): TNF alpha inhibitors -risk of TB - screen all patients before starting treatment and monitor them closely	
Ixekizumab   80mg/1mL injection (see also section 13.5.3)      	RESTRICTED Consultants only in line with NICE
Rituximab   injection; infusion (see also section 8.2.3)      	RESTRICTED Consultants only in line with NICE / NHSE
Sarilumab   <i>Kevzara</i> ® 150mg/1.14mL injection      	RESTRICTED Rheumatology Consultants only in line with NICE
Secukinumab   <i>Cosentyx</i> ® 150mg/1mL injection (see also section 13.5.3)      	RESTRICTED Rheumatology Consultants only in line with NICE
Tocilizumab   infusion      	RESTRICTED Consultants only in line with NICE
MHRA Drug Safety Update (Jul-19): Tocilizumab (RoActemra): rare risk of serious liver injury including cases requiring transplantation	
Tofacitinib   <i>Xeljanz</i> ® 5mg; 10mg tablets (see also section 1.5.3)      	RESTRICTED Consultants only in line with NICE
MHRA Drug Safety Update (Apr-23): JAK inhibitors: new measures to reduce risks of major CV events, malignancy, VTE, serious infections & increased mortality	
MHRA Drug Safety Update (Oct-21): Tofacitinib (Xeljanz▼): new measures to minimise risk of major adverse cardiovascular events and malignancies	
MHRA Drug Safety Update (Mar-20): Tofacitinib (Xeljanz▼): new measures to minimise risk of venous thromboembolism and of serious and fatal infections	
MHRA Drug Safety Update (May-19): Tofacitinib (Xeljanz▼): restriction of 10 mg twice-daily dose in patients at high risk of PE while safety review is ongoing	
Upadacitinib   MR tablet (see also sections 1.5.3 & 13.5.3)      	RESTRICTED Consultants only in line with NICE
MHRA Drug Safety Update (Apr-23): JAK inhibitors: new measures to reduce risks of major CV events, malignancy, VTE, serious infections & increased mortality	
Ustekinumab   injection; infusion (see also section 13.5.3)      	RESTRICTED Dermatology TA340 / Gastro 3 rd line Crohn's
MHRA Drug Safety Update (Jan-15): Ustekinumab (Stelara): risk of exfoliative dermatitis	

10.1.4 Gout and cytotoxic induced hyperuricaemia	
Acute attacks of gout	
Colchicine	
tablets	 
Long-term control of gout	
Allopurinol	
tablets	 
	1st line use
Febuxostat	
	
tablets	   
<p>MHRA Drug Safety Update (May-23): Febuxostat: updated advice for the treatment of patients with a history of major cardiovascular disease</p> <p>MHRA Drug Safety Update (Jul-19): Febuxostat: increased risk of CV death and all-cause mortality in clinical trial in patients with a history of major CV disease</p> <p>MHRA Drug Safety Update (Jun-12): Febuxostat (Adenuric▼): stop treatment if signs or symptoms of serious hypersensitivity</p>	
Hyperuricaemia associated with cytotoxic drugs	
Rasburicase	
 	
Fasturtec® infusion	    
10.1.5 Other drugs for rheumatic diseases	
	NICE CG177
	NICE TA477
	NICE TA508

10.2 Drugs used in neuromuscular disorders		GMMMG
10.2.1 Drugs that enhance neuromuscular transmission		
Anticholinesterases		
Pyridostigmine Bromide		1st line use
tablets	 	
Neostigmine		
tablets; injection	 	
Edrophonium Chloride		RESTRICTED diagnosis of myasthenia gravis Licensed product discontinued
injection	 	
10.2.2 Skeletal muscle relaxants		
Baclofen		1st line use
10mg tablets; 5mg/mL oral solution	 	
Dantrolene Sodium		
25mg; 100mg capsules; Ryanodex 250mg/20mL vial	 	
Diazepam		
tablets; liquid; injection; rectal tube (see also sections 4.1.2, 4.8 & 15.1.4.1)	 	
Tizanidine		RESTRICTED Consultant Neurologist only
Amber 2mg; 4mg tablets	 	
Nocturnal leg cramps		
Quinine Sulfate		
tablets (see also section 5.4.1)	 	
MHRA Drug Safety Update (Nov-17): Quinine: reminder of dose-dependent QT-prolonging effects; updated interactions		
MHRA Drug Safety Update (Jun-10): Quinine: not to be used routinely for nocturnal leg cramps		
10.2.3 Drugs used in neuromuscular disorders		
Ataluren		Specialist use only in line with NICE HST22
Red  oral suspension sachets	     	
Atidarsagene autotemcel		Specialist use only in line with NICE HST18
Red  Libmeldy® infusion	     	
Nusinersen		Specialist use only in line with NICE TA588 / NHSE Named patient access
Red  injection	     	
MHRA Drug Safety Update (Sep-18): Nusinersen (Spinraza ▼): reports of communicating hydrocephalus; discuss symptoms with patients & carers - investigate urgently		
Onasemnogene abeparvovec		RESTRICTED Paediatric Neurology Consultants only NICE / NHSE
Red  Zolgensma® infusion	     	
Risdiplam		Specialist use only in line with NICE TA755
Red  oral solution	     	

10.3 Drugs for the relief of soft-tissue inflammation		GMMMG
10.3.1 Enzymes		
Hyaluronidase Red injection BNF  		RESTRICTED extravasation
10.3.2 Rubefacients & other topical antirheumatics		
Piroxicam 0.5% gel BNF  		
Capsaicin DNP cream, patch MMC  BNF  		Patch restricted to peripheral neuropathic pain specialists at TGH

10.4 Miscellaneous preparations



Glucarpidase



Voraxaze® 1,000 unit injection ([see also sections 1.10, 8.4 & 13.14](#))



RESTRICTED
2nd line rescue therapy

Section 11: Eye

Supported by the
formulary ([click here](#))



11.3 Anti-infective eye preparations

11.3.1 Antibacterials

11.3.3 Antivirals

11.4 Corticosteroid & other anti-inflammatory preparations

11.4.1 Corticosteroids

11.4.2 Other anti-inflammatory preparations

11.5 Mydriatics & cycloplegics

11.6 Treatment of glaucoma

11.7 Local anaesthetics

11.8 Miscellaneous ophthalmic preparations

11.8.1 Tear deficiency, ocular lubricants & astringents

11.8.2 Ocular diagnostic & peri-operative preparations & photodynamic treatment

11.8.3 Other preparations

Trust Guidelines

Adult medicines and prescribing guidelines
 Paediatric medicines and prescribing guidelines
 Neonatal guidelines (link to Staffnet site)
[Non-formulary Conversion Table](#)

NICE Guidance

Glaucoma: diagnosis and management (NG81)
 Macular degeneration (age related) ranibizimab & pegaptanib (TA155)
 Macular oedema (retinal vein occlusion) - dexamethasone (TA229)
 Macular oedema (diabetic) - ranibizumab (TA274)
 Macular oedema (retinal vein occlusion) - ranibizumab (TA283)
 Macular degeneration (wet age-related) - aflibercept (1st line) (TA294)
 Vitreomacular traction - ocriplasmin (TA297)
 Choroidal neovascularisation (pathological myopia) - ranibizumab (TA298)
 Diabetic macular oedema - fluocinolone acetonide intravitreal implant (rapid review of TA271) (TA301)
 Macular oedema (central retinal vein occlusion) - aflibercept solution for injection (TA305)
 Aflibercept for treating diabetic macular oedema (TA346)
 Ciclosporin for treating dry eye disease that has not improved despite treatment with artificial tears (TA369)
 Aflibercept for treating visual impairment caused by macular oedema after branch retinal vein occlusion (TA409)
 Adalimumab and dexamethasone for treating non-infectious uveitis (TA460)
 Holoclar for treating limbal stem cell deficiency after eye burns (TA467)
 Aflibercept for treating choroidal neovascularisation (TA486)
 Cenegermin for treating neurotrophic keratitis (TA532)
 Fluocinolone acetonide intravitreal implant for treating recurrent non-infectious uveitis (TA590)
 Voretigene neparvovec for treating inherited retinal dystrophies caused by RPE65 gene mutations (HST11)
 Brolucizumab for treating wet age-related macular degeneration (TA672)
 Faricimab for treating diabetic macular oedema (TA799)
 Faricimab for treating wet age-related macular degeneration (TA800)
 Brolucizumab for treating diabetic macular oedema (TA820)
 Dexamethasone intravitreal implant for treating diabetic macular oedema (replacing TA349) (TA824)

GMMMG Formulary

Formulary Homepage
 Chapter 11: Eye (Complete)
 GMMMG Adult [Red/Amber/Green](#); DNP and Grey Drug List
 GMMMG Paediatric [Red/Amber/Green](#) Drug List

11.3 Anti-infective eye preparations		GMMMG
11.3.1 Antibacterials		
Chloramphenicol		
0.5% eye drops, 1% eye ointment	 	
MHRA Drug Safety Update (Jul-21): Chloramphenicol eye drops containing borax or boric acid buffers: use in children younger than 2 years		
Fusidic Acid (ophthalmic)		
1% eye drops	 	
Amikacin (ophthalmic)  	 	RESTRICTED microbial keratitis. Consultant Ophthalmologist only
2.5% eye drops	 	NOT STOCKED
Amphotericin		
0.15% eye drops	 	RESTRICTED Consultant Ophthalmologist only
Azithromycin (ophthalmic)		
	 	RESTRICTED Consultant Ophthalmologist only
Azyter® 1.5% eye drops	  	
Ceftazidime (ophthalmic)		
	 	RESTRICTED Consultant Ophthalmologist only
5% eye drops	 	NOT STOCKED
Cefuroxime (ophthalmic)		
 	 	RESTRICTED Consultant Ophthalmologist only
5% eye drops	 	
Cefuroxime (intracameral injection)		
	 	RESTRICTED Consultant Ophthalmologist only
Ximaract® 50mg in 5mL intracameral injection	  	
Chlorhexidine (ophthalmic)		
 	 	RESTRICTED acanthamoeba keratitis. Consultant only
0.02% eye drops	 	
Ciprofloxacin (ophthalmic)		
	 	RESTRICTED microbial keratitis. Consultant Ophthalmologist only
0.3% eye drops	 	
MHRA Drug Safety Update (Sep-23): Fluoroquinolone antibiotics: suicidal thoughts and behaviour		
MHRA Drug Safety Update (Aug-23): Fluoroquinolone antibiotics: reminder of the risk of disabling and potentially long-lasting or irreversible side effects		
MHRA Drug Safety Update (Dec-20): Systemic & inhaled fluoroquinolones: small risk of heart valve regurgitation; consider other therapeutic options first in patients at risk		
MHRA Drug Safety Update (Mar-19): Fluoroquinolones: new restrictions & precautions for use due to rare reports of disabling & long-lasting / irreversible side effects...		
Erythromycin (ophthalmic)		
	 	RESTRICTED superficial eye infections
0.5% eye ointment	 	
Gentamicin (ophthalmic)		
 	 	RESTRICTED Consultant Ophthalmologist only
1.5% eye drops (Use with cefuroxime eye drops)	 	
Levofloxacin (ophthalmic)		
	 	RESTRICTED Consultant only corneal ulcers/ keratitis
0.5% eye drops	  	
MHRA Drug Safety Update (Sep-23): Fluoroquinolone antibiotics: suicidal thoughts and behaviour		
MHRA Drug Safety Update (Aug-23): Fluoroquinolone antibiotics: reminder of the risk of disabling and potentially long-lasting or irreversible side effects		
MHRA Drug Safety Update (Dec-20): Systemic & inhaled fluoroquinolones: small risk of heart valve regurgitation; consider other therapeutic options first in patients at risk		
MHRA Drug Safety Update (Mar-19): Fluoroquinolones: new restrictions & precautions for use due to rare reports of disabling & long-lasting / irreversible side effects...		
Natamycin		
	 	RESTRICTED fungal keratitis, conjunctivitis, fungal blepharitis
5% eye drops	 	
Ofloxacin		
	 	RESTRICTED Consultant Ophthalmologist only
0.3% eye drops	  	
MHRA Drug Safety Update (Sep-23): Fluoroquinolone antibiotics: suicidal thoughts and behaviour		
MHRA Drug Safety Update (Aug-23): Fluoroquinolone antibiotics: reminder of the risk of disabling and potentially long-lasting or irreversible side effects		
MHRA Drug Safety Update (Dec-20): Systemic & inhaled fluoroquinolones: small risk of heart valve regurgitation; consider other therapeutic options first in patients at risk		
MHRA Drug Safety Update (Mar-19): Fluoroquinolones: new restrictions & precautions for use due to rare reports of disabling & long-lasting / irreversible side effects...		
Penicillin (ophthalmic)		
 	 	RESTRICTED microbial keratitis. Consultant Ophthalmologist only
2,500 units/mL eye drops	 	
Polyhexamethylene Biguanide (PHMB)		
 	 	NOT STOCKED
0.02% eye drops	 	

<p>Polymyxin B Sulfate</p> <p>eye ointment</p>	 	<p>RESTRICTED gram negative bacteria, including pseudomonas</p>
<p>Propamidine Isetionate</p> <p>Green</p> <p>0.1% eye drops</p>	 	<p>RESTRICTED Consultant Ophthalmologist only</p>
<p>Vancomycin (ophthalmic)</p> <p>U</p> <p>5% eye drops</p>	 	<p>RESTRICTED gram positives, including MRSA but not VRE NOT STOCKED</p>
<p>11.3.3 Antivirals</p>		
<p>Ganciclovir</p> <p>Green</p> <p>0.15% eye gel</p>	 	
<p>Trifluorothymidine</p> <p>U Red</p> <p>1% eye drops</p>	 	

11.4 Corticosteroid & other anti-inflammatory preparations		GMMMG
11.4.1 Corticosteroids		
MHRA Drug Safety Update (Aug-17): Corticosteroids: rare risk of central serous chorioretinopathy with local as well as systemic administration		
Betamethasone 0.1% eye drops & ointment	 	
Dexamethasone 0.1% eye drops & minims	 	
Dexamethasone (intravitreal implant)   Ozurdex® 700micrograms intravitreal implant	    	RESTRICTED as per NICE TA229; TA460 & TA824
Fluocinolone Acetonide   Iluvien® 190micrograms intravitreal implant	    	RESTRICTED as per NICE TA301 & TA590
Prednisolone 0.5% & 1% eye drops; 0.5% minims	 	
Fluorometholone  0.1% eye drops	 	
Hydrocortisone sodium phosphate Softacort® 3.35 mg/mL PF single use eye drops	  	
Triamcinolone Acetonide   Kenalog® 40mg/mL injectable suspension	  	RESTRICTED intralesional injection in skin grafts
Triamcinolone Acetonide  Triesence® 40mg/mL injectable suspension	  	RESTRICTED uveitis; sympathetic ophthalmia
Triamcinolone Acetonide  Intracinol® 40mg/mL ophthalmic suspension	  	RESTRICTED opacification of the vitreous humour
Corticosteroids preparations with antibiotics		
Betamethasone / Neomycin Sulphate 0.1% / 0.5% eye drops (Betnesol-N®)	 	
Dexamethasone / Neomycin Sulphate / Polymyxin B Sulphate 1 mg/mL : 3500 IU/mL : 6000 IU/mL (Maxitrol® eye drops & ointment)	 	
11.4.2 Other anti-inflammatory preparations		
Sodium Cromoglicate 2% eye drops	 	
Adalimumab   Amgevita® injection (see also sections 1.5.3, 10.1.3 & 13.5.3)	    	RESTRICTED Consultant Ophthalmologist only Non-infectious Uveitis
Antazoline with Xylometazoline 0.5% eye drops	 	
Azelastine 0.05% eye drops	 	RESTRICTED allergic conjunctivitis, children only
Ketotifen hydrogen fumarate Ketofall® 0.25mg/mL PF eye drops	 	
Lodoxamide 0.1% eye drops	 	RESTRICTED allergic conjunctivitis
Olopatadine 1mg/mL eye drops	  	RESTRICTED Seasonal allergic conjunctivitis
Potassium Ascorbate  10% eye drops	 	RESTRICTED management of chemical burns to the cornea

11.5 Mydriatics & cycloplegics		GMMMG
Antimuscarinics		
Atropine Sulphate		
1% minims	 	
Cyclopentolate Hydrochloride		
1% eye drops, 0.5% & 1% minims	 	
Tropicamide		
0.5% & 1% eye drops, 0.5% & 1% minims	 	
Sympathomimetics		
Phenylephrine Hydrochloride		10% contraindicated in children & the elderly
2.5% & 10% minims	 	
Sympathomimetics with tropicamide		
Phenylephrine Hydrochloride with Tropicamide		RESTRICTED Pre-operative mydriasis in cataract patients
Mydriaser [®] 5.4mg / 280micrograms ophthalmic insert	  	

11.6 Treatment of glaucoma		GMMMG
Beta-blockers		NICE NG81
Timolol		
0.25% & 0.5% eye drops	 	
Timolol once-daily		
0.25% eye drops, <i>Tiopex</i> ® 0.1% gel, 0.5% long-acting ophthalmic gel	 	
Betaxolol		
0.25% & 0.5% eye drops, 0.25% minims	 	
Levobunolol Hydrochloride		
0.5% eye drops	 	
Prostaglandin analogues and prostamides		
Bimatoprost		
100 microgram/mL eye drops	  	
Latanoprost		
50 microgram/mL eye drops	 	
MHRA Drug Safety Update (Jul-15): Latanoprost (Xalatan): increased reporting of eye irritation since reformulation		
Latanoprost (preservative free)		
50 microgram/mL preservative free eye drops	  	
MHRA Drug Safety Update (Jul-15): Latanoprost (Xalatan): increased reporting of eye irritation since reformulation		
Travoprost		
40 microgram/mL eye drops	  	
Prostaglandin analogues (combination products)		
Latanoprost / Timolol		
50microgram/mL / 5mg/mL eye drops; preservative free eye drops	  	
Sympathomimetics		
Brimonidine Tartrate		
0.2% eye drops	  	
Apraclonidine		
 or 		RESTRICTED to delay laser treatment / surgery in uncontrolled glaucoma
0.5%; 1% eye drops	 	
Carbonic anhydrase inhibitors & systemic drugs		
Acetazolamide		
		
250mg tablets; <i>Diamox SR</i> ® 250mg capsules	 	
Brinzolamide		
10mg/mL eye drops	 	
Brinzolamide / Brimonidine		
<i>Simbrinza</i> ® 2% eye drops	  	RESTRICTED glaucoma patients in whom monotherapy provides insufficient IOP reduction
Dorzolamide		
2% eye drops; also preservative free	 	
Dorzolamide / Timolol		
<i>Cosopt</i> ® 2% eye drops; also preservative free	 	
Miotics		
Pilocarpine		
1%, 2% & 4% eye drops, 2% minims	 	
Pilocarpine		
4% ophthalmic gel	 	

11.7 Local anaesthetics



Ocular Local anaesthetics

Lidocaine (Lignocaine) and Fluorescein (minims)

4% / 0.25% eye drops



Oxybuprocaine (minims)

0.4% eye drops



Proxymetacaine (minims)

0.5% eye drops



Tetracaine (Amethocaine) (minims)

1% & 2% eye drops



11.8 Miscellaneous ophthalmic preparations		GMMMG
Other preparations		
Botulinum toxin type A		RESTRICTED Consultant Ophthalmologist only blepharospasm & strabismus
Xeomin® injection	MMC BNF emc	
Ciclosporin (eye)		RESTRICTED Consultant Ophthalmologist only
U 2% eye drops	BNF emc	
Ciclosporin (Ikervis®)		RESTRICTED Consultant Ophthalmologist only in line with NICE TA369
Green 1mg/mL eye drops	NICE MMC BNF emc	
Ciclosporin (Verkazia®)		RESTRICTED Paediatrics for vernal keratoconjunctivitis / severe allergic eye disease
Green 1mg/mL eye drops	MMC BNF emc	
Mercaptamine		RESTRICTED Specialist use only NHSE
Red FF Cystadrops® eye drops	PbR x MMC BNF blueiq emc	NHS England
Sodium Chloride		
U Red 5% eye drops	BNF emc	
Allogeneic Serum eye drops		RESTRICTED Consultant Ophthalmologist only
U Red eye drops (minims) (from NHS Blood & Transplant Service) (not a medicine)	MMC blueiq	NHS England
11.8.1 Tear deficiency, ocular lubricants & astringents		
Acetylcysteine		
U Ilube® 5% eye drops	BNF emc	
Alteplase		RESTRICTED Consultant Ophthalmologist only
25microgram in 0.1mL intravitreal injection	MMC BNF emc	
Carbomers		
Viscotears® 0.2% eye drops	MMC BNF emc	
Carmellose Sodium		
Celluvisc® 0.5% eye drops	BNF emc	
Cationorm®		
preservative free eye drops	MMC BNF emc	
Hydroxyethylcellulose		
Minims® Artificial Tears preservative free eye drops	BNF emc	
Hypromellose		
0.3% eye drops	MMC BNF emc	
Liquid Paraffin		
Lacri-Lube® ointment	BNF emc	
Poly (carboxymethylglucose sulfate)		RESTRICTED Consultant Ophthalmologist only NOT STOCKED
Cacicol® eye drops (0.33mL)	MMC BNF emc	
Polyvinyl Alcohol		
Liquifilm Tears® 1.4% eye drops	MMC BNF emc	
Sodium Chloride (minims)		
0.9% eye drops	BNF emc	
Sodium Hyaluronate		
Hyo-Forte® 0.2% eye drops	MMC BNF emc	

11.8.2 Ocular diagnostic & peri-operative preparations & photodynamic treatment		
Ocular diagnostic preparations		
Fluorescein Sodium		
1% & 2% preservative free eye drops	 	
Fluorescein Sodium 		RESTRICTED Specialist use only fundus fluorescein angiography
100mg/mL injection	  	
Indocyanine green (ICG) 		RESTRICTED Specialist use only
Verdye® 5mg/mL injection	  	
Ocular peri-operative drugs		
Acetylcholine Chloride		
1% intraocular irrigation	 	RESTRICTED Consultant Ophthalmologist only
Apraclonidine		
lopidine® 0.5% eye drops; 1% preservative free eye drops	 	RESTRICTED Consultant Ophthalmologist only
Bromfenac		
Yellox® 0.9 mg/mL eye drops	  	RESTRICTED Consultant only for pseudophakic CMO
Ketorolac Trometamol 		
Acular® 0.5% eye drops	 	RESTRICTED Consultant Ophthalmologist only
Nepafenac		
Nevanac® 1 mg/mL eye drops	  	RESTRICTED. 1 st line post cataract surgery in diabetics. 2 nd line CMO
Povidone-Iodine		
5% eye drops	  	RESTRICTED Consultant Ophthalmologist only
Heavy Silicone oil		
Densiron® 68 - 10mL syringe	 	RESTRICTED intraocular tamponade of inferior retinal breaks
Subfoveal choroidal neovascularisation		
Aflibercept  		
Eylea® 40mg in 1mL injection	    	RESTRICTED Consultant Ophthalmologist only
Bevacizumab   		
Avastin® 100mg in 4mL vial	    	RESTRICTED Consultant Ophthalmologist only
Brolucizumab  		
Beovu® 120mg in 1mL injection	    	RESTRICTED Consultant Ophthalmologist only
MHRA Drug Safety Update (Jan-22): Brolucizumab (Beovu▼): risk of intraocular inflammation and retinal vascular occlusion increased with short dosing intervals		
Faricimab  		
Vabysmo® 120mg/mL injection	    	RESTRICTED Consultant Ophthalmologist in line with NICE
Ranibizumab  		
Lucentis® / Ongavia® 10mg/mL injection	    	RESTRICTED Consultant Ophthalmologist only 
Verteporfin  		
Visudyne® 15mg vial	   	RESTRICTED Consultant Ophthalmologist only
Vitreomacular traction		
Ocriplasmin  		
Jetrea® 0.5 mg/0.2mL injection	    	RESTRICTED Consultant Ophthalmologist only
11.8.3 Other preparations		
Voretigene		
Voretigene neparvec  		
Luxturna® 2mL vial	    	RESTRICTED Consultant Ophthalmologist in line with NICE
Insulin eye drops		
Insulin (soluble) eye drops  		
Humulin S® in Systane® lubricant eye drops		RESTRICTED Consultant Ophthalmologist

Section 12: Ear, nose & oropharynx

Supported by the
formulary ([click here](#))



12.1 Drugs acting on the ear

- 12.1.1 Otitis externa
- 12.1.3 Removal of ear wax

12.2 Drugs acting on the nose

- 12.2.1 Drugs used in nasal allergy
- 12.2.2 Topical nasal decongestants
- 12.2.3 Nasal preparations for infection

12.3 Drugs acting on the oropharynx

- 12.3.1 Drugs for oral ulceration & inflammation
- 12.3.2 Oropharyngeal anti-infective drugs
- 12.3.4 Mouthwashes, gargles & dentifrices
- 12.3.5 Treatment of dry mouth

Trust Guidelines

Adult medicines and prescribing guidelines
Paediatric medicines and prescribing guidelines
Neonatal guidelines (link to Staffnet site)
[Non-formulary Conversion Table](#)

NICE Guidance

Sinusitis (acute): antimicrobial prescribing (NG79)
Sore throat (acute): antimicrobial prescribing (NG84)
Otitis media (acute): antimicrobial prescribing (NG91)
Tinnitus: assessment and management (NG155)
Otitis media with effusion in under 12s (NG233)
Allergic rhinitis (CKS)

GMMM Formulary

Formulary Homepage
Chapter 12: Ear, nose & oropharynx (Complete)
GMMM Adult [Red/Amber/Green](#); DNP and Grey Drug List
GMMM Paediatric [Red/Amber/Green](#) Drug List

12.1 Drugs acting on the ear		GMMMG
12.1.1 Otitis externa		
Astringent preparations		
Aluminium Acetate		
ear drops	 	
Anti-inflammatory preparations		
Betamethasone Sodium Phosphate		
Betnesol® 0.1% ear drops	 	
Prednisolone Sodium Phosphate		
Predsol® 0.5% ear drops	 	
Anti-inflammatory with antibacterial preparations		
Dexamethasone / Neomycin Sulphate		
Otomize® 0.1% / 3250u per mL ear spray	 	
Dexamethasone / Framycetin Sulphate / Gramicidin		
Sofradex® 0.05% / 0.5% / 0.005% ear/eye drops	 	
Flumetasone Pivalate / Clioquinol		
Locorten-Vioform® 0.02% / 1% ear drops	 	
Hydrocortisone / Gentamicin		
1% / 0.3% ear drops	 	
Hydrocortisone / Neomycin Sulfate / Polymyxin B Sulphate		
Otosporin® 1% : 3400u/mL : 10,000u/mL ear drops	 	
Analgesic / Anti-inflammatory / local anaesthetic preparations		
Phenazone with Lidocaine		
Otigo® 40mg/g / 10mg/g ear drops	   	RESTRICTED paeds in line with NICE NG91
Anti-infective preparations		
Ciprofloxacin		
	  	
Cetralax® 0.2% ear drops		
MHRA Drug Safety Update (Sep-23): Fluoroquinolone antibiotics: suicidal thoughts and behaviour		
MHRA Drug Safety Update (Aug-23): Fluoroquinolone antibiotics: reminder of the risk of disabling and potentially long-lasting or irreversible side effects		
MHRA Drug Safety Update (Dec-20): Systemic & inhaled fluoroquinolones: small risk of heart valve regurgitation; consider other therapeutic options first in patients at risk		
MHRA Drug Safety Update (Mar-19): Fluoroquinolones: new restrictions / precautions for use due to reports of disabling & potentially long-lasting or irreversible side effects		
Clotrimazole		
1% ear drops	 	
12.1.3 Removal of ear wax		
Chlorobutanol / Arachis oil		
Cerumol® ear drops	 	
Olive oil ear drops		
	 	
ear drops		
Sodium Bicarbonate		
	 	
5% ear drops		

12.2 Drugs acting on the nose		GMMMG
12.2.1 Drugs used in nasal allergy		
Antihistamines		
Azelastine Hydrochloride		
140micrograms nasal spray	NICE BNF emc	
Corticosteroids		
MHRA Drug Safety Update (Aug-17): Corticosteroids: rare risk of central serous chorioretinopathy with local as well as systemic administration		
Beclometasone Dipropionate		1 st line use
50micrograms nasal spray	BNF emc	
Betamethasone Sodium Phosphate		
0.1% nose drops	BNF emc	
Mometasone Furoate		1 st line use nasal polyps
50micrograms nasal spray	MMC BNF emc	
Fluticasone Furoate		
Avamys® 27.5micrograms nasal spray	MMC BNF emc	
Fluticasone Propionate / Azelastine Hydrochloride		RESTRICTED 3 rd line use
Green Dymista® 50micrograms / 137micrograms nasal spray	NICE MMC BNF emc	
Cromoglicate		
Sodium Cromoglicate		
4% nasal spray	BNF emc	
12.2.2 Topical nasal decongestants		
Sympathomimetics		
Ephedrine Hydrochloride		1 st line use
0.5%; 1% nasal drops	BNF emc	
Sodium Chloride		
0.9% nasal drops	BNF emc	
Xylometazoline Hydrochloride		
0.1% nasal drops	BNF emc	
Antimuscarinics		
Ipratropium Bromide		Rhinorrhoea associated with allergic & non-allergic rhinitis
0.03% nasal spray	BNF emc	
12.2.3 Nasal preparations for infection		
Chlorhexidine Dihydrochloride / Neomycin		1 st line use staphylococcal infections
Naseptin® 0.1% / 0.5% nasal cream	MMC BNF emc	
Mupirocin		RESTRICTED MRSA / post nasal cautery
2% nasal ointment	MMC BNF emc	

12.3 Drugs acting on the oropharynx		GMMMG
12.3.1 Drugs for oral ulceration & inflammation		
Local Analgesics		
Benzylamine Hydrochloride Green		
0.15% oral rinse; 0.15% spray	 	
Carmellose Sodium		
30g protective paste	 	
Corticosteroids		
Hydrocortisone		
muco-adhesive buccal tablets	 	
12.3.2 Oropharyngeal anti-infective drugs		
Oropharyngeal fungal infections		
Miconazole DNP		
2% oral gel	 	
MHRA Drug Safety Update (Sep-17): Miconazole (Daktarin): over-the-counter oral gel contraindicated in patients taking warfarin		
Nystatin DNP		
100,000 units/mL oral suspension	 	
12.3.4 Mouthwashes, gargles & dentifrices		
Chlorhexidine Gluconate		
0.2% mouthwash; 1% dental gel	 	
12.3.5 Treatment of dry mouth		
Local treatment		
AS Saliva Orthana®		
spray; lozenges	 	
BioXtra®		
oral gel	 	
Systemic treatment		
Pilocarpine		RESTRICTED Consultant use only following irradiation for head & neck cancer
5mg tablets	 	
Treatment of Dental Caries		
Silver Diamine Fluoride (SDF) 38%		
liquid	 	

Section 13: Skin

Supported by the
formulary (click here)



13.2 Emollient & barrier preparations

13.2.1 Emollients

13.2.2 Barrier preparations

13.3 Topical local anaesthetics & antipruritics

13.4 Topical corticosteroids

13.5 Preparations for eczema & psoriasis

13.5.1 Preparations for eczema

13.5.2 Preparations for psoriasis

13.5.3 Drugs affecting the immune response

Cytokine Modulators

13.6 Acne & Rosacea

13.6.1 Topical preparations for acne

13.6.2 Oral preparations for acne

13.7 Preparations for warts & calluses

13.8 Sunscreens & camouflagers

13.8.1 Sunscreen preparations

13.9 Shampoos & other preparations for scalp/hair conditions

13.10 Anti-infective skin preparations

13.10.1 Antibacterial preparations

13.10.2 Antifungal preparations

13.10.3 Antiviral preparations

13.10.4 Parasitocidal preparations

13.10.5 Preparations for minor cuts & abrasions

13.11 Skin cleansers, antiseptics & desloughing agents

13.11.1 Alcohols & saline

13.11.2 Chlorhexidine salts

13.11.4 Iodine

13.11.6 Oxidisers & dyes

13.11.7 Desloughing agents

13.12 Antiperspirants

13.13 Topical circulatory preparations

13.14 Miscellaneous preparations

Non-Formulary Items

Trust Guidelines

Adult medicines and prescribing guidelines
 Paediatric medicines and prescribing guidelines
 Neonatal guidelines (link to Staffnet site)
[Non-formulary Conversion Table](#)

NICE Guidance

Biosimilar Medicines (KTT15)
 Atopic eczema in children (CG57)
 Psoriasis: assessment and management (CG153)
 Pressure Ulcers (CG179)
 Pubic lice CKS (2011)
 Scabies CKS (2011)
 Acne vulgaris CKS (2014)
 Head lice CKS (2015)
 Surgical site infections: prevention and treatment (NG125)
 Atopic dermatitis (eczema) - topical steroids (TA81)
 Atopic dermatitis (eczema) - pimecrolimus and tacrolimus (TA82)
 Psoriasis - efalizumab and etanercept (TA103) EMA (efalizumab)
 Psoriasis - infliximab (TA134)
 Psoriasis - adalimumab (TA146)
 Alitretinoin for the treatment of severe chronic hand eczema (TA177)
 Psoriasis - ustekinumab (TA180)
 Melanoma (stage III or IV) - ipilimumab (TA268)
 Melanoma (BRAF V600 mutation positive, unresectable metastatic) - vemurafenib (TA269)
 Ustekinumab for treating active psoriatic arthritis (rapid review of TA313) (TA340)
 Secukinumab for treating moderate to severe plaque psoriasis (TA350)
 Adalimumab for treating moderate to severe hidradenitis suppurativa (TA392)
 Nivolumab in combination with ipilimumab for treating advanced melanoma (TA400)
 Apremilast for treating moderate to severe plaque psoriasis (replaces TA368) (TA419)
 Apremilast for treating active psoriatic arthritis (TA433)
 Ixekizumab for treating moderate to severe plaque psoriasis (TA442)
 Adalimumab, etanercept and ustekinumab for treating plaque psoriasis in children and young people (TA455)
 Dimethyl fumarate for treating moderate to severe plaque psoriasis (TA475)
 Brodalumab for treating moderate to severe plaque psoriasis (TA511)
 Guselkumab for treating moderate to severe plaque psoriasis (TA521)
 Dupilumab for treating moderate to severe atopic dermatitis (TA534)
 Certolizumab pegol for treating moderate to severe plaque psoriasis (TA574)
 Tildrakizumab for treating moderate to severe plaque psoriasis (TA575)
 Risankizumab for treating moderate to severe plaque psoriasis (TA596)
 Baricitinib for treating moderate to severe atopic dermatitis (TA681)
 Secukinumab for treating moderate to severe plaque psoriasis in children and young people (TA734)
 Risankizumab for treating active psoriatic arthritis after inadequate response to DMARDs (TA803)
 Abrocitinib, tralokinumab or upadacitinib for treating moderate to severe atopic dermatitis (TA814)
 Pembrolizumab for adjuvant treatment of resected stage 2B or 2C melanoma (TA837)
 Difelikefalin for treating pruritus in people having haemodialysis (TA890)
 Deucravacitinib for treating moderate to severe plaque psoriasis (TA907)
 Bimekizumab for treating active psoriatic arthritis (TA916)

GMMMG Formulary

Formulary Homepage
 Chapter 13: Skin (Complete)
 GMMMG Adult Red/Amber/Green; DNP and Grey Drug List
 GMMMG Paediatric Red/Amber/Green Drug List

13.2 Emollient & barrier preparations		GMMMG
13.2.1 Emollients		
Non-Proprietary emollient preparations		
MHRA Drug Safety Update (Aug-20): Emollients and risk of severe and fatal burns: new resources available		
MHRA Drug Safety Update (Jul-20): Safe use of emollient skin creams to treat dry skin conditions		
MHRA Drug Safety Update (Dec-18): Emollients: new information about risk of severe and fatal burns with paraffin-containing and paraffin-free emollients		
MHRA Patient Info Leaflet (Jul-20): Skin creams - risk of fire and burns		
Aqueous cream BP		
cream	 	
Emulsifying ointment BP		
ointment	 	
Liquid & white soft paraffin		
ointment	 	
Paraffin, white soft BP		
white petroleum jelly	 	
Paraffin, yellow soft BP		
yellow petroleum jelly	 	
Proprietary emollient preparations		
Diprobase®		
cream; ointment	 	
Doublebase®		
gel	 	
Hydromol®		
cream; ointment	  	
Oilatum®		
	 	
Preparations containing urea		
Balneum® Plus		
	 	
With antimicrobials		
Dermol® & Dermol® 500		
	  	RESTRICTED patients unable to tolerate 1 st / 2 nd line antimicrobial washes
13.2.1.1 Emollient bath and shower preparations DNP		
Emollient bath and shower preparations without antimicrobials		
When used for the management of eczema in children or adults. This recommendation does not apply to the use of standard emollients when used in the bath or shower as a soap substitute		DNP
With antimicrobials		
Dermol® 600		
Grey Green		
bath emollient	 	
Oilatum® Plus		
bath emollient	 	2nd line MRSA decolonisation therapy
13.2.2 Barrier preparations		
Proprietary barrier preparations		
Metanium®		
ointment	 	2nd line only at parental request
Sudocrem®		
cream	 	2nd line only at parental request

13.3 Topical local anaesthetics & antipruritics

GMMMG

13.3 Topical local anaesthetics & antipruritics**Crotamiton**

cream; lotion

**Mepyramine Maleate**

2% w/w cream



13.4 Topical corticosteroids		GMMMG
Corticosteroid only preparations		NICE TA81
MHRA Drug Safety Update (Sep-21): Topical corticosteroids: information on the risk of topical steroid withdrawal reactions		
MHRA Drug Safety Update (Aug-17): Corticosteroids: rare risk of central serous chorioretinopathy with local as well as systemic administration		
HYDROCORTISONE		Potency
Canesten HC®		Mild
hydrocortisone 1% plus clotrimazole 1% cream	 	
Daktacort®		Mild
hydrocortisone 1%, miconazole nitrate 2% cream; ointment	 	
Eurax-Hydrocortisone®		Mild
hydrocortisone 0.25%, crotamiton 10% cream	 	
Fucidin H®		Mild
hydrocortisone 1%, fusidic acid 1% cream	 	
BETAMETHASONE ESTERS		Potency
MHRA Drug Safety Update (Sep-21): Topical corticosteroids: information on the risk of topical steroid withdrawal reactions		
Betamethasone valerate		Moderate
0.025% ointment, cream	 	
Betnovate-RD®		Moderate
Betamethasone valerate 0.025% cream; ointment	 	
CLOBETASONE BUTYRATE		Potency
MHRA Drug Safety Update (Sep-21): Topical corticosteroids: information on the risk of topical steroid withdrawal reactions		
Eumovate®		Moderate
0.05% cream; ointment	 	
BETAMETHASONE ESTERS		Potency
MHRA Drug Safety Update (Sep-21): Topical corticosteroids: information on the risk of topical steroid withdrawal reactions		
Betamethasone valerate		Potent
0.1% ointment; cream; lotion; scalp lotion	 	
Betnovate®		Potent
0.1% cream; ointment; scalp application; lotion	 	
Betamethasone valerate / Clioquinol		Potent
0.1% / 3% ointment; cream	 	
Betamethasone valerate / Neomycin sulfate		Potent
0.1% / 0.5% cream; ointment	 	
Diprosalic®		Potent
Betamethasone dipropionate 0.05%, salicylic acid 3% ointment	 	
Fucibet®		Potent
Betamethasone valerate 0.1% plus fusidic acid 2% cream	 	
Betnovate®		Potent
ointment 25% in coal tar	 	DERMATOLOGY ONLY
CLOBETASOL PROPIONATE		Potency
MHRA Drug Safety Update (Sep-21): Topical corticosteroids: information on the risk of topical steroid withdrawal reactions		
Dermovate®		Very potent
clobetasol propionate 0.05% ointment; cream; lotion; scalp lotion	 	
Dermovate NN®		Very potent
clobetasol propionate 0.05% / neomycin / nystatin cream	 	
Etrivex®		Very potent
clobetasol propionate 500micrograms/g shampoo	  	RESTRICTED - 1 st Care referral
DIFLUCORTOLONE VALERATE		Potency
Diflucortolone valerate 		Very potent
0.3% oily cream	  	RESTRICTED Consultant Gynaecologist

13.5 Preparations for eczema & psoriasis		GMMMG
13.5.1 Preparations for eczema		
Alitretinoin   10mg; 30mg capsules     		RESTRICTED Dermatology Consultants only
MHRA Drug Safety Update (Jul-21): Oral retinoid medicines (isotretinoin ▼, alitretinoin ▼ & acitretin ▼): temporary monitoring advice during COVID-19 pandemic MHRA Drug Safety Update (Jun-19): Oral retinoid medicines ▼: revised and simplified pregnancy prevention educational materials for healthcare professionals & women		
13.5.2 Preparations for psoriasis		
Topical preparations for psoriasis		NICE CG153
Calcipotriol Dovonex® ointment; with Betamethasone (Dovobet® 0.05% ointment)  		RESTRICTED Dermatology Consultants only
Dithranol   (unlicensed preps) Dithocream® 0.1% & 0.25% cream  		RESTRICTED Dermatology Consultants only
Salicylic acid Zinc & Salicylic acid paste BP (Lassar's Paste)  		RESTRICTED Dermatology Consultants only
Tacalcitol Curatoderm® lotion; ointment  		RESTRICTED Dermatology Consultants only
Tars		
Coal tar paste BP paste  		RESTRICTED Dermatology Consultants only
Coccolis® scalp ointment  		RESTRICTED Dermatology Consultants only
Oral retinoids for psoriasis		
Acitretin  10mg; 25mg capsules  		RESTRICTED Dermatology Consultants only
Dimethyl Fumarate   30mg; 120mg tablets      		RESTRICTED 3 rd /4 th line as per NICE/GMMMG Referral to SRFT
13.5.3 Drugs affecting the immune response		
Abrocitinib   Cibingo® 50mg; 100mg; 200mg tablets      		RESTRICTED Dermatology Consultants only in line with NICE
MHRA Drug Safety Update (Apr-23): JAK inhibitors: new measures to reduce risks of major CV events, malignancy, VTE, serious infections and increased mortality		
Azathioprine  25mg; 50mg tablets (see also sections 1.5.3, 8.2.1 & 10.1.3)  		RESTRICTED Dermatology Consultants only
Ciclosporin  25mg, 50mg & 100mg caps; 100mg/1mL oral soln; Infusion (see also section 8.2.2)    		RESTRICTED Dermatology Consultants only
Methotrexate  2.5mg tablets (see also sections 8.1.3 & 10.1.3)   		RESTRICTED Dermatology Consultants only
Pimecrolimus  1% cream    		RESTRICTED Dermatology Consultants only
Tacrolimus (specially made by SRFT)  0.03%; 0.1% ointment     		RESTRICTED Dermatology Consultants only
Upadacitinib   Rinvoq® 15mg; 30mg MR tablets (see also sections 1.5.3 & 10.1.3)      		RESTRICTED Dermatology Consultants only in line with NICE
MHRA Drug Safety Update (Apr-23): JAK inhibitors: new measures to reduce risks of major CV events, malignancy, VTE, serious infections and increased mortality		

Cytokine Modulators		(see also section 10.1.3)
Adalimumab   injection (see also sections 1.5.3, 10.1.3 & 11.4.2)	     	RESTRICTED Dermatology Consultants only
Apremilast   10mg; 20mg; 30mg tablets	    	RESTRICTED 3 rd /4 th line as per NICE/GMMMG Referral to SRFT
Bimekizumab   <i>Bimzelx</i> ® injection (see also section 10.1.3)	     	RESTRICTED in line with NICE
Brodalumab   <i>Kyntheum</i> ® 140mg/mL injection	    	RESTRICTED Dermatology only in line with NICE
Certolizumab   <i>Cimzia</i> ® 200mg injection (see also section 10.1.3)	    	RESTRICTED Dermatology only in line with NICE
Dupilumab   <i>Dupixent</i> ® 150mg/mL injection (see also section 3.4.2)	     	RESTRICTED Dermatology only in line with NICE
Etanercept   injection (see also section 10.1.3)	     	RESTRICTED Dermatology Consultants only
Guselkumab   100mg/mL injection	    	RESTRICTED in line with NICE
Infliximab   100mg injection (see section 10.1.3)	     	RESTRICTED Dermatology only in line with NICE
Ixekizumab   80mg/1mL injection (see also section 10.1.3)	    	RESTRICTED Dermatology only in line with NICE
Risankizumab   75mg; 150mg injection	     	RESTRICTED Specialist use only in line with NICE
Secukinumab   150mg/1mL injection	     	RESTRICTED Dermatology only in line with NICE
Tildrakizumab   100mg injection	    	RESTRICTED Dermatology only in line with NICE NOT STOCKED
Ustekinumab   injection (see section 10.1.3)	     	RESTRICTED Dermatology NICE TA180 & 455 / Gastro 3 rd line Crohn's

13.6 Acne & Rosacea		GMMMG
13.6.1 Topical preparations for acne		NICE CKS: Acne
For mild to moderate acne, use topical benzyl peroxide or a topical retinoid 1st line. Topical antibiotic should be reserved for patients who have not responded to other topical preparations.		
Benzyl peroxide & azelaic acid		
Benzoyl Peroxide DNP	 	1 st line
4% cream; 5% gel		
Azelaic acid	 	2 nd line
Skinoren® 20% cream		
Topical antibacterials for acne		
Clindamycin	 	2 nd / 3 rd line
Dalacin T® 1% topical lotion		
Erythromycin	 	2 nd / 3 rd line
Zineryt® 40mg/mL erythromycin; zinc acetate 12mg/mL lotion		
Topical retinoids & related preparations for acne		
Adapalene	 	1 st line
Differin® 0.1% cream; 0.1% gel		
Topical retinoids with antibacterial		
Isotretinoin with Erythromycin	 	RESTRICTED Dermatology Consultants only
Isotrexin® 500micrograms/1g : 20mg/1g gel		
13.6.2 Oral preparations for acne		NICE CKS: Acne
Oral antibiotics should be reserved for moderate to severe acne or where topical preparations have failed. Please refer to Chapter 5.		
Lymecycline	  	RESTRICTED GP referral only
408mg capsules (see also section 5.1.3)		
Hormone treatment for acne		
Co-cyprindiol	 	RESTRICTED GP referral only
Cyproterone acetate 2mg / ethinylestradiol 35micrograms tablets		
Oral retinoid for acne		
Isotretinoin Red	 	RESTRICTED Dermatology Consultants only
5mg; 10mg; 20mg; 40mg capsules		
<p>MHRA Drug Safety Update (Oct-23): Isotretinoin (Roaccutane ▼): introduction of new safety measures, including additional oversight on initiation of treatment in under 18s</p> <p>MHRA Drug Safety Update (Apr-23): Isotretinoin (Roaccutane ▼): new safety measures, including additional oversight on initiation of treatment in under 18s</p> <p>MHRA Drug Safety Update (Jul-21): Oral retinoid medicines (isotretinoin ▼, alitretinoin ▼, and acitretin ▼): temporary monitoring advice during COVID-19 pandemic</p> <p>MHRA Drug Safety Update (Nov-20): Isotretinoin (Roaccutane ▼): contribute to expert review</p> <p>MHRA Drug Safety Update (Aug-20): Isotretinoin (Roaccutane ▼): reminder of important risks and precautions</p> <p>MHRA Drug Safety Update (Jun-19): Oral retinoid medicines ▼: revised and simplified pregnancy prevention educational materials for healthcare professionals and women</p> <p>MHRA Drug Safety Update (Oct-17): Isotretinoin (Roaccutane): rare reports of erectile dysfunction and decreased libido</p> <p>MHRA Drug Safety Update (Dec-14): Isotretinoin (Roaccutane): reminder of possible risk of psychiatric disorders</p>		

13.7 Preparations for warts & calluses		GMMMG
13.7 Preparations for warts & calluses		
Salicylic acid DNP ointment; liquid	 	
Silver Nitrate pencil	 	RESTRICTED Dermatology Consultants only
Silver Nitrate 75% applicator	  	RESTRICTED ENT - nasal cautery
Anogenital warts		
Podophyllotoxin 0.15% cream	 	1st line
Imiquimod Green 5% cream	  	RESTRICTED GUM Consultant only

13.8 Sunscreens & camouflagers		GMMMG
13.8.1 Sunscreen preparations		
Photodamage		
Methyl-5-Aminolevulinate  160mg/g cream 	RESTRICTED Dermatology Consultants & Vulval Intraepithelial Neoplasia (VIN) only	
Diclofenac Sodium Solaraze® 3% gel 	RESTRICTED Dermatology Consultants	
Fluorouracil / Salicylic acid Actikerall® 0.5% / 10% cutaneous solution 	RESTRICTED Dermatology Consultants as per MMC	

13.9 Shampoos & other preparations for scalp / hair conditions		GMMMG
Shampoos		
Ketoconazole		RESTRICTED persistent / severe seborrhoeic dermatitis / dandruff
<i>Nizoral</i> ® 2% shampoo	 	
Capasal ®		RESTRICTED Dermatology Consultants only
coal tar 1%, coconut oil 1% &, salicylic acid 0.5% shampoo	 	
Ceanel Concentrate ®		RESTRICTED Dermatology Consultants only
cetrimide 10%, undecenoic acid 1% & phenylethyl alcohol 7.5% shampoo	 	
Other scalp preparations		
Polytar ®		
40mg/mL coal tar scalp shampoo	 	
Hirsutism		
Eflornithine		RESTRICTED Dermatology Consultants only
<i>Vaniqa</i> ® 11.5% cream	  	

13.10 Anti-infective skin preparations		GMMMG
13.10.1 Antibacterial preparations		
Topical antibacterials should generally be avoided for the treatment of infections		
13.10.1.1 Antibacterial preparations only used topically		
Mupirocin		
2% cream; ointment	MMC BNF emc	
Fusidic acid		RESTRICTED superficial impetigo
2% cream; ointment	BNF emc	
Metronidazole		RESTRICTED topical treatment of rosacea
0.75% topical gel; cream	BNF emc	
Silver Sulfadiazine		RESTRICTED Treatment/prophylaxis of burns
1% w/w cream	BNF emc	
13.10.2 Antifungal preparations		
Amorolfine		1st line antifungal for nail infections
5% nail lacquer	MMC BNF emc	
Benzoic acid ointment, compound, BP		1st line treatment of ringworm
benzoic acid 6% / salicylic acid 3% / in emulsifying ointment	BNF emc	
Clotrimazole		1st line fungal skin infections
1% cream	BNF emc	
Miconazole		2nd line fungal skin infections
2% cream	BNF emc	
Terbinafine		2nd line fungal skin infections
1% cream	BNF emc	
13.10.3 Antiviral preparations		
Aciclovir		1st line
5% cream	BNF emc	
13.10.4 Parasitocidal preparations		
		NICE CKS: Head lice
		NICE CKS: Pubic lice
		NICE CKS: Scabies
Ivermectin		
U tablets	MMC BNF emc	
Malathion		
0.5% aqueous solution	BNF emc	
Permethrin		
1% crème rinse; 5% dermal cream	BNF emc	
MHRA Drug Safety Update (Mar-18): Head lice eradication products: risk of serious burns if treated hair is exposed to open flames or other sources of ignition...		
13.10.5 Preparations for minor cuts & abrasions		
Proflavine cream, BPC		
0.1% cream	BNF emc	
Brulidine		RESTRICTED Theatres only
0.15% w/w cream	emc	
Preparations for boils		
Magnesium Sulfate		
paste, BP	emc	
Skin tissue adhesive		
Histoacryl®		RESTRICTED Theatres only
0.5mL skin adhesive	BNF emc	

13.11 Skin cleansers, antiseptics & desloughing agents		GMMMG
13.11.1 Alcohols & saline		
Isopropyl Alcohol 70%	 	
Sodium Chloride	 	
0.9% irrigation solution		
13.11.2 Chlorhexidine salts		
Chlorhexidine Gluconate	 	
13.11.4 Iodine		
Alcoholic Iodine solution BP	 	
Iodine weak solution	 	
Povidone-Iodine	 	
13.11.6 Oxidisers & dyes		
Hydrogen Peroxide solution, BP	 	RESTRICTED Specialist use only
3% solution; 6% solution		
Potassium Permanganate	 	RESTRICTED Specialist use only
400mg tablets for cutaneous solution		
National Patient Safety Alert (Apr-22): Inadvertent oral administration of potassium permanganate		
13.11.7 Desloughing agents		
CONTACT THE TISSUE VIABILITY TEAM on x64042		

13.12 Antiperspirants		GMMMG
Aluminium salts		
Aluminium Chloride Hexahydrate		
20% solution	 	
Glycopyrronium Bromide		
Glycopyrronium Bromide		
Robinul®	  	
Glycopyrrolate		
 0.5% cream	  	RESTRICTED Diabetes Consultants only (gustatory sweating)

13.13 Topical circulatory preparations



Topical circulatory preparations

Hirudoid®

0.3% cream; 0.3% gel



13.14 Miscellaneous preparations		GMMMG
8-Methoxypsoralen  10mg tablets MMC 		RESTRICTED Dermatology Consultants only
Fumaric Acid Esters  Fumaderm® tablets MMC 		RESTRICTED Dermatology Consultants only
Glucarpidase   Voraxaze® 1,000 unit injection (see also sections 1.10, 8.4 & 10.4) PBR X MMC 		RESTRICTED 2 nd line rescue therapy
Hyaluronic acid / Lidocaine  Juveferm® / Belotero® injection MMC 		RESTRICTED vocal cord paralysis
Non-Formulary Items		
Ingenol Mebutate Picato® 150 micrograms/g gel (face & scalp); 500 micrograms/g gel (trunk & extremities) MMC  		WITHDRAWN
MHRA Drug Safety Update (Feb-20): Ingenol mebutate gel (Picato▼): suspension of the licence due to risk of skin malignancy MHRA Drug Safety Update (Oct-19): Ingenol mebutate gel (Picato▼): increased incidence of skin tumours seen in some clinical studies		

Section 14: Immunological products & vaccines

Supported by the
formulary ([click here](#))



14.4 Vaccines & antisera

- Bacillus Calmette-Guérin (BCG) vaccines
- Botulism antitoxin
- COVID-19 vaccine
- Diphtheria vaccines (children under 10yrs old)
- Diphtheria vaccines (children over 10yrs old & adults)
- Haemophilus type B conjugate vaccine
- Hepatitis A vaccine
- Hepatitis B vaccine
- Human papilloma virus vaccine
- Influenza vaccine
- Measles, Mumps & Rubella (MMR) vaccine
- Meningococcal vaccines
- Pneumococcal vaccines
- Poliomyelitis vaccines
- Rabies vaccines
- Tetanus vaccines
- Typhoid vaccines
- Varicella-zoster vaccines

14.5 Immunoglobulins

- 14.5.1 Normal immunoglobulin
- 14.5.2 Disease-specific immunoglobulins
- 14.5.3 Anti-D (Rh₀) immunoglobulin

Trust Guidelines

Adult medicines and prescribing guidelines
Paediatric medicines and prescribing guidelines
Neonatal guidelines (link to Staffnet site)
Guidelines for the Prescribing and Administration of Intravenous Immunoglobulin
Immunoglobulin follow up form
Immunoglobulin Prescribing and Administration Guidelines
Immunoglobulin Prescribing Flow Chart
Immunoglobulin request form
National Demand Programme for Immunoglobulin - Clinical Info
[Non-formulary Conversion Table](#)

NICE Guidance

Pregnancy - routine anti-D prophylaxis for rhesus negative women (TA156)

GMMM Formulary

Formulary Homepage
Chapter 14: Immunological products & vaccines (**ON HOLD**)
GMMM Adult **Red/Amber/Green**; DNP and Grey Drug List
GMMM Paediatric **Red/Amber/Green** Drug List

Other Links

National Immunoglobulin Database
DH: Clinical guidelines for immunoglobulin use (2nd edition update)
Immunoglobulin handbook (HPA)

14.4 Vaccines & antisera		
MHRA Drug Safety Update (Apr-16): Live attenuated vaccines: avoid use in those who are clinically immunosuppressed		
Bacillus Calmette-Guérin (BCG) vaccines		
Bacillus Calmette-Guérin (BCG) vaccine		
injection	 	
BCG vaccine diagnostic agent (Tuberculin purified protein derivative (PPD))		
injection	 	
Botulism antitoxin		
Botulism antitoxin		
injection	 	RESTRICTED Emergencies only
COVID-19 vaccine		
		UK HSA: The Green book Ch14a
Pfizer-BioNTech COVID-19 vaccine (Tozinameran / Famtozinameran)		
Comirnaty® Original/Omicron BA.4-5 (15/15 micrograms)/dose (GREY cap)	  	12 years of age and older pending availability of XBB1.5
Pfizer-BioNTech COVID-19 vaccine (Raxtozinameran)		
Comirnaty® Omicron XBB.1.5 - 30micrograms/dose injection (GREY cap)	  	12 years of age and older
Pfizer-BioNTech COVID-19 vaccine (Raxtozinameran)		
Comirnaty® Omicron XBB.1.5 - 10micrograms/dose injection (BLUE cap)	  	5 to 11 year olds
AstraZeneca COVID-19 vaccine		
Vaxzevria® injection	  	DISCONTINUED
Moderna Biotech COVID-19 vaccine		
Spikevax® injection	  	DISCONTINUED
Novavax COVID-19 vaccine		
Nuvaxovid® injection	  	PAUSED by JCVI
MHRA Drug Safety Update (Mar-23): COVID-19 vaccines: updates for March 2023		
MHRA Drug Safety Update (Feb-23): COVID-19 vaccines: updates for February 2023		
MHRA Drug Safety Update (Jan-23): COVID-19 vaccines: updates for January 2023		
MHRA Drug Safety Update (Dec-22): COVID-19 vaccines: updates for December 2022		
MHRA Drug Safety Update (Nov-22): COVID-19 vaccines: updates for November 2022		
MHRA Drug Safety Update (Oct-22): COVID-19 vaccines: updates for October 2022		
MHRA Drug Safety Update (Sep-22): COVID-19 vaccines: updates for September 2022		
MHRA Drug Safety Update (Aug-22): COVID-19 vaccines: updates for August 2022		
MHRA Drug Safety Update (Jul-22): COVID-19 vaccines: updates for July 2022		
MHRA Drug Safety Update (Jun-22): COVID-19 vaccines: updates for June 2022		
MHRA Drug Safety Update (May-22): COVID-19 vaccines: updates for May 2022		
MHRA Drug Safety Update (Apr-22): COVID-19 vaccines: updates for April 2022		
MHRA Drug Safety Update (Mar-22): COVID-19 vaccines: updates for March 2022		
MHRA Drug Safety Update (Feb-22): COVID-19 vaccines: updates for February 2022		
MHRA Drug Safety Update (Jan-22): COVID-19 vaccines: updates for January 2022		
MHRA Drug Safety Update (Dec-21): COVID-19 vaccines: updates for December 2021		
MHRA Drug Safety Update (Nov-21): COVID-19 vaccines: updates for November 2021		
MHRA Drug Safety Update (Oct-21): COVID-19 vaccines: updates for October 2021		
MHRA Drug Safety Update (Sep-21): COVID-19 vaccines: updates for September 2021		
MHRA Drug Safety Update (Aug-21): COVID-19 vaccines: updates for August 2021		
MHRA Drug Safety Update (Jul-21): COVID-19 vaccines: updates for July 2021		
MHRA Drug Safety Update (Jun-21): COVID-19 vaccines: updates for June 2021		
MHRA Drug Safety Update (May-21): COVID-19 vaccines: updates for May 2021		
MHRA Drug Safety Update (Feb-21): COVID-19 vaccines and medicines: updates for February 2021		
MHRA Drug Safety Update (Jan-21): COVID-19 vaccines (Pfizer/BioNTech and COVID-19 Vaccine AstraZeneca): current advice		
MHRA (Dec-20): Regulatory approval of Pfizer/BioNTech vaccine for COVID-19		
Diphtheria vaccines (children under 10yrs old)		
PediaceI®		
injection	 	
Infanrix-IPV+Hib®		
injection	 	
Infanrix-IPV®		
injection	 	
Repevax®		
injection	 	

Diphtheria vaccines (children over 10yrs old & adults)		
Revaxis®		
injection	 	
Haemophilus type B conjugate vaccine		
Haemophilus Influenzae B vaccine		
Hiberix® injection	 	
Haemophilus Influenzae B & Meningitis C vaccine		
Menitorix® injection	 	
Hepatitis A vaccine		
Hepatitis A vaccine single component		
Havrix Monodose®; Havrix Junior Monodose®; Vaqta® Paediatric injection	 	
Hepatitis B vaccine		
Hepatitis B single component		
Engerix B®; Engerix B® Paediatric injection	 	
Hepatitis B single component		
HBvaxPRO®; HBvaxPRO® Paediatric injection	 	
Human papilloma virus (HPV) vaccine		
Human Papilloma Virus (HPV) quadrivalent vaccine		RESTRICTED Paediatric Immunology Consultant
Gardasil® injection	  	

Influenza vaccine		
Influenza vaccine		
injection, intranasal	 	
Measles, Mumps & Rubella (MMR) vaccine		
Measles, Mumps & Rubella vaccine		
injection	 	
Meningococcal vaccines		
Meningococcal Polysaccharide A, C, W135 & Y vaccine		
injection	 	
Meningococcal group B vaccine		RESTRICTED childhood immunisation schedule & high risk patients
Bexsero® injection	  	
Meningococcal group C vaccine		
injection	 	
Pneumococcal vaccines		
Pneumococcal Polysaccharide vaccine		
injection	 	
Poliomyelitis vaccines		
Poliomyelitis vaccine inactivated		
	 	
Rabies vaccines		
Rabies vaccine inactivated		RESTRICTED Not Stocked
Rabipur® injection	 	
Tetanus vaccines		
Tetanus vaccine adsorbed		
injection	 	
Typhoid vaccines		
Typhoid polysaccharide vaccine		
Typhim Vi® injection	 	
Varicella-zoster vaccines		
Varicella-Zoster live attenuated vaccine		
Varivax® injection	 	

14.5 Immunoglobulins		IVIG Request Form
14.5.1 Normal immunoglobulin Red (for ITP & home treatment programmes)		
<i>For intramuscular use</i>		
Normal immunoglobulin injection		
Red ££	injection PbR X BNF emc	RESTRICTED Specialist use only IVIG Request Form
<i>For subcutaneous use</i>		
Normal immunoglobulin injection		
Red ££	injection PbR X MMC BNF emc	RESTRICTED Specialist use only IVIG Request Form
<i>For intravenous use</i>		
Human normal immunoglobulin		
Red ££	injection PbR X MMC BNF emc	RESTRICTED Specialist use only IVIG Request Form
14.5.2 Disease-specific immunoglobulins		
<i>Hepatitis B immunoglobulin</i>		
Hepatitis B immunoglobulin		
	injection BNF emc	RESTRICTED Not Stocked
<i>Tetanus immunoglobulin</i>		
Tetanus immunoglobulin		
	injection BNF emc	
<i>Varicella-Zoster immunoglobulin</i>		
Varicella-Zoster immunoglobulin		
Green	injection BNF emc	RESTRICTED Not Stocked
<i>Cytomegalovirus (CMV) immunoglobulin</i>		
Human normal immunoglobulin (CMV)		
	injection MMC BNF emc	RESTRICTED Specialist use only
14.5.3 Anti-D (Rh₀) immunoglobulin		
Anti-D (Rh₀) immunoglobulin		
Red	injection NICE MMC BNF emc	

Section 15: Anaesthesia

Supported by the
formulary ([click here](#))



15.1 General anaesthesia

- 15.1.1 Intravenous anaesthetics
- 15.1.2 Inhalational anaesthetics
- 15.1.3 Antimuscarinic drugs
- 15.1.4 Sedative & analgesic post-operative drugs
 - 15.1.4.1 Benzodiazepines
 - 15.1.4.2 Non-opioid analgesics
 - 15.1.4.3 Opioid analgesics
 - 15.1.4.4 Other drugs for sedation
- 15.1.5 Neuromuscular blocking drugs
 - Non-depolarising neuromuscular blocking drugs
 - Depolarising neuromuscular blocking drugs
- 15.1.6 Drugs for reversal of neuromuscular blockade
 - Anticholinesterases
 - Other drugs for reversal of neuromuscular blockade
- 15.1.7 Antagonists for central & respiratory depression
- 15.1.8 Drugs for malignant hyperthermia

15.2 Local anaesthesia

- Local Anaesthetic Toxicity
- Other agents

Trust Guidelines

Adult medicines and prescribing guidelines
Paediatric medicines and prescribing guidelines
Neonatal guidelines (link to Staffnet site)
Paediatric Anaesthesia Website
Children's Pain Management Website
PICU Emergency Drugs Calculator
[Non-formulary Conversion Table](#)

NICE Guidance

Sedation in under 19s: using sedation for diagnostic and therapeutic procedures (CG112)

GMMMG Formulary

Formulary Homepage
Chapter 15: Anaesthesia (**ON HOLD**)
GMMMG Adult **Red/Amber/Green**; DNP and Grey Drug List
GMMMG Paediatric **Red/Amber/Green** Drug List

15.1 General anaesthesia

15.1.1 Intravenous anaesthetics

Etomidate

injection



Ketamine

Red

injection



Propofol

injection; infusion



Thiopental Sodium

injection



15.1.2 Inhalational anaesthetics

Volatile liquid anaesthetics

Desflurane

anaesthetic agent



RESTRICTED
Theatres only

Isoflurane

anaesthetic agent



Methoxyflurane

Penthrox® inhalation vapour



RESTRICTED
ED only

Sevoflurane

anaesthetic agent



Nitrous oxide

Nitrous Oxide



Nitrous Oxide 50% & Oxygen 50%

Entonox®



15.1.3 Antimuscarinic drugs

Atropine Sulfate

600microgram/1mL injection



Adults 600microgram/1mL
I.M. or I.V.

Glycopyrronium Bromide

200micrograms/1mL; 600micrograms/3mL injection



Adults 200-400microgram I.V.

Hyoscine Hydrobromide

400microgram/mL injection



15.1.4 Sedative & analgesic post-operative drugs

15.1.4.1 Benzodiazepines

Diazepam

tablets; liquid; injection; rectal tube (see also sections 4.1.2 & 4.8.2)



NICE CG112

Lorazepam

tablets; injection (see also sections 4.1.2 & 4.8.2)



Midazolam

Green

oromucosal solution; injection; infusion (see also section 4.8.2)



Temazepam

tablets; oral solution (see also section 4.1.1)



15.1.4.2 Non-opioid analgesics

Ketorolac Trometamol

injection



Parecoxib

injection



RESTRICTED
Theatres only - acute postop. pain

15.1.4.3 Opioid analgesics		
Alfentanil		
 injection	 	
Fentanyl		
 injection (see also section 4.7.2)	 	
Remifentanyl		RESTRICTED Specialist use only
 injection	  	
15.1.4.4 Other drugs for sedation		
Dexmedetomidine		RESTRICTED Specialist use only
infusion	  	
15.1.5 Neuromuscular blocking drugs		
Non-depolarising neuromuscular blocking drugs		
Atracurium Besilate		
injection	 	
Cisatracurium		RESTRICTED Consultant only
injection	  	
Mivacurium		
injection	 	
Rocuronium Bromide		
injection	 	
Vecuronium Bromide		
injection	 	
Depolarising neuromuscular blocking drugs		
Suxamethonium Chloride		
injection	 	
15.1.6 Drugs for reversal of neuromuscular blockade		
Anticholinesterases		
Neostigmine Metilsulfate		
injection	 	
Neostigmine Metilsulfate with Glycopyrronium Bromide		
injection	 	
Other drugs for reversal of neuromuscular blockade		
Sugammadex		RESTRICTED - Consultant (Emergency) use in Theatres only Complete Trust incident & audit forms
Bridion® injection	  	
15.1.7 Antagonists for central & respiratory depression		
Doxapram Hydrochloride		
injection (see also section 3.5.1)	 	
Flumazenil		
injection	 	
Naloxone Hydrochloride		
injection	 	
15.1.8 Drugs for malignant hyperthermia		
Dantrolene Sodium		
injection	 	
MHRA Drug Safety Update (Jul-14): Intravenous dantrolene: risk of undissolved crystals		

15.2 Local anaesthesia	AAGBI SAFETY GUIDELINE
15.2 Local anaesthesia	
Lidocaine Hydrochloride	
Lidocaine	
0.5%, 1% & 2% injection	 
with adrenaline	
Lidocaine with Adrenaline	
1%, 2% injection	 
for surface anaesthesia	
Lidocaine with Chlorhexidine	
<i>Instillagel</i> ® 2% gel	 
Lidocaine with Phenylephrine	
<i>Co-phenylcaine</i> ® 5% / 0.5% spray	  
Lidocaine with Prilocaine	
<i>EMLA</i> ® 5% cream	 
Lidocaine	
4% topical solution	 
Lidocaine	
<i>Laryngojet</i> ® 4% (160mg/4mL) jet spray	 
Lidocaine	
5% ointment	 
Lidocaine	
<i>Xylocaine</i> ® 10% spray	 
Lidocaine	
 	RESTRICTED Consultant / specialist pain team only
<i>Versatis</i> ® 700mg medicated plaster	
Bupivacaine Hydrochloride	
Bupivacaine Hydrochloride	
0.25% Infusion (500mL)	 
Bupivacaine Hydrochloride with Glucose	
<i>Marcain Heavy</i> ® 0.5% Injection	 
with adrenaline	
Bupivacaine and Adrenaline	
0.25% with 1:200,000 injection	 
Bupivacaine and Adrenaline	
0.5% with 1:200,000 injection	 
with other ingredients	
Bupivacaine and Fentanyl	
 0.125% with 1mg/500mL infusion	 
Bupivacaine and Sodium Chloride	
0.08% in 0.9%	 
Bupivacaine Hydrochloride with Glucose	
20mg with 320mg/4mL spinal injection	 
Levobupivacaine	
Levobupivacaine	
<i>Chirocaine</i> ® 25mg/10mL; 50mg/10mL; 75mg/10mL injection; epidural 250mg/200mL	  
Levobupivacaine with Fentanyl	
 0.1% with 2microgram/mL epidural	 

Prilocaine Hydrochloride		
Prilocaine Hydrochloride		
<i>Citanest</i> ® 1% injection	 	
Prilocaine Hydrochloride		
<i>Prilotekal</i> ® 2% injection	  	
Prilocaine with Felypressin		
<i>Octapressin</i> ® 3% cartridges (30mg/mL Citanest with 0.54micrograms/mL)	 	
Ropivacaine Hydrochloride		
Ropivacaine		For Consultant use on CDU (elective CS), Theatre 1 (ortho) & wards 1 & 2 (following surgery in Th. 1)
injection; infusion	  	
Tetracaine (Amethocaine)		
Tetracaine		RESTRICTED children under 1yr by specific doctor request or /V team
4% gel	  	
Local Anaesthetic Toxicity		AAGBI SAFETY GUIDELINE
Intralipid 20%		
20% injection	 	
Other agents		
Cocaine		
 5% solution	 	
Ethyl Chloride		
<i>Cryogesic</i> ® spray	  	
Mepivacaine Hydrochloride		
3% injection	 	
Neomycin Sulfate / Fluocinolone Acetonide / Lidocaine Hydrochloride		RESTRICTED Paediatrics. Intra-urethral steroid ointment
<i>Nefluan</i> ® 10g gel	 	

Section 16: Miscellaneous

Supported by the
formulary ([click here](#))



16.1 Organ Perfusion Fluids

- 16.1.1 Cardiac Perfusion Fluids
- 16.1.2 Kidney / Pancreas / Liver perfusion fluids
- 16.1.3 Contrast Agents

Trust Guidelines

Adult medicines and prescribing guidelines

Paediatric medicines and prescribing guidelines

Neonatal guidelines (link to Staffnet site)

[Non-formulary Conversion Table](#)

NICE Guidance

Machine perfusion systems and cold static storage of kidneys from deceased donors (TA165)

GMMMG Formulary

Formulary Homepage

GMMMG Adult [Red/Amber/Green](#); DNP and Grey Drug List

GMMMG Paediatric [Red/Amber/Green](#) Drug List

16.1 Organ Perfusion fluids		
16.1.1 Cardiac perfusion fluids		
Aspartate / Glutamate Solution U 100mL	MMC	
Bretschneiders Histidine-Tryptophan-Ketoglutarate (HTK) U Custodiol Cardioplegia® solution (1000mL)	MMC	emc⊕
Cardioplegia in Ringer's Solution U 1000mL	MMC	
Cardioplegic ULTH Formula A U 500mL	MMC	
Cardioplegic ULTH Formula B U 500mL	MMC	
Sterile Concentrate for Cardioplegia Infusion 20mL	MMC	emc⊕
16.1.2 Kidney / Pancreas / Liver perfusion fluids		
Cold Storage Solution (UW Solution) Belzer UW® (1000mL)	MMC	emc⊕
Kidney Perfusion Fluid Soltran® (1000mL)	MMC	emc⊕
Lung Perfusion Solution Perfadex® (1000mL)	MMC	emc⊕
Machine Perfusion Solution Belzer MPS® UW machine perfusion solution (1000mL)	MMC	emc⊕
16.1.3 Contrast Agents		
Gadobutrol Gadovist® (1.0mmol/mL) injection	MMC	emc⊕
Gadoteric acid Dotarem® (0.5mmol/mL) injection	MMC	emc⊕
Gadoxetic acid Primovist® (0.25mmol/mL) injection	MMC	emc⊕
Perflutren Luminity® (150microlitres/mL) lipid microspheres for injection	MMC	emc⊕
Sulphur Hexafluoride SonoVue® (8microlitre/mL) injection	MMC	emc⊕